

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> s l1 full

FULL SEARCH INITIATED 18:21:32 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 113018 TO ITERATE

100.0% PROCESSED 113018 ITERATIONS

917 ANSWERS

SEARCH TIME: 00.00.02

L3 917 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

178.36

178.57

FILE 'CAPLUS' ENTERED AT 18:21:38 ON 31 MAR 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 31 Mar 2008 VOL 148 ISS 14

FILE LAST UPDATED: 30 Mar 2008 (20080330/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s l3

L4 82 L3

=> s l3 and (pd<=20040402 or ad<=20040402 or prd<=20040402)

82 L3

24808831 PD<=20040402

(PD<=20040402)

4843478 AD<=20040402

(AD<=20040402)

4322758 PRD<=20040402

(PRD<=20040402)

L5 70 L3 AND (PD<=20040402 OR AD<=20040402 OR PRD<=20040402)

=> d l5 60-70 ibib hitstr

L5 ANSWER 60 OF 70 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1991:598449 CAPLUS

DOCUMENT NUMBER: 115:198449

TITLE: The discriminative stimulus effects of diazepam in rats at two training doses

AUTHOR(S): Tang, Andrew H.; Franklin, Stanley R.

CORPORATE SOURCE: Upjohn Co., Kalamazoo, MI, 49001, USA


SOURCE: Journal of Pharmacology and Experimental Therapeutics
(1991), 258(3), 926-31
CODEN: JPETAB; ISSN: 0022-3565

DOCUMENT TYPE: Journal
LANGUAGE: English

IT 124423-84-3, U78875
RL: BIOL (Biological study)
(discriminative behavior response to diazepam in relation to)

RN 124423-84-3 CAPLUS

CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-
5-(1-methylethyl)- (CA INDEX NAME)



L5 ANSWER 61 OF 70 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1991:550266 CAPLUS

DOCUMENT NUMBER: 115:150266

TITLE: Role of cGMP in the mechanism of anxiolytic activity
of U-78875

AUTHOR(S): Sethy, Vimala H.; Oien, Tim T.

CORPORATE SOURCE: CNS Res., Upjohn Co., Kalamazoo, MI, 49001, USA


SOURCE: Pharmacology, Biochemistry and Behavior (1991
, 39(2), 379-82
CODEN: PBBHAU; ISSN: 0091-3057

DOCUMENT TYPE: Journal
LANGUAGE: English

IT 124423-84-3, U-78875
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); BIOL (Biological study)
(anxiolytic activity of, benzodiazepine receptor and cGMP in relation
to)

RN 124423-84-3 CAPLUS

CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-
5-(1-methylethyl)- (CA INDEX NAME)



L5 ANSWER 62 OF 70 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1991:514549 CAPLUS

DOCUMENT NUMBER: 115:114549

TITLE: Preparation of 3-isoxazolyl-4-oxoimidazo[1,5-
a]quinoxalines as central nervous system agents

INVENTOR(S): Waetjen, Frank; Hansen, Holger Claus
 PATENT ASSIGNEE(S): Novo-Nordisk A/S, Den.
 SOURCE: PCT Int. Appl., 32 pp.

CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9107407	A1	19910530	WO 1990-DK301	19901122 <--
W: AU, CA, FI, HU, JP, KR, NO				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE				
IL 96373	A	19941021	IL 1990-96373	19901116 <--
ZA 9009303	A	19910925	ZA 1990-9303	19901120 <--
US 5116841	A	19920526	US 1990-615707	19901120 <--
CA 2073041	A1	19910523	CA 1990-2073041	19901122 <--
AU 9067535	A	19910613	AU 1990-67535	19901122 <--
AU 645276	B2	19940113		
EP 502038	A1	19920909	EP 1990-917268	19901122 <--
EP 502038	B1	19970205		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
JP 05503082	T	19930527	JP 1991-500072	19901122 <--
HU 63421	A2	19930830	HU 1992-1710	19901122 <--
AT 148703	T	19970215	AT 1990-917268	19901122 <--
ES 2098276	T3	19970501	ES 1990-917268	19901122 <--
NO 9201887	A	19920513	NO 1992-1887	19920513 <--
NO 180634	B	19970210		
NO 180634	C	19970521		
FI 9202267	A	19920519	FI 1992-2267	19920519 <--
FI 97227	B	19960731		
FI 97227	C	19961111		
PRIORITY APPLN. INFO.:			DK 1989-5884	A 19891122 <--
			WO 1990-DK301	A 19901122 <--


OTHER SOURCE(S): MARPAT 115:114549

IT 135645-01-1P 135645-02-2P 135645-03-3P
 135645-04-4P 135645-05-5P 135645-06-6P
 135645-08-8P 135645-09-9P 135645-10-2P
 135645-11-3P 135645-12-4P 135645-13-5P
 135645-27-1P 135662-01-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of, as central nervous system agent)

RN 135645-01-1 CAPLUS


CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 5-(1,1-dimethylethyl)-3-(3-methyl-5-isoxazolyl)- (CA INDEX NAME)



RN 135645-02-2 CAPLUS


CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 5-(1,1-dimethylethyl)-3-(5-methyl-3-

isoxazolyl)- (CA INDEX NAME)




RN 135645-03-3 CAPLUS

CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 5-(1-methylethyl)-3-(3-methyl-5-isoxazolyl)- (CA INDEX NAME)




RN 135645-04-4 CAPLUS

CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 6-chloro-3-(5-cyclopropyl-3-isoxazolyl)-5-methyl- (CA INDEX NAME)




RN 135645-05-5 CAPLUS

CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 3-(5-cyclopropyl-3-isoxazolyl)-5-(1,1-dimethylethyl)- (CA INDEX NAME)




RN 135645-06-6 CAPLUS

CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 3-(5-cyclopropyl-4-methyl-3-isoxazolyl)-5-(1-methylethyl)- (CA INDEX NAME)




RN 135645-08-8 CAPLUS

CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 5-ethyl-3-[(5-(methoxymethyl)-3-isoxazolyl)- (CA INDEX NAME)




RN 135645-09-9 CAPLUS

CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 3-(5-methyl-3-isoxazolyl)-5-(2-methylpropyl)- (CA INDEX NAME)




RN 135645-10-2 CAPLUS

CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 5-methyl-3-(3-methyl-5-isoxazolyl)- (CA INDEX NAME)




RN 135645-11-3 CAPLUS

CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 5-[(3-methoxyphenyl)methyl]-3-(3-methyl-5-isoxazolyl)- (CA INDEX NAME)




RN 135645-12-4 CAPLUS

CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 3-(3-methyl-5-isoxazolyl)-5-(2-oxo-2-phenylethyl)- (CA INDEX NAME)




RN 135645-13-5 CAPLUS

CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 5-(3-methyl-2-butenyl)-3-(3-methyl-5-isoxazolyl)- (9CI) (CA INDEX NAME)




RN 135645-27-1 CAPLUS


CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 5-ethyl-3-(3-isoxazolyl)- (CA INDEX NAME)



RN 135662-01-0 CAPLUS
 CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 3-(5-cyclopropyl-3-isoxazolyl)-5-(1-methylethyl)- (CA INDEX NAME)




L5 ANSWER 63 OF 70 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1991:156496 CAPLUS
 DOCUMENT NUMBER: 114:156496
 TITLE: Determination of 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-5-(1-methylethyl)imidazo[1,5-a]quinoxalin-4(5H)-one in serum by high-performance liquid chromatography
 Zhong, W. Z.
 AUTHOR(S): Drug Metab. Res., Upjohn Co., Kalamazoo, MI, 49001, USA
 CORPORATE SOURCE: Journal of Chromatography (1991), 563(2), 427-34
 SOURCE: CODEN: JOCRAM; ISSN: 0021-9673
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 IT 124423-84-3, U 78875
 RL: ANT (Analyte); ANST (Analytical study)
 (determination of, in blood by HPLC)
 RN 124423-84-3 CAPLUS
 CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-5-(1-methylethyl)- (CA INDEX NAME)




L5 ANSWER 64 OF 70 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1990:572052 CAPLUS

DOCUMENT NUMBER: 113:172052
 TITLE: Preparation of imidazoquinoxalines as anticonvulsants and anxiolytics
 INVENTOR(S): Watjen, Frank; Hansen, Holger Claus
 PATENT ASSIGNEE(S): Aktieselskabet Ferrosan, Den.
 SOURCE: Eur. Pat. Appl., 8 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 368652	A1	19900516	EP 1989-311587	19891109 <--
EP 368652	B1	19950301		
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
ZA 8908051	A	19900829	ZA 1989-8051	19891024 <--
AU 8944393	A	19900517	AU 1989-44393	19891103 <--
AU 622941	B2	19920430		
FI 92931	B	19941014	FI 1989-5257	19891106 <--
FI 92931	C	19950125		
JP 02178285	A	19900711	JP 1989-288081	19891107 <--
DK 8905562	A	19900511	DK 1989-5562	19891108 <--
DK 163511	B	19920309		
DK 163511	C	19920831		
US 4999353	A	19910312	US 1989-433668	19891108 <--
CA 2002624	A1	19900510	CA 1989-2002624	19891109 <--
NO 8904474	A	19900511	NO 1989-4474	19891109 <--
NO 173827	B	19931101		
NO 173827	C	19940209		
ES 2068903	T3	19950501	ES 1989-311587	19891109 <--
PRIORITY APPLN. INFO.:			DK 1988-6262	A 19881110 <--
OTHER SOURCE(S): MARPAT 113:172052				
IT 126991-08-0P 126991-09-1P 126991-10-4P				
126991-11-5P 126991-12-6P 126991-13-7P				
126991-14-8P 126991-15-9P 126991-16-0P				
126991-17-1P 126991-18-2P 129799-93-5P				
129799-94-6P				
RL: SPN (Synthetic preparation); PREP (Preparation)				
(preparation of, as anticonvulsant and anxiolytic)				
RN 126991-08-0 CAPLUS				
CN Imidazo[1,5-a]quinoxaline-5(4H)-acetic acid, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-4-oxo-, ethyl ester (CA INDEX NAME)				




RN 126991-09-1 CAPLUS
 CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-5-(3-methyl-2-butenyl)- (9CI) (CA INDEX NAME)




RN 126991-10-4 CAPLUS

CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-5-(2-propenyl)- (9CI) (CA INDEX NAME)




RN 126991-11-5 CAPLUS

CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-5-(2-oxo-2-phenylethyl)- (CA INDEX NAME)



RN 126991-12-6 CAPLUS


CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-5-(2-oxopropyl)- (CA INDEX NAME)



RN 126991-13-7 CAPLUS


CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-

5-[(2-fluorophenyl)methyl]- (CA INDEX NAME)




RN 126991-14-8 CAPLUS

CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-5-[(2-methylphenyl)methyl]- (CA INDEX NAME)




RN 126991-15-9 CAPLUS

CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 5-[(2-bromophenyl)methyl]-3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)- (CA INDEX NAME)




RN 126991-16-0 CAPLUS

CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-5-[(3-methoxyphenyl)methyl]- (CA INDEX NAME)




RN 126991-17-1 CAPLUS

CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-5-(2-ethoxyethyl)- (CA INDEX NAME)




RN 126991-18-2 CAPLUS

CN 1H-isindole-1,3(2H)-dione, 2-[4-[[3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-4-oxoimidazo[1,5-a]quinoxalin-5(4H)-yl]methyl]phenyl]- (CA INDEX NAME)




RN 129799-93-5 CAPLUS

CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-5-(1,1-dimethylethyl)- (CA INDEX NAME)



RN 129799-94-6 CAPLUS
 CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 3-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-5-(1,1-dimethylethyl)- (CA INDEX NAME)



L5 ANSWER 65 OF 70 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1990:216962 CAPLUS

DOCUMENT NUMBER: 112:216962

TITLE: Preparation of oxadiazolylimidazoquinoxalinone derivatives as central nervous system agents

INVENTOR(S): Hansen, Holger Claus; Watjen, Frank

PATENT ASSIGNEE(S): Aktieselskabet Ferrosan, Den.

SOURCE: Eur. Pat. Appl., 14 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 344943	A1	19891206	EP 1989-304982	19890517 <--
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
US 5075304	A	19911224	US 1989-353793	19890518 <--
ZA 8903872	A	19900228	ZA 1989-3872	19890523 <--
DK 8902582	A	19891202	DK 1989-2582	19890526 <--
DK 161022	B	19910521		
DK 161022	C	19911028		
AU 8935174	A	19891207	AU 1989-35174	19890526 <--
AU 627181	B2	19920820		
CA 1315786	C	19930406	CA 1989-601114	19890530 <--
NO 8902204	A	19891204	NO 1989-2204	19890531 <--
NO 173185	B	19930802		
NO 173185	C	19931110		
FI 8902684	A	19891202	FI 1989-2684	19890601 <--
FI 92203	B	19940630		
FI 92203	C	19941010		
JP 02025486	A	19900126	JP 1989-137578	19890601 <--
PRIORITY APPLN. INFO.:			DK 1988-2971	A 19880601 <--
			DK 1988-6259	A 19881110 <--
OTHER SOURCE(S):	MARPAT	112:216962		


IT 126990-89-4P 126990-90-7P 126990-91-8P
 126990-92-9P 126990-93-0P 126990-94-1P
 126990-95-2P 126990-96-3P 126990-97-4P
 126990-98-5P 126990-99-6P 126991-04-6P
 126991-05-7P 126991-06-8P 126991-07-9P
 126991-08-0P 126991-09-1P 126991-10-4P
 126991-11-5P 126991-12-6P 126991-13-7P
 126991-14-8P 126991-15-9P 126991-16-0P
 126991-17-1P 126991-18-2P 126991-19-3P
 126991-20-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of, as central nervous system agent)


RN 126990-89-4 CAPLUS

CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-5-(phenylmethyl)- (CA INDEX NAME)




RN 126990-90-7 CAPLUS

CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-5-methyl-6-(trifluoromethyl)- (CA INDEX NAME)




RN 126990-91-8 CAPLUS

CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-5-(2-phenylethyl)- (CA INDEX NAME)




RN 126990-92-9 CAPLUS

CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 5-[(2-chlorophenyl)methyl]-3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)- (CA INDEX NAME)




RN 126990-93-0 CAPLUS

CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-5-[(4-methoxyphenyl)methyl]- (CA INDEX NAME)




RN 126990-94-1 CAPLUS

CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 3-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-5-methyl-6-(trifluoromethyl)- (CA INDEX NAME)




RN 126990-95-2 CAPLUS

CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 6-chloro-5-[(2-chlorophenyl)methyl]-3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)- (CA INDEX NAME)




RN 126990-96-3 CAPLUS

CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-5-(2-pyridinylmethyl)- (CA INDEX NAME)




RN 126990-97-4 CAPLUS

CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-5-[2-(2-methoxyphenyl)methyl]- (CA INDEX NAME)




RN 126990-98-5 CAPLUS

CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-5-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)




RN 126990-99-6 CAPLUS

CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 5-(cyclopropylmethyl)-3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)- (CA INDEX NAME)




RN 126991-04-6 CAPLUS

CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 3-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-5,6-dimethyl- (9CI) (CA INDEX NAME)




RN 126991-05-7 CAPLUS

CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 5-[(2-chlorophenyl)methyl]-3-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)- (CA INDEX NAME)




RN 126991-06-8 CAPLUS

CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 3-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-5-[(4-methoxyphenyl)methyl]- (CA INDEX NAME)




RN 126991-07-9 CAPLUS

CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 3-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-5-ethyl-6-methyl- (CA INDEX NAME)




RN 126991-08-0 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-acetic acid, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-4-oxo-, ethyl ester (CA INDEX NAME)




RN 126991-09-1 CAPLUS

CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-5-(3-methyl-2-butenyl)- (9CI) (CA INDEX NAME)




RN 126991-10-4 CAPLUS

CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-5-(2-propenyl)- (9CI) (CA INDEX NAME)



RN 126991-11-5 CAPLUS


CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-5-(2-oxo-2-phenylethyl)- (CA INDEX NAME)



RN 126991-12-6 CAPLUS


CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-

5-(2-oxopropyl)- (CA INDEX NAME)




RN 126991-13-7 CAPLUS

CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-5-[(2-fluorophenyl)methyl]- (CA INDEX NAME)




RN 126991-14-8 CAPLUS

CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-5-[(2-methylphenyl)methyl]- (CA INDEX NAME)




RN 126991-15-9 CAPLUS

CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 5-[(2-bromophenyl)methyl]-3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)- (CA INDEX NAME)




RN 126991-16-0 CAPLUS

CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-5-[(3-methoxyphenyl)methyl]- (CA INDEX NAME)




RN 126991-17-1 CAPLUS

CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-5-(2-ethoxyethyl)- (CA INDEX NAME)




RN 126991-18-2 CAPLUS

CN 1H-isoindole-1,3(2H)-dione, 2-[4-[[3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-4-oxoimidazo[1,5-a]quinoxalin-5(4H)-yl]methyl]phenyl]- (CA INDEX NAME)




RN 126991-19-3 CAPLUS

CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 5-[(4-aminophenyl)methyl]-3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)- (CA INDEX NAME)



RN 126991-20-6 CAPLUS

CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 5-[(4-azidophenyl)methyl]-3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)- (CA INDEX NAME)



L5 ANSWER 66 OF 70 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1990:35889 CAPLUS

DOCUMENT NUMBER: 112:35889

TITLE: Preparation of imidazoquinoxalines and analogs as anticonvulsants, anxiolytics, and hypnotics

INVENTOR(S): Hansen, Holger Claus; Watjen, Frank

PATENT ASSIGNEE(S): Aktieselskabet Ferrosan, Den.

SOURCE: Eur. Pat. Appl., 16 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 320136	A2	19890614	EP 1988-310982	19881121 <--
EP 320136	A3	19901219		
EP 320136	B1	19940727		
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
DK 8706422	A	19890609	DK 1987-6422	19871208 <--
DK 160879	B	19910429		
DK 160876	C	19911014		
IL 88313	A	19930610	IL 1988-88313	19881107 <--
ZA 8808558	A	19890830	ZA 1988-8558	19881116 <--
ES 2056941	T3	19941016	ES 1988-310982	19881121 <--
FI 8805518	A	19890609	FI 1988-5518	19881128 <--
FI 90548	B	19931115		
FI 90548	C	19940225		
CA 1327797	C	19940315	CA 1988-584610	19881130 <--
AU 8826602	A	19890608	AU 1988-26602	19881206 <--
AU 613125	B2	19910725		
KR 133079	B1	19980417	KR 1988-16202	19881206 <--
NO 8805442	A	19890609	NO 1988-5442	19881207 <--
NO 169540	B	19920330		
NO 169540	C	19920708		
US 4968682	A	19901106	US 1988-281090	19881207 <--
JP 01190684	A	19890731	JP 1988-308994	19881208 <--
US 4999354	A	19910312	US 1990-460310	19900103 <--
FI 93836	B	19950228	FI 1992-5309	19921123 <--
FI 93836	C	19950612		

PRIORITY APPLN. INFO.:

DK 1987-6422	A	19871208 <--
US 1988-281090	A3	19881207 <--


OTHER SOURCE(S): CASREACT 112:35889; MARPAT 112:35889

IT 124423-83-2P 124423-84-3P 124423-85-4P
124423-87-6P 124423-88-7P 124423-89-8P
124423-90-1P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as anticonvulsant, anxiolytic, and hypnotic)


RN 124423-83-2 CAPLUS

CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 5-(1-methylethyl)-3-(5-methyl-1,2,4-oxadiazol-3-yl)- (CA INDEX NAME)




RN 124423-84-3 CAPLUS

CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-5-(1-methylethyl)- (CA INDEX NAME)




RN 124423-85-4 CAPLUS

CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 6-chloro-3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-5-(1-methylethyl)- (CA INDEX NAME)




RN 124423-87-6 CAPLUS

CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 3-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-5-(1-methylethyl)- (CA INDEX NAME)




RN 124423-88-7 CAPLUS

CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 5-(1-methylethyl)-3-(3-methyl-1,2,4-oxadiazol-5-yl)- (CA INDEX NAME)




RN 124423-89-8 CAPLUS

CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 3-[3-(methoxymethyl)-1,2,4-oxadiazol-5-yl]-5-(1-methylethyl)- (CA INDEX NAME)



RN 124423-90-1 CAPLUS

CN Imidazo[1,5-a]pyrido[2,3-e]pyrazin-4(5H)-one, 3-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-5-(1-methylethyl)- (CA INDEX NAME)



L5 ANSWER 67 OF 70 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1989:57685 CAPLUS

DOCUMENT NUMBER: 110:57685

TITLE: Preparation of tricyclic heterocyclic compounds as central nervous system agents

INVENTOR(S): Watjen, Frank; Hansen, Holger Claus
 PATENT ASSIGNEE(S): Aktieselskabet Ferrosan, Den.
 SOURCE: Eur. Pat. Appl., 19 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 283162	A2	19880921	EP 1988-301783	19880301 <--
EP 283162	A3	19900530		
EP 283162	B1	19930811		
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
DK 8701374	A	19880919	DK 1987-1374	19870318 <--
DK 155524	B	19890417		
DK 155524	C	19890911		
IL 85295	A	19911212	IL 1988-85295	19880202 <--
US 4873244	A	19891010	US 1988-156363	19880216 <--
ZA 8801140	A	19881026	ZA 1988-1140	19880218 <--
FI 8800815	A	19880919	FI 1988-815	19880222 <--
FI 92700	B	19940915		
FI 92700	C	19941227	FI 1988-815	19880222 <--
AT 92926	T	19930815	AT 1988-301783	19880301 <--
ES 2058251	T3	19941101	ES 1988-301783	19880301 <--
NO 8801191	A	19880919	NO 1988-1191	19880317 <--
NO 169340	B	19920302		
NO 169340	C	19920610		
JP 01063581	A	19890309	JP 1988-62068	19880317 <--
CA 1308712	C	19921013	CA 1988-561758	19880317 <--
AU 8813259	A	19880922	AU 1988-13259	19880318 <--
AU 607469	B2	19910307		
US 4902686	A	19900220	US 1989-340901	19890420 <--
FI 93837	B	19950228	FI 1992-5310	19921123 <--
FI 93837	C	19950612		
PRIORITY APPLN. INFO.:			DK 1987-1374	A 19870318 <--
			US 1988-156363	A3 19880216 <--
			EP 1988-301783	A 19880301 <--

OTHER SOURCE(S): CASREACT 110:57685; MARPAT 110:57685


IT 118471-10-6P 118471-32-2P 118471-34-4P

118471-37-7P 118471-38-8P 118471-39-9P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of, as nervous system agent)


RN 118471-10-6 CAPLUS

CN Imidazo[1,5-a]pyrido[2,3-e]pyrazin-4(5H)-one, 3-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-5-ethyl- (CA INDEX NAME)




RN 118471-32-2 CAPLUS

CN Imidazo[1,5-a]pyrido[2,3-e]pyrazin-4(5H)-one, 5-methyl-3-(5-methyl-1,2,4-oxadiazol-3-yl)- (CA INDEX NAME)




RN 118471-34-4 CAPLUS

CN Imidazo[1,5-a]pyrido[2,3-e]pyrazin-4(5H)-one, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-5-ethyl- (CA INDEX NAME)




RN 118471-37-7 CAPLUS

CN Imidazo[1,5-a]pyrido[2,3-e]pyrazin-4(5H)-one, 3-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-5-methyl- (CA INDEX NAME)




RN 118471-38-8 CAPLUS

CN Imidazo[1,5-a]pyrido[2,3-e]pyrazin-4(5H)-one, 5-ethyl-3-(3-methyl-1,2,4-oxadiazol-5-yl)- (CA INDEX NAME)




RN 118471-39-9 CAPLUS

CN Imidazo[1,5-a]pyrido[2,3-e]pyrazin-4(5H)-one, 5-ethyl-3-(3-ethyl-1,2,4-oxadiazol-5-yl)- (CA INDEX NAME)




L5 ANSWER 68 OF 70 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1988:510456 CAPLUS
DOCUMENT NUMBER: 109:110456
TITLE: Preparation of oxadiazolylimidazo[1,5-a]quinoxalines
as central nervous system agents
INVENTOR(S): Watjen, Frank; Engelstoft, Mogens
PATENT ASSIGNEE(S): Upjohn Co., USA
SOURCE: S. African, 27 pp.
CODEN: SFXXAB
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	ZA 8701534	A	19871028	ZA 1987-1534	19870303 <--
PRIORITY APPLN. INFO.:				ZA 1987-1534	19870303 <--
IT	115618-87-6P	115618-88-7P	115618-89-8P		
	115618-94-5P	115618-97-8P			
	RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of, as nervous system agent)				
RN	115618-87-6	CAPLUS			
CN	Imidazo[1,5-a]quinoxalin-4(5H)-one, 3-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-5-methyl- (CA INDEX NAME)				




RN 115618-88-7 CAPLUS
CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 3-[3-(methoxymethyl)-1,2,4-oxadiazol-5-yl]-5-methyl- (CA INDEX NAME)




RN 115618-89-8 CAPLUS

CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 6-chloro-3-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-5-methyl- (CA INDEX NAME)




RN 115618-94-5 CAPLUS

CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-3,3a-dihydro-5-methyl- (9CI) (CA INDEX NAME)



RN 115618-97-8 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-4,5-dihydro-5-methyl-, hydrochloride (9CI) (CA INDEX NAME)



● x HCl

L5 ANSWER 69 OF 70 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1984:407202 CAPLUS

DOCUMENT NUMBER: 101:7202

ORIGINAL REFERENCE NO.: 101:1231a,1234a

TITLE: Imidazoquinoxaline compounds

INVENTOR(S): Lee, Thomas D.; Brown, Richard E.

PATENT ASSIGNEE(S): USV Pharmaceutical Corp., USA


SOURCE: U.S., 9 pp. Cont.-in-part of U.S. Ser. No. 283,717, abandoned.

CODEN: USXXAM


DOCUMENT TYPE: Patent

LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4440929	A	19840403	US 1982-362713	19820329 <--
EP 70518	A2	19830126	EP 1982-106315	19820714 <--
EP 70518	A3	19840222		
R: BE, CH, DE, FR, GB, IT, LI, NL, SE				
AU 8286103	A	19830120	AU 1982-86103	19820716 <--
AU 561530	B2	19870514		
JP 58023693	A	19830212	JP 1982-123077	19820716 <--
ZA 8205094	A	19830427	ZA 1982-5094	19820716 <--
CA 1216291	A1	19870106	CA 1982-407473	19820716 <--
PRIORITY APPLN. INFO.:			US 1981-283717	A2 19810716 <--
			US 1982-362713	A 19820329 <--
OTHER SOURCE(S): CASREACT 101:7202				
IT 86110-71-6P 86110-72-7P				
RL: SPN (Synthetic preparation); PREP (Preparation)				
(preparation of)				
RN 86110-71-6 CAPLUS				
CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 5-methyl- (CA INDEX NAME)				




RN 86110-72-7 CAPLUS
CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 5-methyl-7-(trifluoromethyl)- (CA INDEX NAME)




L5 ANSWER 70 OF 70 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1983:422496 CAPLUS
DOCUMENT NUMBER: 99:22496
ORIGINAL REFERENCE NO.: 99:3645a,3648a
TITLE: Imidazoquinoxaline compounds
INVENTOR(S): Lee, Thomas Daw Yuan; Brown, Richard E.
PATENT ASSIGNEE(S): U.S.V. Pharmaceutical Corp., USA
SOURCE: Eur. Pat. Appl., 36 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 70518	A2	19830126	EP 1982-106315	19820714 <--
EP 70518	A3	19840222		
R: BE, CH, DE, FR, GB, IT, LI, NL, SE				
US 4440929	A	19840403	US 1982-362713	19820329 <--
PRIORITY APPLN. INFO.:			US 1981-283717	A 19810716 <--
			US 1982-362713	A 19820329 <--
OTHER SOURCE(S): MARPAT 99:22496				
IT 86110-71-6P 86110-72-7P				
RL: SPN (Synthetic preparation); PREP (Preparation of)				
(preparation of)				
RN 86110-71-6 CAPLUS				
CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 5-methyl- (CA INDEX NAME)				



RN 86110-72-7 CAPLUS
CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 5-methyl-7-(trifluoromethyl)- (CA INDEX NAME)




=> d 15 40-59 ibib hitstr

L5 ANSWER 40 OF 70 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1994:482868 CAPLUS
DOCUMENT NUMBER: 121:82868
TITLE: Preparation of carbapenem derivatives
INVENTOR(S): Oida, Sadao; Mori, Makoto; Fujimoto, Katsuhiko
PATENT ASSIGNEE(S): Sankyo Co, Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 28 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------


JP 06025243	A	19940201	JP 1992-180779	19920708 <--
PRIORITY APPLN. INFO.:			JP 1992-180779	19920708 <--
OTHER SOURCE(S):	CASREACT 121:82868; MARPAT 121:82868			
IT 156263-93-3P				
RL: SPN (Synthetic preparation); PREP (Preparation)				
(preparation of, method for)				
RN 156263-93-3 CAPLUS				
CN	1-Azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, 3-[[5-[(5,6-dihydroimidazo[1,5-a]pyrazin-7(8H)-yl)carbonyl]-1-[(4-nitrophenyl)methoxy]carbonyl]-3-pyrrolidinyl]thio]-6-(1-hydroxyethyl)-4-methyl-7-oxo-, (4-nitrophenyl)methyl ester, [4R-[3(3S*,5S*),4 α ,5 β ,6 β (R*)]]- (9CI) (CA INDEX NAME)			

Absolute stereochemistry.




L5 ANSWER 41 OF 70 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1994:435535 CAPLUS
 DOCUMENT NUMBER: 121:35535
 TITLE: Antagonist, Partial Agonist, and Full Agonist
 Imidazo[1,5-a]quinoxaline Amides and Carbamates Acting
 through the GABAA/Benzodiazepine Receptor
 AUTHOR(S): TenBrink, Ruth E.; Im, Wha B.; Sathy, Vimala H.; Tang,
 Andrew H.; Carter, Don B.
 CORPORATE SOURCE: Department of Medicinal Chemistry, Upjohn Company,
 Kalamazoo, MI, 49001, USA
 SOURCE: Journal of Medicinal Chemistry (1994),
 37(6), 758-68
 CODEN: JMCMAR; ISSN: 0022-2623
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 121:35535
 IT 148010-85-9P 155335-36-7P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation and reaction of, in preparation of imidazoquinoxaline
 GABAA/benzodiazepine receptor ligands)
 RN 148010-85-9 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxylic acid, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-6-fluoro-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 155335-36-7 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carbonyl chloride, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-4,4-dimethyl- (CA INDEX NAME)



IT 148010-75-7P 148010-76-8P 148010-77-9P

148011-22-7P 148011-26-1P 148011-29-4P

148011-30-7P 148011-31-8P 148011-34-1P


148011-37-4P 148011-38-5P 148011-39-6P

RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of, as GABAA/benzodiazepine receptor ligand)


RN 148010-75-7 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxylic acid, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 148010-76-8 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 5-benzoyl-3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-4,5-dihydro- (9CI) (CA INDEX NAME)




RN 148010-77-9 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 5-acetyl-3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-4,5-dihydro- (9CI) (CA INDEX NAME)




RN 148011-22-7 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 5-(2-chlorobenzoyl)-3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-4,5-dihydro- (9CI) (CA INDEX NAME)




RN 148011-26-1 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 5-acetyl-3-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-4,5-dihydro- (9CI) (CA INDEX NAME)




RN 148011-29-4 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 5-acetyl-3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-6-fluoro-4,5-dihydro- (9CI) (CA INDEX NAME)




RN 148011-30-7 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 5-benzoyl-3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-6-fluoro-4,5-dihydro- (9CI) (CA INDEX NAME)




RN 148011-31-8 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 5-acetyl-3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-7-fluoro-4,5-dihydro- (9CI) (CA INDEX NAME)




RN 148011-34-1 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 5-benzoyl-3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-7-fluoro-4,5-dihydro- (9CI) (CA INDEX NAME)




RN 148011-37-4 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 5-acetyl-3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-4,5-dihydro-4,4-dimethyl- (9CI) (CA INDEX NAME)




RN 148011-38-5 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxylic acid, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-4,4-dimethyl-, methyl ester (CA INDEX NAME)



RN 148011-39-6 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxylic acid, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-4,4-dimethyl-, 1-methylethyl ester (CA INDEX NAME)



L5 ANSWER 42 OF 70 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1994:134524 CAPLUS

DOCUMENT NUMBER: 120:134524

TITLE: 3-Substituted imidazo[1,5-a]quinoxalines and
-quinazolines with central nervous system activity

INVENTOR(S): Ten Brink, Ruth Elizabeth; Jacobsen, Eric Jon; Hester,
Jackson B., Jr.; Skaletzky, Louis L.

PATENT ASSIGNEE(S): Upjohn Co., USA

SOURCE: PCT Int. Appl., 43 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9317025	A1	19930902	WO 1993-US291	19930125 <--
W: AT, AU, BB, BG, BR, CA, CH, CZ, DE, DK, ES, FI, GB, HU, JP, KR, KR, LK, LU, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, SN, TD, TG				
AU 9334434	A	19930913	AU 1993-34434	19930125 <--
EP 626966	A1	19941207	EP 1993-903088	19930125 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
JP 07503970	T	19950427	JP 1993-514826	19930125 <--
PRIORITY APPLN. INFO.:			US 1992-838519	A2 19920219 <--
			WO 1993-US291	A 19930125 <--


OTHER SOURCE(S): MARPAT 120:134524

IT 152806-35-4 152806-36-5

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(central nervous system activity of)


RN 152806-35-4 CAPLUS

CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 3-(1-methylethyl)-3-(1-methyl-1H-1,2,4-triazol-5-yl)- (CA INDEX NAME)



RN 152806-36-5 CAPLUS

CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 3-(3-methoxyphenyl)-5-(1-methylethyl)-
(CA INDEX NAME)




IT 152805-98-6P 152805-99-7P 152806-00-3P
 152806-01-4P 152806-02-5P 152806-04-7P
 152806-05-8P 152806-06-9P 152806-07-0P
 152806-08-1P 152806-12-7P 152806-18-3P
 152806-20-7P 152806-21-8P 152806-22-9P
 152806-23-0P 152806-24-1P 152806-25-2P
 152806-26-3P 152806-27-4P 152806-28-5P
 152806-29-6P 152806-30-9P 152806-32-1P
 152806-33-2P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (preparation and central nervous system activity of)


RN 152805-98-6 CAPLUS

CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 3-(4-methoxyphenyl)-5-(1-methylethyl)-
 (CA INDEX NAME)




RN 152805-99-7 CAPLUS

CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 7-fluoro-5-(1-methylethyl)-3-phenyl-
 (CA INDEX NAME)




RN 152806-00-3 CAPLUS

CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 3-(4-fluorophenyl)-5-(1-methylethyl)-
 (CA INDEX NAME)




RN 152806-01-4 CAPLUS

CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 7-fluoro-3-(4-fluorophenyl)-5-(1-methylethyl)- (CA INDEX NAME)




RN 152806-02-5 CAPLUS

CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 6-chloro-3-(4-fluorophenyl)-5-(1-methylethyl)- (CA INDEX NAME)




RN 152806-04-7 CAPLUS

CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 5-(1-methylethyl)-3-phenyl- (CA INDEX NAME)




RN 152806-05-8 CAPLUS

CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 3-(2-furanyl)-5-(1-methylethyl)- (CA INDEX NAME)




RN 152806-06-9 CAPLUS

CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 5-(1-methylethyl)-3-(4-methylphenyl)-
(CA INDEX NAME)




RN 152806-07-0 CAPLUS

CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 3-(2-benzoxazolyl)-5-(1-methylethyl)-
(CA INDEX NAME)




RN 152806-08-1 CAPLUS

CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 3-(2-benzoxazolyl)-7-fluoro-5-(1-methylethyl)-
(CA INDEX NAME)




RN 152806-12-7 CAPLUS

CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 5-(1-methylethyl)-2-(2-thiazolyl)-
(9CI) (CA INDEX NAME)




RN 152806-18-3 CAPLUS

CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 5-(1-methylethyl)-3-(1-methyl-1H-1,2,4-triazol-3-yl)- (CA INDEX NAME)




RN 152806-20-7 CAPLUS

CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 3-(3-fluorophenyl)-5-(1-methylethyl)- (CA INDEX NAME)




RN 152806-21-8 CAPLUS

CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 7-fluoro-3-(3-fluorophenyl)-5-(1-methylethyl)- (CA INDEX NAME)




RN 152806-22-9 CAPLUS

CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 6-chloro-3-(3-fluorophenyl)-5-(1-methylethyl)- (CA INDEX NAME)




RN 152806-23-0 CAPLUS

CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 7-fluoro-3-(4-methoxyphenyl)-5-(1-methylethyl)- (CA INDEX NAME)




RN 152806-24-1 CAPLUS

CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 6-chloro-3-(4-methoxyphenyl)-5-(1-methylethyl)- (CA INDEX NAME)




RN 152806-25-2 CAPLUS

CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 6-chloro-3-(3-methoxyphenyl)-5-(1-methylethyl)- (CA INDEX NAME)




RN 152806-26-3 CAPLUS

CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 7-fluoro-5-(1-methylethyl)-3-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 152806-27-4 CAPLUS

CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 5-(1-methylethyl)-3-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 152806-28-5 CAPLUS

CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 3-(4-methoxyphenyl)-6-methyl-5-(1-methylethyl)- (CA INDEX NAME)




RN 152806-29-6 CAPLUS

CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 3-(4-fluorophenyl)-6-methyl-5-(1-methylethyl)- (CA INDEX NAME)




RN 152806-30-9 CAPLUS

CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 3-(4-cyclopropyl-2-thiazolyl)-5-(1-methylethyl)- (CA INDEX NAME)




RN 152806-32-1 CAPLUS

CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 3-(4-cyclopropyl-2-oxazolyl)-5-(1-methylethyl)- (CA INDEX NAME)



RN 152806-33-2 CAPLUS

CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 3-(4-cyclopropyl-2-oxazolyl)-7-fluoro-5-(1-methylethyl)- (CA INDEX NAME)




IT 152806-09-2P 152806-14-9P 152806-17-2P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation and central nervous system activity of, reaction of)


RN 152806-09-2 CAPLUS

CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 3-(4,5-dihydro-2-oxazolyl)-5-(1-methylethyl)- (CA INDEX NAME)




RN 152806-14-9 CAPLUS

CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 5-(1-methylethyl)-3-(1H-1,2,4-triazol-3-yl)- (9CI) (CA INDEX NAME)



RN 152806-17-2 CAPLUS

CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 5-(1-methylethyl)-3-(5-methyl-1H-1,2,4-triazol-3-yl)- (9CI) (CA INDEX NAME)



L5 ANSWER 43 OF 70 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1994:124029 CAPLUS

DOCUMENT NUMBER: 120:124029

TITLE: The use of liquid chromatography/thermospray mass spectrometry with online ultraviolet diode array and radiochemical detection: characterization of the putative metabolites of U-78875 in female rat feces

AUTHOR(S): Speed, W.; Parton, A. H.; Martin, I. J.; Howard, M. R.
CORPORATE SOURCE: Upjohn Lab. Europe, Crawley, RH10 2LZ, UK
SOURCE: Biological Mass Spectrometry (1994), 23(1),

1-5

CODEN: BIMSEH; ISSN: 1052-9306

DOCUMENT TYPE: Journal

LANGUAGE: English


IT 124423-84-3D, U-78875, metabolites

RL: PRP (Properties)


(characterization of, female rat feces, liquid chromatog./thermospray mass spectrometry with online UV diode array and radiochem. detection in)

RN 124423-84-3 CAPLUS

CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-5-(1-methylethyl)- (CA INDEX NAME)



L5 ANSWER 44 OF 70 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1994:95439 CAPLUS
 DOCUMENT NUMBER: 120:95439
 TITLE: Potentiation of γ -aminobutyric acid-induced chloride currents by various benzodiazepine site agonists with the $\alpha 1\gamma 2$, $\beta 2\gamma 2$ and $\alpha 1\beta 2\gamma 2$ subtypes of cloned γ -aminobutyric acid type A receptors
 AUTHOR(S): Im, Haesook K.; Im, Wha Bin; Hamilton, Beverly J.; Carter, Donald B.; VonVoigtlander, Philip F.
 CORPORATE SOURCE: Upjohn Co., Kalamazoo, MI, 49001, USA
 SOURCE: Molecular Pharmacology (1993), 44(4), 866-70
 CODEN: MOPMA3; ISSN: 0026-895X
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 IT 124423-85-4, U 79098
 RL: BIOL (Biological study)
 (GABAA receptor benzodiazepine site binding by, specificity of)
 RN 124423-85-4 CAPLUS
 CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 6-chloro-3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-5-(1-methylethyl)- (CA INDEX NAME)




L5 ANSWER 45 OF 70 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1994:62166 CAPLUS
 DOCUMENT NUMBER: 120:62166
 TITLE: Effects of particle size of bulk drug and food on the bioavailability of U-78875 in dogs
 AUTHOR(S): Nishihata, Toshiaki; Ishizaka, Mayumi; Yokohama, Sigeharu; Martino, Alice C.; Gordon, Roger E.
 CORPORATE SOURCE: Tsukuba Res., Upjohn Pharm. Ltd., Tsukuba, 300-42, Japan
 SOURCE: Drug Development and Industrial Pharmacy (1993), 19(20), 2679-98
 CODEN: DDIPD8; ISSN: 0363-9045
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 IT 124423-84-3, U-78875
 RL: BIOL (Biological study)

(bioavailability of, from oral dosage forms, particle size and food effect on)

RN 124423-84-3 CAPLUS

CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-5-(1-methylethyl)- (CA INDEX NAME)



L5 ANSWER 46 OF 70 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1994:30782 CAPLUS

DOCUMENT NUMBER: 120:30782

TITLE: 3-Substituted imidazo[1,5-a]- and imidazo[1,5-a]triazolo[1,5-c]quinoxalines and quinazolines with CNS activity

INVENTOR(S): Gammill, Ronald; Skaletzky, Louis L.

PATENT ASSIGNEE(S): Upjohn Co., USA

SOURCE: PCT Int. Appl., 316 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9312113	A1	19930624	WO 1992-US10388	19921207 <--
RW: AU, BB, BG, BR, CA, CS, FI, HU, JP, KP, KR, NO, NZ, PL, RO, RU, US				
AU 9340358	A	19930719	AU 1993-40358	19921207 <--
PRIORITY APPLN. INFO.:			US 1991-809564	A2 19911217 <--
			US 1992-840063	A2 19920221 <--
			WO 1992-US10388	A 19921207 <--


OTHER SOURCE(S): MARPAT 120:30782

IT 151448-30-5

RL: RCT (Reactant); RACT (Reactant or reagent)
(benzodiazepine receptor binding activity of)

RN 151448-30-5 CAPLUS

CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 7-fluoro-3-[5-(1-methoxycyclopentyl)-1,2,4-oxadiazol-3-yl]-5-(1-methylethyl)- (CA INDEX NAME)




IT 151448-13-4P 151448-15-6P 151448-16-7P

151448-17-8P 151448-20-3P 151448-21-4P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and benzodiazepine receptor binding activity of)


RN 151448-13-4 CAPLUS

CN Imidazo[1,5-a]quinoxaline-4(5H)-one, 3-[5-(1-methylcyclopropyl)-1,2,4-oxadiazol-3-yl]-5-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 151448-15-6 CAPLUS

CN Imidazo[1,5-a]quinoxaline-4(5H)-one, 7-fluoro-3-[5-(1-methylcyclopropyl)-1,2,4-oxadiazol-3-yl]-5-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 151448-16-7 CAPLUS

CN Imidazo[1,5-a]quinoxaline-4(5H)-one, 7-chloro-3-[5-(1-methylcyclopropyl)-1,2,4-oxadiazol-3-yl]-5-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 151448-17-8 CAPLUS


CN Imidazo[1,5-a]quinoxaline-4(5H)-one, 7-fluoro-3-[5-(2-methylcyclopropyl)-1,2,4-oxadiazol-3-yl]-5-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 151448-20-3 CAPLUS
 CN Imidazo[1,5-a]quinoxaline-4(5H)-one, 7-chloro-3-[5-(2-methylcyclopropyl)-1,2,4-oxadiazol-3-yl]-5-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 151448-21-4 CAPLUS
 CN Imidazo[1,5-a]quinoxaline-4(5H)-one, 3-[5-(1-methoxycyclopentyl)-1,2,4-oxadiazol-3-yl]-5-(1-methylethyl)- (9CI) (CA INDEX NAME)



L5 ANSWER 47 OF 70 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1994:23089 CAPLUS

DOCUMENT NUMBER: 120:23089

TITLE: Differential affinity of dihydroimidazoquinoxalines and diimidazoquinazolines to the $\alpha 1\beta 2\gamma 2$ and $\alpha 6\beta 2\gamma 2$ subtypes of cloned GABAA receptors

AUTHOR(S): Im, Wha Bin; Im, Haesook K.; Pregenzer, Jeffrey F.; Hamilton, Beverly J.; Carter, Donald B.; Jacobsen, E. Jon; TenBrink, Ruth E.; VonVoigtlander, Philip F.
 CORPORATE SOURCE: CNS Dis. Res., Upjohn Co., Kalamazoo, MI, 49001, USA
 SOURCE: British Journal of Pharmacology (1993), 110(2), 677-80

CODEN: BJPCBM; ISSN: 0007-1188

DOCUMENT TYPE: Journal


LANGUAGE: English

IT 148010-86-0, U 92330


RL: BIOL (Biological study)
 (benzodiazepine receptor $\alpha 1\beta 2\gamma 2$ and $\alpha 6\beta 2\gamma 2$ subtypes binding by, structure in relation to)

RN 148010-86-0 CAPLUS


CN Imidazo[1,5-a]quinoxaline, 5-acetyl-7-chloro-3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-4,5-dihydro- (9CI) (CA INDEX NAME)



L5 ANSWER 48 OF 70 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1993:671108 CAPLUS
 DOCUMENT NUMBER: 119:271108
 TITLE: The synthesis of 5'-[14C] and 3a,4-[13C2] labeled Panadiplon [U-78875; 3-(5'-cyclopropyl-1,2,4-oxadiazol-3-yl)-5-(1-methylethyl)imidazo[1,5a]quinoxalin-4(5H)-one]
 AUTHOR(S): Ackland, M. J.; Howard, M. R.; Dring, L. G.
 CORPORATE SOURCE: Upjohn Lab. Europe, Upjohn Ltd., Crawley/West Sussex, RH10 2LZ, UK
 SOURCE: Journal of Labelled Compounds and Radiopharmaceuticals (1993), 33(6), 517-25
 CODEN: JLCRD4; ISSN: 0362-4803
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 119:271108
 IT 151534-03-1P 151534-04-2P
 RL: SPN (Synthetic preparation); PREP (Preparation of preparation of)
 RN 151534-03-1 CAPLUS
 CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-5-14C)-5-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 151534-04-2 CAPLUS
 CN Imidazo[1,5-a]quinoxalin-4(5H)-one-4,5-13C2, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-5-(1-methylethyl)- (9CI) (CA INDEX NAME)



L5 ANSWER 49 OF 70 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1993:662028 CAPLUS

DOCUMENT NUMBER: 119:262028

TITLE: U-78,875 a novel analog of imidazoquinoxaline
anxiolytic

AUTHOR(S): Liou, Shyh Yuh; Ohyama, Miwako; Takahashi, Masaru;
Kunihara, Mineo

CORPORATE SOURCE: Tsukuba Res. Lab., Upjohn Pharm. Ltd., Japan

SOURCE: Yakubutsu, Seishin, Kodo (1991), 11(6), 433

CODEN: YSKODB; ISSN: 0285-5313

DOCUMENT TYPE: Journal


LANGUAGE: Japanese

IT 124423-84-3, U-78875

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmacol of, as anxiolytic)

RN 124423-84-3 CAPLUS

CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-5-(1-methylethyl)- (CA INDEX NAME)



L5 ANSWER 50 OF 70 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1993:472624 CAPLUS

DOCUMENT NUMBER: 119:72624

TITLE: Imidazo[1,5-a]quinoxalines

INVENTOR(S): Tenbrink, Ruth Elizabeth; Jacobsen, Eric Jon; Gammill, Ronald Bruce

PATENT ASSIGNEE(S): Upjohn Co., USA

SOURCE: PCT Int. Appl., 184 pp.

CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9222552	A1	19921223	WO 1992-US4434	19920601 <--
W: AU, BB, BG, BR, CA, CS, FI, HU, JP, KP, KR, LK, MG, MN, MW, NO, PL, RO, RU, SD, US				
RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, DE, DK, ES, FR, GA, GB, GN, GR, IT, LU, MC, ML, MR, NL, SE, SN, TD, TG				
CA 2110942	A1	19921223	CA 1992-2110942	19920601 <--
AU 9221704	A	19930112	AU 1992-21704	19920601 <--
AU 657986	B2	19950330		
EP 590022	A1	19940406	EP 1992-913318	19920601 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, MC, NL, SE				
JP 06508366	T	19940922	JP 1992-500877	19920601 <--
JP 3147902	B2	20010319	JP 1993-500877	19920601 <--
PRIORITY APPLN. INFO.:				
US 1991-715930 A 19910614 <--				
US 1992-843650 A2 19920228 <--				
WO 1992-US4434 A 19920601 <--				
OTHER SOURCE(S): CASREACT 119:72624; MARPAT 119:72624				
IT 148858-14-4P				
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)				
(preparation and deprotection of)				
RN 148858-14-4 CAPLUS				
CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 5-(1,1-dimethylethyl)-3-(4-fluorophenyl)- (CA INDEX NAME)				




IT 148010-51-9P 148010-52-0P 148010-53-1P
148010-54-2P 148010-55-3P 148010-56-4P
148010-57-5P 148010-58-6P 148010-59-7P
148010-62-2P 148010-72-4P 148010-73-5P
148010-75-7P 148010-76-8P 148010-77-9P
148010-78-0P 148010-79-1P 148010-80-4P
148010-81-5P 148010-82-6P 148010-84-8P
148010-85-9P 148010-86-0P 148010-87-1P
148010-90-6P 148010-91-7P 148010-92-8P
148010-93-9P 148010-95-1P 148010-97-3P
148010-99-5P 148011-00-1P 148011-01-2P
148011-02-3P 148011-03-4P 148011-04-5P
148011-05-6P 148011-06-7P 148011-07-8P
148011-10-3P 148011-11-4P 148011-12-5P
148011-14-7P 148011-15-8P 148011-16-9P
148011-18-1P 148011-20-5P 148011-21-6P
148011-22-7P 148011-23-8P 148011-24-9P
148011-25-0P 148011-26-1P 148011-27-2P
148011-28-3P 148011-29-4P 148011-30-7P
148011-31-8P 148011-32-9P 148011-33-0P
148011-34-1P 148011-35-2P 148011-36-3P
148011-37-4P 148011-38-5P 148011-39-6P
148011-40-9P 148011-41-0P 148011-42-1P
148011-43-2P 148011-44-3P 148011-45-4P

148011-46-5P 148011-47-6P 148011-48-7P
 148011-49-8P 148011-50-1P 148011-51-2P
 148011-52-3P 148011-53-4P 148011-54-5P
 148011-55-6P 148011-56-7P 148011-57-8P
 148011-58-9P 148011-59-0P 148011-60-3P
 148011-61-4P 148011-62-5P 148011-63-6P
 148011-64-7P 148011-65-8P 148011-68-1P
 148011-69-2P 148011-72-7P 148011-73-8P
 148011-74-9P 148011-79-4P 148011-80-7P
 148011-81-8P 148011-85-2P 148011-86-3P
 148011-95-4P 148011-96-5P 148011-98-7P
 148011-99-8P 148012-02-6P 148012-03-7P
 148012-04-8P 148012-05-9P 148012-06-0P
 148012-07-1P 148012-08-2P 148012-09-3P
 148012-10-6P 148012-11-7P 148012-12-8P
 148012-14-0P 148012-15-1P 148012-17-3P
 148012-19-5P 148012-21-9P 148012-22-0P
 148012-23-1P 148012-26-4P 148012-27-5P
 148012-30-0P 148012-31-1P 148012-32-2P
 148012-33-3P 148012-34-4P 148012-35-5P
 148012-36-6P 148012-37-7P 148012-38-8P
 148012-39-9P 148012-40-2P 148012-41-3P
 148012-42-4P 148012-44-6P 148012-46-8P
 148012-47-9P 148012-48-0P 148012-49-1P
 148012-50-4P 148012-51-5P 148012-52-6P
 148012-53-7P 148012-54-8P 148012-55-9P
 148012-56-0P 148012-57-1P 148012-58-2P
 148012-59-3P 148012-60-6P 148012-61-7P
 148012-62-8P 148012-63-9P 148012-64-0P
 148012-65-1P 148012-67-3P 148012-69-5P
 148012-71-9P 148012-72-0P 148012-73-1P
 148012-74-2P 148012-75-3P 148012-76-4P
 148012-77-5P 148012-78-6P 148012-80-0P
 148012-82-2P 148012-83-3P 148012-85-5P
 148858-22-4P 148858-23-5P 148858-28-0P
 148858-29-1P 148858-30-4P 148858-34-8P
 148858-39-3P 148858-43-9P 148858-44-0P
 148858-45-1P 148858-48-4P 148858-50-8P
 148858-51-9P 148858-52-0P 148858-53-1P
 148858-54-2P 148858-55-3P 148858-56-4P
 148858-57-5P 148858-58-6P 148858-59-7P
 148858-60-0P 148858-61-1P 148858-63-3P
 148858-64-4P 148858-65-5P 148858-66-6P
 148858-67-7P 148858-68-8P 148858-69-9P
 148858-95-1P 148858-96-2P 148858-97-3P
 148858-98-4P 148858-99-5P 148859-00-1P
 148859-08-9P 148859-09-0P 148859-10-3P
 148859-11-4P 148859-12-5P 148859-13-6P
 148859-14-7P 148859-15-8P 148859-16-9P
 148859-17-0P 148859-18-1P 148859-19-2P
 148859-20-5P 148859-21-6P 148859-22-7P
 148859-23-8P 148859-24-9P 148859-25-0P
 148859-26-1P 148859-27-2P 148859-28-3P
 148859-29-4P 148859-30-7P 148859-31-8P
 148859-35-2P 148859-36-3P 148859-37-4P
 148859-38-5P


RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)

RN 148010-51-9 CAPLUS
 CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxamide, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-N,N,4,4-tetramethyl- (CA INDEX NAME)




RN 148010-52-0 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carbothioic acid, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-4,4-dimethyl-, S-phenyl ester (CA INDEX NAME)




RN 148010-53-1 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxamide, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-4,4-dimethyl- (CA INDEX NAME)




RN 148010-54-2 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxamide, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-N,N-diethyl-4,4-dimethyl- (CA INDEX NAME)




RN 148010-55-3 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxamide, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-N,4,4-trimethyl- (CA INDEX NAME)




RN 148010-56-4 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxamide, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-N-ethyl-4,4-dimethyl- (CA INDEX NAME)




RN 148010-57-5 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carbothioic acid, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-4,4-dimethyl-, S-methyl ester (CA INDEX NAME)




RN 148010-58-6 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carbothioic acid, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-4,4-dimethyl-, S-ethyl ester (CA INDEX NAME)




RN 148010-59-7 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxaldehyde, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-4,4-dimethyl- (CA INDEX NAME)




RN 148010-62-2 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 7-chloro-3-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-4,5-dihydro-5-[(2,4,6-trimethyl-1-piperazinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 148010-72-4 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 6-fluoro-4,5-dihydro-3-[5-(1-methylethyl)-1,2,4-oxadiazol-3-yl]-5-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 148010-73-5 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 7-fluoro-4,4-dimethyl-3-[5-(1-methylethyl)-1,2,4-oxadiazol-3-yl]-5-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 148010-75-7 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxylic acid, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 148010-76-8 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 5-benzoyl-3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-4,5-dihydro- (9CI) (CA INDEX NAME)




RN 148010-77-9 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 5-acetyl-3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-4,5-dihydro- (9CI) (CA INDEX NAME)




RN 148010-78-0 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-5-(2-furanylcarbonyl)-4,5-dihydro- (9CI) (CA INDEX NAME)




RN 148010-79-1 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxylic acid, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-6-methyl-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 148010-80-4 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 7-chloro-3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-4,5-dihydro-5-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 148010-81-5 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxamide, 7-chloro-3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-N,N-dimethyl- (CA INDEX NAME)




RN 148010-82-6 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxylic acid, 7-chloro-3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 148010-84-8 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 5-benzoyl-7-chloro-3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-4,5-dihydro- (9CI) (CA INDEX NAME)




RN 148010-85-9 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxylic acid, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-6-fluoro-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 148010-86-0 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 5-acetyl-7-chloro-3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-4,5-dihydro- (9CI) (CA INDEX NAME)




RN 148010-87-1 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 7-chloro-3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-4,5-dihydro-5-(1-oxopropyl)- (9CI) (CA INDEX NAME)




RN 148010-90-6 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 7-chloro-4,5-dihydro-3-[5-(1-methylethyl)-1,2,4-oxadiazol-3-yl]-5-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 148010-91-7 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxamide, 7-chloro-N,N-dimethyl-3-[5-(1-methylethyl)-1,2,4-oxadiazol-3-yl]- (CA INDEX NAME)




RN 148010-92-8 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 7-chloro-3-(5-ethyl-1,2,4-oxadiazol-3-yl)-4,5-dihydro-5-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 148010-93-9 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxamide, 7-chloro-3-(5-ethyl-1,2,4-oxadiazol-3-yl)-N,N-dimethyl- (CA INDEX NAME)




RN 148010-95-1 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 7-fluoro-4,5-dihydro-3-[5-(1-methylethyl)-1,2,4-oxadiazol-3-yl]-5-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 148010-97-3 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 6-chloro-4,5-dihydro-3-[5-(1-methylethyl)-1,2,4-oxadiazol-3-yl]-5-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 148010-99-5 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 6-chloro-3-(5-ethyl-1,2,4-oxadiazol-3-yl)-4,5-dihydro-5-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 148011-00-1 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxamide, 6-chloro-N,N-dimethyl-3-[5-(1-methylethyl)-1,2,4-oxadiazol-3-yl]- (CA INDEX NAME)




RN 148011-01-2 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 6-chloro-4,5-dihydro-3-[3-(1-methylethyl)-1,2,4-oxadiazol-5-yl]-5-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 148011-02-3 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxamide, 6-chloro-3-(5-ethyl-1,2,4-oxadiazol-3-yl)-N,N-dimethyl- (CA INDEX NAME)




RN 148011-03-4 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxamide, 6-chloro-N,N-dimethyl-3-[3-(1-methylethyl)-1,2,4-oxadiazol-5-yl]- (CA INDEX NAME)




RN 148011-04-5 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 7-chloro-3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-4,5-dihydro-4,4-dimethyl-5-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 148011-05-6 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxamide, 7-chloro-3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-N,N,4,4-tetramethyl- (CA INDEX NAME)




RN 148011-06-7 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 7-chloro-4,5-dihydro-4,4-dimethyl-3-[5-(1-methylethyl)-1,2,4-oxadiazol-3-yl]-5-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 148011-07-8 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxamide, 7-chloro-N,N,4,4-tetramethyl-3-[5-(1-methylethyl)-1,2,4-oxadiazol-3-yl]- (CA INDEX NAME)




RN 148011-10-3 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxamide, 7-chloro-N,N,4,4-tetramethyl-3-[3-(1-methylethyl)-1,2,4-oxadiazol-5-yl]- (CA INDEX NAME)




RN 148011-11-4 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 7-chloro-3-(5-ethyl-1,2,4-oxadiazol-3-yl)-4,5-dihydro-4,4-dimethyl-5-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 148011-12-5 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxamide, 7-chloro-3-(5-ethyl-1,2,4-oxadiazol-3-yl)-N,N,4,4-tetramethyl- (CA INDEX NAME)




RN 148011-14-7 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 6-chloro-4,5-dihydro-4,4-dimethyl-3-[5-(1-methylethyl)-1,2,4-oxadiazol-3-yl]-5-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 148011-15-8 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxamide, 6-chloro-N,N,4,4-tetramethyl-3-[5-(1-methylethyl)-1,2,4-oxadiazol-3-yl]- (CA INDEX NAME)




RN 148011-16-9 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 6-chloro-3-(5-ethyl-1,2,4-oxadiazol-3-yl)-4,5-dihydro-4,4-dimethyl-5-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 148011-18-1 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxamide, 6-chloro-3-(5-ethyl-1,2,4-oxadiazol-3-yl)-N,N,4,4-tetramethyl- (CA INDEX NAME)




RN 148011-20-5 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-4,5-dihydro-5-(1-oxopropyl)- (9CI) (CA INDEX NAME)




RN 148011-21-6 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-acetic acid, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)- α -oxo-, ethyl ester (CA INDEX NAME)




RN 148011-22-7 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 5-(2-chlorobenzoyl)-3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-4,5-dihydro- (9CI) (CA INDEX NAME)




RN 148011-23-8 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-4,5-dihydro-5-(4-morpholinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 148011-24-9 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-5-[(3,5-dimethyl-1H-pyrazol-1-yl)carbonyl]-4,5-dihydro- (9CI) (CA INDEX NAME)




RN 148011-25-0 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 5-acetyl-3-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-4,5-dihydro-4,4-dimethyl- (9CI) (CA INDEX NAME)




RN 148011-26-1 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 5-acetyl-3-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-4,5-dihydro- (9CI) (CA INDEX NAME)




RN 148011-27-2 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxamide, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-6-fluoro-N,N-dimethyl- (CA INDEX NAME)




RN 148011-28-3 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-6-fluoro-4,5-dihydro-5-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 148011-29-4 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 5-acetyl-3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-6-fluoro-4,5-dihydro- (9CI) (CA INDEX NAME)




RN 148011-30-7 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 5-benzoyl-3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-6-fluoro-4,5-dihydro- (9CI) (CA INDEX NAME)




RN 148011-31-8 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 5-acetyl-3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-7-fluoro-4,5-dihydro- (9CI) (CA INDEX NAME)




RN 148011-32-9 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxamide, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-7-fluoro-N,N-dimethyl- (CA INDEX NAME)




RN 148011-33-0 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-7-fluoro-4,5-dihydro-5-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 148011-34-1 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 5-benzoyl-3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-7-fluoro-4,5-dihydro- (9CI) (CA INDEX NAME)




RN 148011-35-2 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-7-fluoro-4,5-dihydro-5-(1H-imidazol-1-ylcarbonyl)- (9CI) (CA INDEX NAME)




RN 148011-36-3 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-7-fluoro-4,5-dihydro-5-(4-morpholinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 148011-37-4 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 5-acetyl-3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-4,5-dihydro-4,4-dimethyl- (9CI) (CA INDEX NAME)




RN 148011-38-5 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxylic acid, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-4,4-dimethyl-, methyl ester (CA INDEX NAME)




RN 148011-39-6 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxylic acid, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-4,4-dimethyl-, 1-methylethyl ester (CA INDEX NAME)




RN 148011-40-9 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-acetic acid, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-4,4-dimethyl-α-oxo-, ethyl ester (CA INDEX NAME)




RN 148011-41-0 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxylic acid, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-4,4-dimethyl-, phenyl ester (CA INDEX NAME)




RN 148011-42-1 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-4,5-dihydro-4,4-dimethyl-5-(oxo-1-pyrrolidinylacetyl)- (9CI) (CA INDEX NAME)




RN 148011-43-2 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 6-chloro-3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-4,5-dihydro-5-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 148011-44-3 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxamide, 6-chloro-3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-N,N-dimethyl- (CA INDEX NAME)




RN 148011-45-4 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carbothioic acid, 6-chloro-3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-, S-methyl ester (CA INDEX NAME)




RN 148011-46-5 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-4,5-dihydro-5-(trifluoroacetyl)- (9CI) (CA INDEX NAME)




RN 148011-47-6 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-4,5-dihydro-5-(1H-imidazol-1-ylcarbonyl)- (9CI) (CA INDEX NAME)




RN 148011-48-7 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-4,5-dihydro-5-(2-pyridinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 148011-49-8 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-4,5-dihydro-5-(2-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 148011-50-1 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxamide, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-N-phenyl- (CA INDEX NAME)




RN 148011-51-2 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxamide, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-N,N-dimethyl- (CA INDEX NAME)




RN 148011-52-3 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxamide, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-N-methyl- (CA INDEX NAME)




RN 148011-53-4 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxamide, N-(2-chlorophenyl)-3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)- (CA INDEX NAME)




RN 148011-54-5 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxamide, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-N-(1-methylethyl)- (CA INDEX NAME)




RN 148011-55-6 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxamide, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-N,N-diethyl- (CA INDEX NAME)




RN 148011-56-7 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-4,5-dihydro-5-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 148011-57-8 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carbothioic acid, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-, S-phenyl ester (CA INDEX NAME)




RN 148011-58-9 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carbothioic acid, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-, S-ethyl ester (CA INDEX NAME)




RN 148011-59-0 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxamide, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-N-ethyl- (CA INDEX NAME)




RN 148011-60-3 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxamide, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)- (CA INDEX NAME)




RN 148011-61-4 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carbothioic acid, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-, S-methyl ester (CA INDEX NAME)




RN 148011-62-5 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-4,5-dihydro-4,4-dimethyl-5-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 148011-63-6 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(5-cyclopentyl-1,2,4-oxadiazol-3-yl)-4,5-dihydro-5-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 148011-64-7 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 4,5-dihydro-4,4-dimethyl-3-[3-(1-methylethyl)-1,2,4-oxadiazol-5-yl]-5-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)



RN 148011-65-8 CAPLUS


CN Imidazo[1,5-a]quinoxaline, 7-chloro-4,5-dihydro-4,4-dimethyl-3-[3-(1-methylethyl)-1,2,4-oxadiazol-5-yl]-5-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)



RN 148011-68-1 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 4,5-dihydro-4-methyl-3-[5-(1-methylethyl)-1,2,4-oxadiazol-3-yl]-5-(1-pyrrolidinylcarbonyl)-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 148011-69-2 CAPLUS


CN Imidazo[1,5-a]quinoxaline, 4,5-dihydro-4-methyl-3-[3-(1-methylethyl)-1,2,4-oxadiazol-5-yl]-5-(1-pyrrolidinylcarbonyl)-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 148011-72-7 CAPLUS

CN Spiro[cyclopentane-1,4'-(5'H)-imidazo[1,5-a]quinoxaline], 3'-[3-(1-methylethyl)-1,2,4-oxadiazol-5-yl]-5'-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 148011-73-8 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 7-chloro-4,5-dihydro-3-[3-(1-methylethyl)-1,2,4-oxadiazol-5-yl]-5-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 148011-74-9 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 7-fluoro-4,5-dihydro-3-[3-(1-methylethyl)-1,2,4-oxadiazol-5-yl]-5-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)



RN 148011-79-4 CAPLUS


CN Spiro[cyclopentane-1,4'-(5'H)-imidazo[1,5-a]quinoxaline], 3'-[5-(1-methylethyl)-1,2,4-oxadiazol-3-yl]-5'-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)



RN 148011-80-7 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 7-fluoro-4,5-dihydro-4-methyl-3-[3-(1-methylethyl)-1,2,4-oxadiazol-5-yl]-5-(1-pyrrolidinylcarbonyl)-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 148011-81-8 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 7-fluoro-4,5-dihydro-4-methyl-3-[5-(1-methylethyl)-1,2,4-oxadiazol-3-yl]-5-(1-pyrrolidinylcarbonyl)-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 148011-85-2 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 4-ethyl-4,5-dihydro-3-[5-(1-methylethyl)-1,2,4-oxadiazol-3-yl]-5-(1-pyrrolidinylcarbonyl)-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 148011-86-3 CAPLUS


CN Imidazo[1,5-a]quinoxaline, 4-ethyl-4,5-dihydro-3-[3-(1-methylethyl)-1,2,4-oxadiazol-5-yl]-5-(1-pyrrolidinylcarbonyl)-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 148011-95-4 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(2-benzoxazolyl)-7-fluoro-4,5-dihydro-5-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 148011-96-5 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 6-chloro-4,5-dihydro-4,4-dimethyl-3-[5-(1-methylethyl)-1,2,4-oxadiazol-3-yl]-5-(4-morpholinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 148011-98-7 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxamide, 4,4-dimethyl-3-[5-(1-methylethyl)-1,2,4-oxadiazol-3-yl]-N,N-dipropyl- (CA INDEX NAME)




RN 148011-99-8 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 7-fluoro-4,5-dihydro-3-phenyl-5-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 148012-02-6 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(2-benzoxazolyl)-4,5-dihydro-5-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 148012-03-7 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 7-fluoro-3-(4-fluorophenyl)-4,5-dihydro-4,4-dimethyl-5-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 148012-04-8 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-[5-(1,1-dimethylethyl)-1,2,4-oxadiazol-3-yl]-7-fluoro-4,5-dihydro-5-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 148012-05-9 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-[5-(1,1-dimethylethyl)-1,2,4-oxadiazol-3-yl]-4,5-dihydro-5-(4-morpholinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 148012-06-0 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-[5-(1,1-dimethylethyl)-1,2,4-oxadiazol-3-yl]-7-fluoro-4,5-dihydro-4,4-dimethyl-5-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 148012-07-1 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-[5-(1,1-dimethylethyl)-1,2,4-oxadiazol-3-yl]-6-fluoro-4,5-dihydro-5-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 148012-08-2 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxamide, 3-(5-ethyl-1,2,4-oxadiazol-3-yl)-N,N-dimethyl- (CA INDEX NAME)




RN 148012-09-3 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxamide, 3-(5-ethyl-1,2,4-oxadiazol-3-yl)-N,N,4,4-tetramethyl- (CA INDEX NAME)




RN 148012-10-6 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(5-ethyl-1,2,4-oxadiazol-3-yl)-4,5-dihydro-4,4-dimethyl-5-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 148012-11-7 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(5-ethyl-1,2,4-oxadiazol-3-yl)-4,5-dihydro-5-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 148012-12-8 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 4,5-dihydro-3-[5-(1-methylethyl)-1,2,4-oxadiazol-3-yl]-5-(1-piperazinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 148012-14-0 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 4,5-dihydro-3-[3-(1-methylethyl)-1,2,4-oxadiazol-5-yl]-5-(1-piperazinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 148012-15-1 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(5-ethyl-1,2,4-oxadiazol-3-yl)-4,5-dihydro-5-(1-piperazinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 148012-17-3 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 4,5-dihydro-4,4-dimethyl-3-[5-(1-methylethyl)-1,2,4-oxadiazol-3-yl]-5-(1-piperazinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 148012-19-5 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxamide, N,N,4,7-pentamethyl-3-[5-(1-methylethyl)-1,2,4-oxadiazol-3-yl]- (CA INDEX NAME)




RN 148012-21-9 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 4,5-dihydro-7-methyl-3-[5-(1-methylethyl)-1,2,4-oxadiazol-3-yl]-5-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 148012-22-0 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxamide, 3-[5-(1,1-dimethylethyl)-1,2,4-oxadiazol-3-yl]-N,N-dimethyl- (CA INDEX NAME)




RN 148012-23-1 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxamide, 3-[5-(1,1-dimethylethyl)-1,2,4-oxadiazol-3-yl]-N,N,4,4-tetramethyl- (CA INDEX NAME)




RN 148012-26-4 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 4,5-dihydro-4,4-dimethyl-3-[5-(1-methylethyl)-1,2,4-oxadiazol-3-yl]-5-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 148012-27-5 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxamide, N,N,4,4-tetramethyl-3-[5-(1-methylethyl)-1,2,4-oxadiazol-3-yl]- (CA INDEX NAME)




RN 148012-30-0 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxamide, N,N-dimethyl-3-[5-(1-methylethyl)-1,2,4-oxadiazol-3-yl]- (CA INDEX NAME)




RN 148012-31-1 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 4,5-dihydro-4,4-dimethyl-3-(4-methylphenyl)-5-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 148012-32-2 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxamide, N,N,4,4-tetramethyl-3-(4-methylphenyl)- (CA INDEX NAME)




RN 148012-33-3 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(4-fluorophenyl)-4,5-dihydro-4,4-dimethyl-5-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 148012-34-4 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxamide, 3-(4-fluorophenyl)-N,N-dimethyl- (CA INDEX NAME)




RN 148012-35-5 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 4,5-dihydro-3-phenyl-5-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 148012-36-6 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 4,5-dihydro-3-[5-(1-methylethyl)-1,2,4-oxadiazol-3-yl]-5-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 148012-37-7 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxamide, N,N-dimethyl-3-[3-(1-methylethyl)-1,2,4-oxadiazol-5-yl]- (CA INDEX NAME)




RN 148012-38-8 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxamide, N,N,4,4-tetramethyl-3-[3-(1-methylethyl)-1,2,4-oxadiazol-5-yl]- (CA INDEX NAME)




RN 148012-39-9 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxamide, N,N,4,4-tetramethyl-3-phenyl-
(CA INDEX NAME)




RN 148012-40-2 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxamide, 6-chloro-N,N,4,4-tetramethyl-3-phenyl-
(CA INDEX NAME)




RN 148012-41-3 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 7-chloro-4,5-dihydro-4,4-dimethyl-3-phenyl-5-(1-pyrrolidinylcarbonyl)- (9CI)
(CA INDEX NAME)




RN 148012-42-4 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxamide, 7-chloro-N,N,4,4-tetramethyl-3-phenyl- (CA INDEX NAME)




RN 148012-44-6 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 4,5-dihydro-6-methyl-3-[5-(1-methylethyl)-1,2,4-oxadiazol-3-yl]-5-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 148012-46-8 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxamide, N,N,6-trimethyl-3-[5-(1-methylethyl)-1,2,4-oxadiazol-3-yl]- (CA INDEX NAME)




RN 148012-47-9 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-[5-(1,1-dimethylethyl)-1,2,4-oxadiazol-3-yl]-4,5-dihydro-5-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 148012-48-0 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-[5-(1,1-dimethylethyl)-1,2,4-oxadiazol-3-yl]-4,5-dihydro-4,4-dimethyl-5-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 148012-49-1 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 7-chloro-3-[5-(1,1-dimethylethyl)-1,2,4-oxadiazol-3-yl]-4,5-dihydro-5-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 148012-50-4 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxamide, 7-chloro-3-[5-(1,1-dimethylethyl)-1,2,4-oxadiazol-3-yl]-N,N-dimethyl- (CA INDEX NAME)




RN 148012-51-5 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxamide, 7-chloro-3-[5-(1,1-dimethylethyl)-1,2,4-oxadiazol-3-yl]-N,N,4,4-tetramethyl- (CA INDEX NAME)




RN 148012-52-6 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 6-chloro-3-[5-(1,1-dimethylethyl)-1,2,4-oxadiazol-3-yl]-4,5-dihydro-4,4-dimethyl-5-(1-pyrrolidinylcarbonyl)- (9CI)
(CA INDEX NAME)




RN 148012-53-7 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxamide, 6-chloro-3-[5-(1,1-dimethylethyl)-1,2,4-oxadiazol-3-yl]-N,N,4,4-tetramethyl- (CA INDEX NAME)




RN 148012-54-8 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 6-chloro-3-[5-(1,1-dimethylethyl)-1,2,4-oxadiazol-3-yl]-4,5-dihydro-5-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 148012-55-9 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxamide, 6-chloro-3-[5-(1,1-dimethylethyl)-1,2,4-oxadiazol-3-yl]-N,N-dimethyl- (CA INDEX NAME)




RN 148012-56-0 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(4-fluorophenyl)-4,5-dihydro-5-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 148012-57-1 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxamide, N,N-dimethyl-3-phenyl- (CA INDEX NAME)




RN 148012-58-2 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 4,5-dihydro-3-phenyl-5-(1-piperazinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 148012-59-3 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 4,5-dihydro-3-(4-methylphenyl)-5-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 148012-60-6 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 5-benzoyl-3-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-4,5-dihydro- (9CI) (CA INDEX NAME)




RN 148012-61-7 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-4,5-dihydro-5-(1-oxopropyl)- (9CI) (CA INDEX NAME)




RN 148012-62-8 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxylic acid, 3-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-, phenyl ester (CA INDEX NAME)




RN 148012-63-9 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxylic acid, 3-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-, ethyl ester (CA INDEX NAME)




RN 148012-64-0 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxamide, 3-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-N,N-diethyl- (CA INDEX NAME)




RN 148012-65-1 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-5-(2-furanylcarbonyl)-4,5-dihydro- (9CI) (CA INDEX NAME)




RN 148012-67-3 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 4,5-dihydro-3-[5-(2-methylpropyl)-1,2,4-oxadiazol-3-yl]-5-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 148012-69-5 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 4,5-dihydro-5-(1-pyrrolidinylcarbonyl)-3-[5-(3,3,3-trifluoropropyl)-1,2,4-oxadiazol-3-yl]- (9CI) (CA INDEX NAME)




RN 148012-71-9 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 7-fluoro-4,5-dihydro-3-[5-(2-methylpropyl)-1,2,4-oxadiazol-3-yl]-5-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 148012-72-0 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 7-fluoro-4,5-dihydro-5-(1-pyrrolidinylcarbonyl)-3-[5-(3,3,3-trifluoro-2-methylpropyl)-1,2,4-oxadiazol-3-yl]- (9CI) (CA INDEX NAME)




RN 148012-73-1 CAPLUS

Imidazo[1,5-a]quinoxaline, 4,5-dihydro-5-(1-pyrrolidinylcarbonyl)-3-[5-(3,3,3-trifluoro-2-methylpropyl)-1,2,4-oxadiazol-3-yl]- (9CI) (CA INDEX NAME)



RN 148012-74-2 CAPLUS


CN Imidazo[1,5-a]quinoxaline, 4,5-dihydro-5-(4-morpholinylcarbonyl)-3-[5-(3,3,3-trifluoro-2-methylpropyl)-1,2,4-oxadiazol-3-yl]- (9CI) (CA INDEX NAME)



RN 148012-75-3 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(5-cyclopentyl-1,2,4-oxadiazol-3-yl)-7-fluoro-4,5-dihydro-4-methyl-5-(4-morpholinylcarbonyl)-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 148012-76-4 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 7-fluoro-4,5-dihydro-4-methyl-3-[5-(1-

methylethyl)-1,2,4-oxadiazol-3-yl]-5-(1-pyrrolidinylcarbonyl)-, (R)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 148012-77-5 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(5-cyclopentyl-1,2,4-oxadiazol-3-yl)-7-fluoro-4,5-dihydro-4-methyl-5-(4-morpholinylacetyl)-, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 148012-78-6 CAPLUS

CN Piperazine, 1-[[3-(5-cyclopentyl-1,2,4-oxadiazol-3-yl)-7-fluoro-4-methylimidazo[1,5-a]quinoxalin-5(4H)-yl]acetyl]-, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 148012-80-0 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(5-cyclopentyl-1,2,4-oxadiazol-3-yl)-7-fluoro-4,5-dihydro-4-methyl-5-(1-pyrrolidinylacetyl)-, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 148012-82-2 CAPLUS

CN Pyrrolidine, 1-[[3-(5-cyclopentyl-1,2,4-oxadiazol-3-yl)-7-fluoro-4-methylimidazo[1,5-a]quinoxalin-5(4H)-yl]acetyl]-, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 148012-83-3 CAPLUS


CN Imidazo[1,5-a]quinoxaline, 7-fluoro-4,5-dihydro-4-methyl-3-[5-(1-methylcyclopropyl)-1,2,4-oxadiazol-3-yl]-5-(2-pyridinylmethyl)-, (R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 148012-85-5 CAPLUS


CN Imidazo[1,5-a]quinoxaline, 7-fluoro-4,5-dihydro-4-methyl-3-[5-(2-methylcyclopropyl)-1,2,4-oxadiazol-3-yl]-5-(2-pyridinylcarbonyl)- (9CI) (CA INDEX NAME)



RN 148858-22-4 CAPLUS


CN Imidazo[1,5-a]quinoxaline, 5-benzoyl-3-[5-(1,1-dimethylethyl)-1,2,4-

oxadiazol-3-yl]-4,5-dihydro- (9CI) (CA INDEX NAME)




RN 148858-23-5 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 5-benzoyl-3-[5-(1,1-dimethylethyl)-1,2,4-oxadiazol-3-yl]-7-fluoro-4,5-dihydro- (9CI) (CA INDEX NAME)




RN 148858-28-0 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxylic acid, 3-[5-(1,1-dimethylethyl)-1,2,4-oxadiazol-3-yl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 148858-29-1 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxylic acid, 3-[5-(1,1-dimethylethyl)-1,2,4-oxadiazol-3-yl]-7-fluoro-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 148858-30-4 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxylic acid, 3-(2-benzoxazolyl)-, methyl ester (CA INDEX NAME)




RN 148858-34-8 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[[3-[5-(1,1-dimethylethyl)-1,2,4-oxadiazol-3-yl]imidazo[1,5-a]quinoxalin-5(4H)-yl]carbonyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 148858-39-3 CAPLUS


CN Imidazo[1,5-a]quinoxaline, 4,5-dihydro-3-(2-oxazolyl)-5-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)



RN 148858-43-9 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-7-fluoro-4,5-dihydro-4-methyl-5-(1-pyrrolidinylcarbonyl)-, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 148858-44-0 CAPLUS


CN Imidazo[1,5-a]quinoxaline, 7-fluoro-4,5-dihydro-4-methyl-3-[5-(1-methylcyclopropyl)-1,2,4-oxadiazol-3-yl]-5-(1-pyrrolidinylcarbonyl)-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 148858-45-1 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-7-fluoro-4,5-dihydro-5-(4-morpholinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 148858-48-4 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-6-fluoro-4,5-dihydro-5-(4-morpholinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 148858-50-8 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-5-[(2,6-dimethyl-4-morpholinyl)carbonyl]-7-fluoro-4,5-dihydro- (9CI) (CA INDEX NAME)




RN 148858-51-9 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-[5-(1,1-dimethylethyl)-1,2,4-oxadiazol-3-yl]-4,5-dihydro-6-methyl-5-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 148858-52-0 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-[5-(1,1-dimethylethyl)-1,2,4-oxadiazol-3-yl]-4,5-dihydro-5-(1-piperazinylicarbonyl)- (9CI) (CA INDEX NAME)




RN 148858-53-1 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-[5-(1,1-dimethylethyl)-1,2,4-oxadiazol-3-yl]-5-(3-fluorobenzoyl)-4,5-dihydro- (9CI) (CA INDEX NAME)




RN 148858-54-2 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxylic acid, 3-[5-(1,1-dimethylethyl)-1,2,4-oxadiazol-3-yl]-, methyl ester (CA INDEX NAME)




RN 148858-55-3 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxylic acid, 7-chloro-3-[5-(1,1-dimethylethyl)-1,2,4-oxadiazol-3-yl]-, methyl ester (CA INDEX NAME)




RN 148858-56-4 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxylic acid, 7-chloro-3-[5-(1,1-dimethylethyl)-1,2,4-oxadiazol-3-yl]-4,4-dimethyl-, methyl ester (CA INDEX NAME)




RN 148858-57-5 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 7-chloro-3-[5-(1,1-dimethylethyl)-1,2,4-oxadiazol-3-yl]-4,5-dihydro-4,4-dimethyl-5-(4-morpholinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 148858-58-6 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-[5-(1,1-dimethylethyl)-1,2,4-oxadiazol-3-yl]-4,5-dihydro-4,4-dimethyl-5-(4-morpholinyl carbonyl)- (9CI) (CA INDEX NAME)




RN 148858-59-7 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-[5-(1,1-dimethylethyl)-1,2,4-oxadiazol-3-yl]-4,5-dihydro-5-(4-nitrobenzoyl)- (9CI) (CA INDEX NAME)




RN 148858-60-0 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 5-(3-chlorobenzoyl)-3-[5-(1,1-dimethylethyl)-1,2,4-oxadiazol-3-yl]-4,5-dihydro- (9CI) (CA INDEX NAME)




RN 148858-61-1 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-[5-(1,1-dimethylethyl)-1,2,4-oxadiazol-3-yl]-5-(2-fluorobenzoyl)-4,5-dihydro- (9CI) (CA INDEX NAME)




RN 148858-63-3 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(4-fluorophenyl)-4,5-dihydro-5-(4-morpholinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 148858-64-4 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 5-(3-fluorobenzoyl)-3-(4-fluorophenyl)-4,5-dihydro- (9CI) (CA INDEX NAME)




RN 148858-65-5 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxylic acid, 3-(4-fluorophenyl)-, methyl ester (CA INDEX NAME)




RN 148858-66-6 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxamide, N-(1,1-dimethylethyl)-3-(4-fluorophenyl)- (CA INDEX NAME)




RN 148858-67-7 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(4-fluorophenyl)-4,5-dihydro-5-[4-(trifluoromethyl)benzoyl]- (9CI) (CA INDEX NAME)




RN 148858-68-8 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxamide, 3-(4-fluorophenyl)- (CA INDEX NAME)




RN 148858-69-9 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxamide, N-ethyl-3-(4-fluorophenyl)- (CA INDEX NAME)




RN 148858-95-1 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 7-chloro-3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-4,5-dihydro-5-(4-morpholinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 148858-96-2 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 7-chloro-3-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-4,5-dihydro-5-[(4-morpholinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 148858-97-3 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 7-chloro-3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-4,5-dihydro-5-[(4-methyl-1-piperazinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 148858-98-4 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 7-chloro-3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-5-[(2,6-dimethyl-4-morpholinyl)carbonyl]-4,5-dihydro- (9CI) (CA INDEX NAME)




RN 148858-99-5 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 7-chloro-3-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-4,5-dihydro-5-[(4-methyl-1-piperazinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 148859-00-1 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxylic acid, 7-chloro-3-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-, 1-methylethyl ester (CA INDEX NAME)




RN 148859-08-9 CAPLUS


CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxamide, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-N-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)




RN 148859-09-0 CAPLUS
 CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxamide, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-N-[2-(diethylamino)ethyl]- (CA INDEX NAME)



RN 148859-10-3 CAPLUS
 CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxamide, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-N-(2-methoxyethyl)- (CA INDEX NAME)




RN 148859-11-4 CAPLUS
 CN Imidazo[1,5-a]quinoxaline, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-5-[(3,5-dimethyl-1-piperazinyl)carbonyl]-4,5-dihydro- (9CI) (CA INDEX NAME)




RN 148859-12-5 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxylic acid, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-, 2-methoxyethyl ester (CA INDEX NAME)




RN 148859-13-6 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxamide, 7-chloro-3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-N-ethyl- (CA INDEX NAME)




RN 148859-14-7 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxamide, 7-chloro-3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)- (CA INDEX NAME)




RN 148859-15-8 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxylic acid, 3-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-7-methyl-, 1-methylethyl ester (CA INDEX NAME)




RN 148859-16-9 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-4,5-dihydro-7-methyl-5-(4-morpholinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 148859-17-0 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-5-[(3,5-dimethyl-1-piperazinyl)carbonyl]-4,5-dihydro-7-methyl- (9CI) (CA INDEX NAME)




RN 148859-18-1 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxamide, 3-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-7-methyl- (CA INDEX NAME)




RN 148859-19-2 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-4,5-dihydro-5-[(3,4,5-trimethyl-1-piperazinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 148859-20-5 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxylic acid, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-, 2-(dimethylamino)ethyl ester (CA INDEX NAME)




RN 148859-21-6 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxamide, 3-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-N-ethyl-7-methyl- (CA INDEX NAME)




RN 148859-22-7 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-4,5-dihydro-7-methyl-5-[(4-methyl-1-piperazinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 148859-23-8 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 7-chloro-3-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-5-[(3,5-dimethyl-1-piperazinyl)carbonyl]-4,5-dihydro- (9CI) (CA INDEX NAME)




RN 148859-24-9 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-4,5-dihydro-6-methyl-5-(4-morpholinylcarbonyl)- (9CI) (CA INDEX NAME)



RN 148859-25-0 CAPLUS


CN Imidazo[1,5-a]quinoxaline, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-4,5-dihydro-6-methyl-5-[(4-methyl-1-piperazinyl)carbonyl]- (9CI) (CA INDEX NAME)



RN 148859-26-1 CAPLUS


CN Imidazo[1,5-a]quinoxaline, 7-chloro-3-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-

4,5-dihydro-5-[(3,4,5-trimethyl-1-piperazinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 148859-27-2 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 5-(2-fluorobenzoyl)-3-(4-fluorophenyl)-4,5-dihydro- (9CI) (CA INDEX NAME)




RN 148859-28-3 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(4-fluorophenyl)-4,5-dihydro-5-[3-(trifluoromethyl)benzoyl]- (9CI) (CA INDEX NAME)




RN 148859-29-4 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 7-fluoro-3-(4-fluorophenyl)-4,5-dihydro-5-(4-morpholinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 148859-30-7 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 7-chloro-3-(4-fluorophenyl)-4,5-dihydro-5-(4-morpholinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 148859-31-8 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxamide, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-7-fluoro-N,N-bis(2-methoxyethyl)- (CA INDEX NAME)




RN 148859-35-2 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxylic acid, 3-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-7-fluoro-, 1-methylethyl ester (CA INDEX NAME)




RN 148859-36-3 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-7-fluoro-4,5-dihydro-5-(1-piperazinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 148859-37-4 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-6-fluoro-4,5-dihydro-5-(1-piperazinylcarbonyl)- (9CI) (CA INDEX NAME)



RN 148859-38-5 CAPLUS

CN Imidazo[1,5-a]quinoxaline-4-carboxylic acid, 7-fluoro-4,5-dihydro-5-(4-morpholinylcarbonyl)-, 1,1-dimethylethyl ester (CA INDEX NAME)




IT 148890-50-0P 148890-81-7P 148890-82-8P
 148890-83-9P 148890-84-0P 148890-85-1P
 148890-86-2P 148890-87-3P 148890-88-4P
 148890-89-5P 148890-90-8P 148890-91-9P
 148890-92-0P 148890-93-1P 148890-94-2P
 148890-95-3P 148890-96-4P 148890-97-5P
 148890-98-6P 148890-99-7P 148891-00-3P
 148891-01-4P 148891-02-5P 148891-03-6P
 148891-04-7P 148891-05-8P 148891-06-9P
 148891-07-0P 148891-08-1P 148891-09-2P
 148891-10-5P 148891-11-6P 148891-12-7P
 148891-13-8P 148891-14-9P 148891-15-0P
 148891-16-1P 148891-17-2P 148891-18-3P
 148891-19-4P 148891-20-7P 148891-21-8P
 148891-22-9P 148891-23-0P 148891-24-1P
 148891-25-2P 148891-26-3P 148891-27-4P
 148891-28-5P 148891-29-6P 148891-30-9P
 148891-31-0P 148891-32-1P 148891-33-2P
 148891-34-3P 148891-35-4P 148891-36-5P
 148891-37-6P 148891-38-7P 148891-39-8P
 148891-40-1P 148891-41-2P 148912-78-1P
 148912-79-2P 148912-80-5P 148912-81-6P
 148912-82-7P 148912-83-8P 148912-84-9P
 148912-85-0P 148912-86-1P 148912-87-2P
 148912-88-3P 148912-89-4P 148913-27-3P
 148913-28-4P 148913-29-5P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)


RN 148890-50-0 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-[5-(1,1-dimethylethyl)-1,2,4-oxadiazol-3-yl]-
 5-(4-fluorobenzoyl)-4,5-dihydro- (9CI) (CA INDEX NAME)




RN 148890-81-7 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-4,5-dihydro-5-[(4-methyl-1-piperazinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 148890-82-8 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-7-fluoro-4,5-dihydro-5-[(4-methyl-1-piperazinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 148890-83-9 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-6-fluoro-4,5-dihydro-5-[(4-methyl-1-piperazinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 148890-84-0 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-4,5-dihydro-5-[(4-methyl-1-piperazinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 148890-85-1 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-7-fluoro-4,5-dihydro-5-[(4-methyl-1-piperazinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 148890-86-2 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-6-fluoro-4,5-dihydro-5-[(4-methyl-1-piperazinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 148890-87-3 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-4,5-dihydro-7-methyl-5-[(4-methyl-1-piperazinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 148890-88-4 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(4-fluorophenyl)-4,5-dihydro-5-[(4-methyl-1-piperazinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 148890-89-5 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 7-chloro-3-(4-fluorophenyl)-4,5-dihydro-5-[(4-methyl-1-piperazinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 148890-90-8 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 7-fluoro-3-(4-fluorophenyl)-4,5-dihydro-5-[(4-methyl-1-piperazinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 148890-91-9 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(4-fluorophenyl)-4,5-dihydro-7-methyl-5-[(4-methyl-1-piperazinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 148890-92-0 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(4-cyclopropyl-2-thiazolyl)-4,5-dihydro-5-[(4-methyl-1-piperazinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 148890-93-1 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(4-cyclopropyl-2-thiazolyl)-7-fluoro-4,5-dihydro-5-[(4-methyl-1-piperazinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 148890-94-2 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(4-cyclopropyl-2-thiazolyl)-6-fluoro-4,5-dihydro-5-[(4-methyl-1-piperazinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 148890-95-3 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(4-cyclopropyl-2-thiazolyl)-4,5-dihydro-7-methyl-5-[(4-methyl-1-piperazinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 148890-96-4 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-7-fluoro-4,5-dihydro-5-[(3,4,5-trimethyl-1-piperazinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 148890-97-5 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-6-fluoro-4,5-dihydro-5-[(3,4,5-trimethyl-1-piperazinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 148890-98-6 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-4,5-dihydro-7-methyl-5-[(3,4,5-trimethyl-1-piperazinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 148890-99-7 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-4,5-dihydro-5-[(3,4,5-trimethyl-1-piperazinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 148891-00-3 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(4-fluorophenyl)-4,5-dihydro-5-[(3,4,5-trimethyl-1-piperazinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 148891-01-4 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 7-chloro-3-(4-fluorophenyl)-4,5-dihydro-5-[(3,4,5-trimethyl-1-piperazinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 148891-02-5 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 7-fluoro-3-(4-fluorophenyl)-4,5-dihydro-5-[(3,4,5-trimethyl-1-piperazinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 148891-03-6 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(4-fluorophenyl)-4,5-dihydro-7-methyl-5-[(3,4,5-trimethyl-1-piperazinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 148891-04-7 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(4-cyclopropyl-2-thiazolyl)-4,5-dihydro-5-[(3,4,5-trimethyl-1-piperazinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 148891-05-8 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 7-chloro-3-(4-cyclopropyl-2-thiazolyl)-4,5-dihydro-5-[(3,4,5-trimethyl-1-piperazinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 148891-06-9 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(4-cyclopropyl-2-thiazolyl)-7-fluoro-4,5-dihydro-5-[(3,4,5-trimethyl-1-piperazinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 148891-07-0 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-5-[(3,5-dimethyl-1-piperazinyl)carbonyl]-7-fluoro-4,5-dihydro- (9CI) (CA INDEX NAME)




RN 148891-08-1 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-5-[(3,5-dimethyl-1-piperazinyl)carbonyl]-6-fluoro-4,5-dihydro- (9CI) (CA INDEX NAME)




RN 148891-09-2 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-5-[(3,5-dimethyl-1-piperazinyl)carbonyl]-4,5-dihydro- (9CI) (CA INDEX NAME)




RN 148891-10-5 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 5-[(3,5-dimethyl-1-piperazinyl)carbonyl]-3-(4-fluorophenyl)-4,5-dihydro- (9CI) (CA INDEX NAME)




RN 148891-11-6 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 7-chloro-5-[(3,5-dimethyl-1-piperazinyl)carbonyl]-3-(4-fluorophenyl)-4,5-dihydro- (9CI) (CA INDEX NAME)




RN 148891-12-7 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 5-[(3,5-dimethyl-1-piperazinyl)carbonyl]-7-fluoro-3-(4-fluorophenyl)-4,5-dihydro- (9CI) (CA INDEX NAME)




RN 148891-13-8 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 5-[(3,5-dimethyl-1-piperazinyl)carbonyl]-3-(4-fluorophenyl)-4,5-dihydro- (9CI) (CA INDEX NAME)




RN 148891-14-9 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(4-cyclopropyl-2-thiazolyl)-5-[(3,5-dimethyl-1-piperazinyl)carbonyl]-4,5-dihydro- (9CI) (CA INDEX NAME)




RN 148891-15-0 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 7-chloro-3-(4-cyclopropyl-2-thiazolyl)-5-[(3,5-dimethyl-1-piperazinyl)carbonyl]-4,5-dihydro- (9CI) (CA INDEX NAME)




RN 148891-16-1 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(4-cyclopropyl-2-thiazolyl)-5-[(3,5-dimethyl-1-piperazinyl)carbonyl]-7-fluoro-4,5-dihydro- (9CI) (CA INDEX NAME)




RN 148891-17-2 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(4-cyclopropyl-2-thiazolyl)-5-[(3,5-dimethyl-1-piperazinyl)carbonyl]-6-fluoro-4,5-dihydro- (9CI) (CA INDEX NAME)




RN 148891-18-3 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(4-cyclopropyl-2-thiazolyl)-5-[(3,5-dimethyl-1-piperazinyl)carbonyl]-4,5-dihydro-7-methyl- (9CI) (CA INDEX NAME)




RN 148891-19-4 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-7-fluoro-4,5-dihydro-5-[(2,4,6-trimethyl-1-piperazinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 148891-20-7 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-4,5-dihydro-7-methyl-5-[(2,4,6-trimethyl-1-piperazinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 148891-21-8 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-4,5-dihydro-5-[(2,4,6-trimethyl-1-piperazinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 148891-22-9 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-6-fluoro-4,5-dihydro-5-[(2,4,6-trimethyl-1-piperazinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 148891-23-0 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(4-fluorophenyl)-4,5-dihydro-5-[(2,4,6-trimethyl-1-piperazinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 148891-24-1 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 7-chloro-3-(4-fluorophenyl)-4,5-dihydro-5-[(2,4,6-trimethyl-1-piperazinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 148891-25-2 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 7-fluoro-3-(4-fluorophenyl)-4,5-dihydro-5-[(2,4,6-trimethyl-1-piperazinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 148891-26-3 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(4-fluorophenyl)-4,5-dihydro-7-methyl-5-[(2,4,6-trimethyl-1-piperazinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 148891-27-4 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(4-cyclopropyl-2-thiazolyl)-4,5-dihydro-5-[(2,4,6-trimethyl-1-piperazinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 148891-28-5 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 7-chloro-3-(4-cyclopropyl-2-thiazolyl)-4,5-dihydro-5-[(2,4,6-trimethyl-1-piperazinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 148891-29-6 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(4-cyclopropyl-2-thiazolyl)-7-fluoro-4,5-dihydro-5-[(2,4,6-trimethyl-1-piperazinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 148891-30-9 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(4-cyclopropyl-2-thiazolyl)-6-fluoro-4,5-dihydro-5-[(2,4,6-trimethyl-1-piperazinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 148891-31-0 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(4-cyclopropyl-2-thiazolyl)-4,5-dihydro-7-methyl-5-[(2,4,6-trimethyl-1-piperazinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 148891-32-1 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-5-[(2,6-dimethyl-1-piperazinyl)carbonyl]-4,5-dihydro- (9CI) (CA INDEX NAME)




RN 148891-33-2 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 7-chloro-3-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-5-[(2,6-dimethyl-1-piperazinyl)carbonyl]-4,5-dihydro- (9CI) (CA INDEX NAME)




RN 148891-34-3 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-5-[(2,6-dimethyl-1-piperazinyl)carbonyl]-7-fluoro-4,5-dihydro- (9CI) (CA INDEX NAME)




RN 148891-35-4 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-5-[(2,6-dimethyl-1-piperazinyl)carbonyl]-6-fluoro-4,5-dihydro- (9CI) (CA INDEX NAME)




RN 148891-36-5 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-5-[(2,6-dimethyl-1-piperazinyl)carbonyl]-4,5-dihydro-7-methyl- (9CI) (CA INDEX NAME)



RN 148891-37-6 CAPLUS


CN Imidazo[1,5-a]quinoxaline, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-5-[(2,6-dimethyl-1-piperazinyl)carbonyl]-4,5-dihydro- (9CI) (CA INDEX NAME)



RN 148891-38-7 CAPLUS


CN Imidazo[1,5-a]quinoxaline, 7-chloro-3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-

5-[(2,6-dimethyl-1-piperazinyl)carbonyl]-4,5-dihydro- (9CI) (CA INDEX NAME)




RN 148891-39-8 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-5-[(2,6-dimethyl-1-piperazinyl)carbonyl]-7-fluoro-4,5-dihydro- (9CI) (CA INDEX NAME)




RN 148891-40-1 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-5-[(2,6-dimethyl-1-piperazinyl)carbonyl]-6-fluoro-4,5-dihydro- (9CI) (CA INDEX NAME)




RN 148891-41-2 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-5-[(2,6-dimethyl-1-piperazinyl)carbonyl]-4,5-dihydro-7-methyl- (9CI) (CA INDEX NAME)




RN 148912-78-1 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 7-chloro-3-(4-cyclopropyl-2-thiazolyl)-4,5-dihydro-5-[(4-methyl-1-piperazinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 148912-79-2 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(4-cyclopropyl-2-thiazolyl)-6-fluoro-4,5-dihydro-5-[(3,4,5-trimethyl-1-piperazinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 148912-80-5 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(4-cyclopropyl-2-thiazolyl)-4,5-dihydro-7-methyl-5-[(3,4,5-trimethyl-1-piperazinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 148912-81-6 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 5-[(2,6-dimethyl-1-piperazinyl)carbonyl]-3-(4-fluorophenyl)-4,5-dihydro- (9CI) (CA INDEX NAME)




RN 148912-82-7 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 7-chloro-5-[(2,6-dimethyl-1-piperazinyl)carbonyl]-3-(4-fluorophenyl)-4,5-dihydro- (9CI) (CA INDEX NAME)




RN 148912-83-8 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 5-[(2,6-dimethyl-1-piperazinyl)carbonyl]-7-fluoro-3-(4-fluorophenyl)-4,5-dihydro- (9CI) (CA INDEX NAME)




RN 148912-84-9 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 5-[(2,6-dimethyl-1-piperazinyl)carbonyl]-3-(4-fluorophenyl)-4,5-dihydro- (9CI) (CA INDEX NAME)




RN 148912-85-0 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(4-cyclopropyl-2-thiazolyl)-5-[(2,6-dimethyl-1-piperazinyl)carbonyl]-4,5-dihydro- (9CI) (CA INDEX NAME)




RN 148912-86-1 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 7-chloro-3-(4-cyclopropyl-2-thiazolyl)-5-[(2,6-dimethyl-1-piperazinyl)carbonyl]-4,5-dihydro- (9CI) (CA INDEX NAME)




RN 148912-87-2 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(4-cyclopropyl-2-thiazolyl)-5-[(2,6-dimethyl-1-piperazinyl)carbonyl]-7-fluoro-4,5-dihydro- (9CI) (CA INDEX NAME)




RN 148912-88-3 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(4-cyclopropyl-2-thiazolyl)-5-[(2,6-dimethyl-1-piperazinyl)carbonyl]-6-fluoro-4,5-dihydro- (9CI) (CA INDEX NAME)




RN 148912-89-4 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(4-cyclopropyl-2-thiazolyl)-5-[(2,6-dimethyl-1-piperazinyl)carbonyl]-4,5-dihydro-7-methyl- (9CI) (CA INDEX NAME)




RN 148913-27-3 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 7-fluoro-4,5-dihydro-4-methyl-3-[5-(2-methylcyclopropyl)-1,2,4-oxadiazol-3-yl]-5-(2-pyridinylmethyl)- (CA INDEX NAME)




RN 148913-28-4 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-7-fluoro-4,5-dihydro-5-(1-piperazinylcarbonyl)-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl


RN 148913-29-5 CAPLUS
 CN Imidazo[1,5-a]quinoxaline, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-6-fluoro-4,5-dihydro-5-(1-piperazinylcarbonyl)-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

L5 ANSWER 51 OF 70 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1993:462921 CAPLUS
 DOCUMENT NUMBER: 119:62921
 TITLE: Antagonism of hypothermia produced by benzodiazepine-related compounds by U-78875 in mice
 AUTHOR(S): Tang, Andrew H.; Code, Robert A.; Himes, Carol S.
 CORPORATE SOURCE: Upjohn Co., Kalamazoo, MI, 49001, USA
 SOURCE: European Journal of Pharmacology (1993), 236(1), 1-5
 CODEN: EJPHAZ; ISSN: 0014-2999
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 IT 124423-84-3, U-78875
 RL: BIOL (Biological study)


(benzodiazepine-induced hypothermia inhibition by)
 RN 124423-84-3 CAPLUS
 CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-
 5-(1-methylethyl)- (CA INDEX NAME)



L5 ANSWER 52 OF 70 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1993:261026 CAPLUS
 DOCUMENT NUMBER: 118:261026
 TITLE: Enteric pharmaceutical compositions containing
 enzyme-sensitive oily vehicle
 INVENTOR(S): Nishihata, Toshiaki; Ishizaka, Mayumi; Yamamoto,
 Takeshi
 PATENT ASSIGNEE(S): Upjohn Co., USA
 SOURCE: Jpn. Kokai Tokkyo Koho, 13 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 05025037	A	19930202	JP 1991-160437	19910701 <--
AU 9222938	A	19930211	AU 1992-22938	19920626 <--
PRIORITY APPLN. INFO.:			JP 1991-160437	A 19910701 <--
			WO 1992-US5245	A 19920626 <--

IT 124423-84-3, U-78875
 RL: BIOL (Biological study)
 (enteric pharmaceutical capsules of, vehicle containing enzyme-sensitive
 substances in)
 RN 124423-84-3 CAPLUS
 CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-
 5-(1-methylethyl)- (CA INDEX NAME)




L5 ANSWER 53 OF 70 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1993:139090 CAPLUS
 DOCUMENT NUMBER: 118:139090
 TITLE: Application of solid-phase extraction in the

AUTHOR(S): determination of U-82217 in rat serum, urine and brain
 Zhong, W. Z.
 CORPORATE SOURCE: Drug Metab. Res., Upjohn Lab., Kalamazoo, MI, 49001,
 USA
 SOURCE: Journal of Chromatography (1993), 629(1),
 83-7
 CODEN: JOCRAM; ISSN: 0021-9673
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 IT 126990-93-0, U 82217
 RL: ANT (Analyte); ANST (Analytical study)
 (determination of, in brain and urine and blood by HPLC, pharmacokinetics in
 relation to)
 RN 126990-93-0 CAPLUS
 CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-
 5-[(4-methoxyphenyl)methyl]- (CA INDEX NAME)




L5 ANSWER 54 OF 70 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1993:66903 CAPLUS
 DOCUMENT NUMBER: 118:66903
 TITLE: Oral formulations for sparingly water-soluble drugs
 INVENTOR(S): Nishihata, Toshiaki; Yamamoto, Takeshi; Emori,
 Hisatoshi; Yokohama, Shigeharu
 PATENT ASSIGNEE(S): Upjohn Co., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 7 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 04243841	A	19920831	JP 1991-19463	19910118 <--
PRIORITY APPLN. INFO.:			JP 1991-19463	19910118 <--
IT 124423-84-3, U 78875				
RL: BIOL (Biological study) (pharmaceutical oral dosage forms of, polysorbate-80 in, for solubility enhancement)				
RN 124423-84-3 CAPLUS				
CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)- 5-(1-methylethyl)- (CA INDEX NAME)				





L5 ANSWER 55 OF 70 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1993:15786 CAPLUS
 DOCUMENT NUMBER: 118:15786
 TITLE: Utility of the parent-neutral loss scan screening
 technique: partial characterization of urinary
 metabolites of U-78875 in monkey urine
 AUTHOR(S): Vrbanac, J. J.; O'Leary, I. A.; Baczynskyj, L.
 CORPORATE SOURCE: Upjohn Co., Kalamazoo, MI, 49001, USA
 SOURCE: Biological Mass Spectrometry (1992), 21(10),
 517-22
 CODEN: BIMSEH; ISSN: 1052-9306
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 IT 144975-13-3 144975-16-6 145003-48-1
 RL: BIOL (Biological study)
 (as U-78875 urine metabolite)
 RN 144975-13-3 CAPLUS
 CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-
 5-(1-methylethyl)-, hydroxy deriv. (9CI) (CA INDEX NAME)




D1-OH

RN 144975-16-6 CAPLUS
 CN β -D-Glucopyranosiduronic acid, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-
 4,5-dihydro-5-(1-methylethyl)-4-oxoimidazo[1,5-a]quinoxaliny (9CI) (CA
 INDEX NAME)




RN 145003-48-1 CAPLUS
 CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-5-(1-methylethyl)-, mono(sulfooxy) deriv. (9CI) (CA INDEX NAME)




D1-OSO₃H

IT 124423-84-3, U-78875
 RL: BIOL (Biological study)
 (biotransformation of, urinary metabolites determination by tandem mass spectrometry with parent-neutral loss scan screening technique in relation to)
 RN 124423-84-3 CAPLUS
 CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-5-(1-methylethyl)- (CA INDEX NAME)



IT 124423-84-3D, U-78875, metabolites
 RL: BIOL (Biological study)
 (urinary, determination of, by tandem mass spectrometry with parent-neutral loss scan screening technique in relation to)
 RN 124423-84-3 CAPLUS

CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-
5-(1-methylethyl)- (CA INDEX NAME)



L5 ANSWER 56 OF 70 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1993:248 CAPLUS

DOCUMENT NUMBER: 118:248

TITLE: Characterization of functional interactions of
imidazoquinoxaline derivatives with
benzodiazepine- γ -aminobutyric acid α receptors

AUTHOR(S): Petke, James D.; Im, Haesook K.; Im, Wha Bin;
Blakeman, David P.; Pregenzer, Jeff F.; Jacobsen, E.
Jon; Hamilton, Beverly J.; Carter, Donald B.

CORPORATE SOURCE: Upjohn Co., Kalamazoo, MI, 49001, USA
SOURCE: Molecular Pharmacology (1992), 42(2),
294-301

CODEN: MOPMA3; ISSN: 0026-895X

DOCUMENT TYPE: Journal

LANGUAGE: English

IT 115618-94-5, U 78263 124423-84-3, U78875

124423-85-4, U 79098 126990-90-7, U 81139

129799-93-5, U 82249 141426-47-3, U 89320


144860-93-5, U 78280

RL: PRP (Properties)

(interaction of, with benzodiazepine-GABA receptors, mol. structure in
relation to)


RN 115618-94-5 CAPLUS

CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-
3,3a-dihydro-5-methyl- (9CI) (CA INDEX NAME)




RN 124423-84-3 CAPLUS

CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-
5-(1-methylethyl)- (CA INDEX NAME)




RN 124423-85-4 CAPLUS

CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 6-chloro-3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-5-(1-methylethyl)- (CA INDEX NAME)




RN 126990-90-7 CAPLUS

CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-5-methyl-6-(trifluoromethyl)- (CA INDEX NAME)




RN 129799-93-5 CAPLUS

CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-5-(1,1-dimethylethyl)- (CA INDEX NAME)




RN 141426-47-3 CAPLUS

CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-6-methoxy-5-(1-methylethyl)- (CA INDEX NAME)




RN 144860-93-5 CAPLUS
 CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-5-ethyl- (CA INDEX NAME)



L5 ANSWER 57 OF 70 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1992:255639 CAPLUS
 DOCUMENT NUMBER: 116:255639
 TITLE: Preparation of imidazo[1,5-a]quinoxalin-4(5H)-ones
 INVENTOR(S): Jacobsen, Eric Jon
 PATENT ASSIGNEE(S): Upjohn Co., USA
 SOURCE: PCT Int. Appl., 28 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9204350	A1	19920319	WO 1991-US5555	19910809 <--
W:	AU, BB, BG, BR, CA, CS, FI, HU, JP, KP, KR, LK, MC, MG, MN, MW, NO, PL, RO, SD, SU, US			
RW:	AT, BE, BF, BJ, CF, CG, CH, CI, CM, DE, DK, ES, FR, GA, GB, GN, GR, IT, LU, ML, MR, NL, SE, SN, TD, TG			
AU 9183964	A	19920330	AU 1991-83964	19910809 <--
JP 06500545	T	19940120	JP 1991-514282	19910809 <--
PRIORITY APPLN. INFO.:			US 1990-577641	A2 19900904 <--
			US 1991-705634	A 19910528 <--
			WO 1991-US5555	A 19910809 <--

OTHER SOURCE(S): MARPAT 116:255639
 IT 141426-44-0P 141426-45-1P 141426-46-2P
 141426-47-3P 141426-48-4P 141426-49-5P
 141426-50-8P 141448-38-6P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of, as CNS agent)
 RN 141426-44-0 CAPLUS
 CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-7-hydroxy-5-(1-methylethyl)- (CA INDEX NAME)




RN 141426-45-1 CAPLUS

CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 7-(acetyloxy)-3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-5-(1-methylethyl)- (CA INDEX NAME)




RN 141426-46-2 CAPLUS

CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-6-hydroxy-5-(1-methylethyl)- (CA INDEX NAME)




RN 141426-47-3 CAPLUS

CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-6-methoxy-5-(1-methylethyl)- (CA INDEX NAME)




RN 141426-48-4 CAPLUS

CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-8-methoxy-5-(1-methylethyl)- (CA INDEX NAME)




RN 141426-49-5 CAPLUS

CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-8-(methoxymethoxy)-5-(1-methylethyl)- (CA INDEX NAME)




RN 141426-50-8 CAPLUS

CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-8-hydroxy-5-(1-methylethyl)- (CA INDEX NAME)



RN 141448-38-6 CAPLUS

CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-7-methoxy-5-(1-methylethyl)- (CA INDEX NAME)




IT 141426-58-6P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as intermediate for CNS agents)


RN 141426-58-6 CAPLUS

CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-7-[(1,1-dimethylethyl)dimethylsilyloxy]-5-(1-methylethyl)- (CA INDEX NAME)

NAME)




L5 ANSWER 58 OF 70 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1992:120264 CAPLUS
DOCUMENT NUMBER: 116:120264
TITLE: Determination of 6-chloro-3-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-5-methylimidazo[1,5-a]quinoxalin-4(5H)-one in rat serum, urine and brain by solid-phase extraction and liquid chromatography
AUTHOR(S): Zhong, W. Z.
CORPORATE SOURCE: Upjohn Lab., Kalamazoo, MI, 49001, USA
SOURCE: Journal of Pharmaceutical and Biomedical Analysis (1991), 9(7), 573-80
CODEN: JPBADA; ISSN: 0731-7085
DOCUMENT TYPE: Journal
LANGUAGE: English
IT 139459-45-3, U 80447
RL: ANT (Analyte); ANST (Analytical study)
(determination of, in blood serum and brain and urine, by solid-phase extraction and liquid chromatog.)
RN 139459-45-3 CAPLUS
CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 6-chloro-3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-5-methyl- (CA INDEX NAME)



L5 ANSWER 59 OF 70 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1991:670533 CAPLUS
DOCUMENT NUMBER: 115:270533
TITLE: Behavioral effects of U-78875, a quinoxalinone anxiolytic with potent benzodiazepine antagonist activity
AUTHOR(S): Tang, Andrew H.; Franklin, S. R.; Himes, C. S.; Ho, P. M.
CORPORATE SOURCE: Upjohn Co., Kalamazoo, MI, 49001, USA
SOURCE: Journal of Pharmacology and Experimental Therapeutics (1991), 259(1), 248-54
CODEN: JPETAB; ISSN: 0022-3565
DOCUMENT TYPE: Journal

LANGUAGE: English
 IT 124423-84-3, U-78875
 RL: PRP (Properties)
 (behavioral and anxiolytic effects of, benzodiazepine
 agonist/antagonist activities in)
 RN 124423-84-3 CAPLUS
 CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-
 5-(1-methylethyl)- (CA INDEX NAME)




=> d 15 1-39 ibib hitstr


L5 ANSWER 1 OF 70 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2006:100738 CAPLUS
 DOCUMENT NUMBER: 144:198849
 TITLE: Novel dosage form comprising modified-release and
 immediate-release active ingredients
 INVENTOR(S): Vaya, Navin; Karan, Rajesh Singh; Sadanand, Sunil;
 Gupta, Vinod Kumar
 PATENT ASSIGNEE(S): India
 SOURCE: U.S. Pat. Appl. Publ., 49 pp., Cont.-in-part of U.S.
 Ser. No. 630,446.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20060024365	A1	20060202	US 2005-134633	20050519 <--
IN 2002MU00697	A	20040529	IN 2002-MU697	20020805 <--
IN 193042	A1	20040626		
IN 2002MU00699	A	20040529	IN 2002-MU699	20020805 <--
IN 2003MU00080	A	20050204	IN 2003-MU80	20030122 <--
IN 2003MU00082	A	20050204	IN 2003-MU82	20030122 <--
US 20040096499	A1	20040520	US 2003-630446	20030729 <--
PRIORITY APPLN. INFO.:				
			IN 2002-MU697	A 20020805 <--
			IN 2002-MU699	A 20020805 <--
			IN 2003-MU80	A 20030122 <--
			IN 2003-MU82	A 20030122 <--
			US 2003-630446	A2 20030729 <--

IT 124423-84-3, Panadiplon
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (novel dosage form comprising modified-release and immediate-release
 active ingredients)
 RN 124423-84-3 CAPLUS
 CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-
 5-(1-methylethyl)- (CA INDEX NAME)



L5 ANSWER 2 OF 70 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2004:861911 CAPLUS
 DOCUMENT NUMBER: 142:298074
 TITLE: Fused Polycyclic Nitrogen-Containing Heterocycles: IX. Oxidative Fusion of Imidazole Ring to 3-Benzoylquinoxalin-2-ones
 AUTHOR(S): Mamedov, V. A.; Kalinin, A. A.; Gorbunova, E. A.; Habicher, W. D.
 CORPORATE SOURCE: Arbuzov Institute of Organic and Physical Chemistry, Kazan Research Center, Russian Academy of Sciences, Tatarstan, 420088, Russia
 SOURCE: Russian Journal of Organic Chemistry (Translation of Zhurnal Organicheskoi Khimii) (2004), 40(7), 1041-1046
 CODEN: RJOCEQ; ISSN: 1070-4280
 PUBLISHER: MAIK Nauka/Interperiodica Publishing
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 142:298074
 IT 847552-59-4P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of imidazoquinoxalinones and bis(imidazoquinoxalyl)benzenes via oxidative cyclocondensation of benzyl- and benzoyl-substituted quinoxalinones)
 RN 847552-59-4 CAPLUS
 CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 5,5'-[1,3-phenylenebis(methylene)]bis[1,3-diphenyl- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 3 OF 70 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2004:143156 CAPLUS
 DOCUMENT NUMBER: 140:199349
 TITLE: Preparation of imidazopyrazines and imidazodiazepines as agents for the treatment of aldosterone mediated conditions
 INVENTOR(S): McKenna, Jeffrey
 PATENT ASSIGNEE(S): Novartis Ag, Switz.; Novartis Pharma GmbH


SOURCE: PCT Int. Appl., 101 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004014914	A1	20040219	WO 2003-EP8720	20030806 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW RW: AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR				
CA 2494636	A1	20040219	CA 2003-2494636	20030806 <--
AU 2003253387	A1	20040225	AU 2003-253387	20030806 <--
EP 1537114	A1	20050608	EP 2003-784194	20030806 <--
EP 1537114	B1	20060809		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003013293	A	20050614	BR 2003-13293	20030806 <--
CN 1688583	A	20051026	CN 2003-823878	20030806 <--
JP 2006505520	T	20060216	JP 2004-526900	20030806 <--
AT 335744	T	20060915	AT 2003-784194	20030806 <--
ES 2270143	T3	20070401	ES 2003-784194	20030806 <--
US 20060166973	A1	20060727	US 2005-523870	20050318 <--
HK 1080290	A1	20070223	HK 2005-111160	20051206 <--
PRIORITY APPLN. INFO.:			US 2002-401693P	P 20020807 <--
			WO 2003-EP8720	W 20030806 <--
OTHER SOURCE(S): MARPAT 140:199349				
IT 660854-65-9P 660854-68-2P				
RL: PAC (Pharmacological activity); PEP (Physical, engineering or chemical process); PYP (Physical process); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses) (preparation of imidazopyrazines and imidazodiazepines as agents for the treatment of aldosterone mediated conditions)				
RN 660854-65-9 CAPLUS				
CN Imidazo[1,5-a]pyrazin-6(5H)-one, 5-(3-bromophenyl)-7-(cyclopropylmethyl)-7,8-dihydro-, monohydrochloride (9CI) (CA INDEX NAME)				



● HCl


RN 660854-68-2 CAPLUS
 CN Imidazo[1,5-a]pyrazin-6(5H)-one, 5-(3-bromophenyl)-7,8-dihydro-7-(phenylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


IT 660854-66-0P 660854-67-1P 660854-69-3P
 660854-70-6P
 RL: PAC (Pharmacological activity); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of imidazopyrazines and imidazodiazepines as agents for the treatment of aldosterone mediated conditions)
 RN 660854-66-0 CAPLUS
 CN Imidazo[1,5-a]pyrazin-6(5H)-one, 5-(3-bromophenyl)-7-(cyclopropylmethyl)-7,8-dihydro-, (5S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 660854-67-1 CAPLUS
 CN Imidazo[1,5-a]pyrazin-6(5H)-one, 5-(3-bromophenyl)-7-(cyclopropylmethyl)-7,8-dihydro-, (5R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 660854-69-3 CAPLUS

CN Imidazo[1,5-a]pyrazin-6(5H)-one, 5-(3-bromophenyl)-7,8-dihydro-7-(phenylmethyl)-, (5S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 660854-70-6 CAPLUS

CN Imidazo[1,5-a]pyrazin-6(5H)-one, 5-(3-bromophenyl)-7,8-dihydro-7-(phenylmethyl)-, (5R)- (CA INDEX NAME)

Absolute stereochemistry.




IT 660854-20-6P 660854-52-4P 660855-52-7P

660855-53-8P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of imidazopyrazines and imidazodiazepines as agents for the treatment of aldosterone mediated conditions)


RN 660854-20-6 CAPLUS

CN Benzonitrile, 4-[5,6,7,8-tetrahydro-6-oxo-7-(phenylmethyl)imidazo[1,5-a]pyrazin-5-yl]- (CA INDEX NAME)




RN 660854-52-4 CAPLUS

CN Imidazo[1,5-a]pyrazin-6(5H)-one, 5-(4-bromophenyl)-7,8-dihydro-7-[(4-methoxyphenyl)methyl]- (CA INDEX NAME)




RN 660855-52-7 CAPLUS

CN Imidazo[1,5-a]pyrazin-6(5H)-one, 5-(3-bromophenyl)-7,8-dihydro-7-(phenylmethyl)- (CA INDEX NAME)



RN 660855-53-8 CAPLUS

CN Imidazo[1,5-a]pyrazin-6(5H)-one, 5-(4-bromophenyl)-7,8-dihydro-7-(phenylmethyl)- (CA INDEX NAME)



IT 660854-18-2P 660854-19-3P 660854-21-7P
 660854-22-8P 660854-23-9P 660854-24-0P
 660854-25-1P 660854-26-2P 660854-27-3P
 660854-28-4P 660854-29-5P 660854-30-8P
 660854-31-9P 660854-32-0P 660854-33-1P
 660854-37-5P 660854-38-6P 660854-39-7P
 660854-40-0P 660854-41-1P 660854-42-2P
 660854-43-3P 660854-44-4P 660854-45-5P
 660854-46-6P 660854-47-7P 660854-48-8P
 660854-49-9P 660854-50-2P 660854-51-3P
 660854-53-5P 660854-54-6P 660854-55-7P
 660854-56-8P 660854-58-0P 660854-59-1P
 660854-60-4P 660854-71-7P 660854-72-8P
 660854-73-9P 660854-74-0P 660854-75-1P
 660854-76-2P 660854-77-3P 660854-78-4P
 660854-79-5P 660854-80-8P 660854-81-9P
 660854-82-0P 660854-83-1P 660854-84-2P
 660854-85-3P 660854-86-4P 660854-87-5P
 660854-88-6P 660854-89-7P 660854-90-0P
 660854-91-1P 660854-92-2P 660854-93-3P
 660854-94-4P 660854-95-5P 660854-96-6P
 660854-97-7P 660854-98-8P 660854-99-9P
 660855-00-5P 660855-01-6P 660855-02-7P
 660855-03-8P 660855-04-9P 660855-05-0P
 660855-06-1P 660855-07-2P 660855-08-3P
 660855-09-4P 660855-10-7P 660855-11-8P
 660855-12-9P 660855-13-0P 660855-14-1P
 660855-15-2P 660855-16-3P 660855-17-4P
 660855-18-5P 660855-19-6P 660855-20-9P
 660855-21-0P 660855-22-1P 660855-23-2P
 660855-24-3P 660855-25-4P 660855-26-5P
 660855-27-6P 660855-28-7P 660855-29-8P
 660855-30-1P 660855-31-2P 660855-32-3P
 660855-33-4P 660855-34-5P 660855-35-6P
 660855-54-9P 660855-55-0P 660855-56-1P
 660855-57-2P 660855-58-3P 660855-59-4P
 660855-60-7P 660855-61-8P 660855-62-9P
 660855-63-0P 660855-64-1P 660855-65-2P
 660855-67-4P 660855-68-5P 660855-69-6P
 660855-70-9P 660855-71-0P 660855-72-1P
 660855-73-2P 660855-74-3P 660855-75-4P
 660855-76-5P 660855-77-6P 660855-78-7P
 660855-79-8P 660855-80-1P 660855-81-2P
 660855-82-3P 660855-83-4P 660855-84-5P
 660855-85-6P 660855-86-7P 660855-87-8P
 660855-88-9P 660855-89-0P 660855-90-3P
 660855-91-4P 660855-92-5P 660855-93-6P
 660855-94-7P 660855-95-8P 660855-96-9P


660855-97-0P 660855-98-1P 660855-99-2P
 660856-00-8P 660856-01-9P 660856-02-0P
 660856-03-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(preparation of imidazopyrazines and imidazodiazepines as agents for the
 treatment of aldosterone mediated conditions)


RN 660854-18-2 CAPLUS

CN Benzonitrile, 4-[7-(cyclopropylmethyl)-5,6,7,8-tetrahydro-6-oxoimidazo[1,5-
 a]pyrazin-5-yl]- (CA INDEX NAME)



RN 660854-19-3 CAPLUS


CN Benzonitrile, 4-[5,6,7,8-tetrahydro-7-methyl-6-oxoimidazo[1,5-a]pyrazin-5-
 yl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 660854-21-7 CAPLUS

CN Benzonitrile, 4-[5,6,7,8-tetrahydro-6-oxo-7-(2-propenyl)imidazo[1,5-
 a]pyrazin-5-yl]- (9CI) (CA INDEX NAME)




RN 660854-22-8 CAPLUS

CN Benzonitrile, 4-(5,6,7,8-tetrahydro-6-oxo-7-propylimidazo[1,5-a]pyrazin-5-yl)- (CA INDEX NAME)




RN 660854-23-9 CAPLUS

CN Benzonitrile, 4-[5,6,7,8-tetrahydro-7-(1-methylethyl)-6-oxoimidazo[1,5-a]pyrazin-5-yl]- (CA INDEX NAME)



RN 660854-24-0 CAPLUS


CN Benzonitrile, 4-[7-[2-(4-fluorophenyl)ethyl]-5,6,7,8-tetrahydro-6-oxoimidazo[1,5-a]pyrazin-5-yl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 660854-25-1 CAPLUS


CN Benzonitrile, 4-[5,6,7,8-tetrahydro-7-[3-(4-morpholinyl)propyl]-6-oxoimidazo[1,5-a]pyrazin-5-yl]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl


RN 660854-26-2 CAPLUS

CN Benzonitrile, 4-[5,6,7,8-tetrahydro-7-[(4-methoxyphenyl)methyl]-6-oxoimidazo[1,5-a]pyrazin-5-yl]- (CA INDEX NAME)




RN 660854-27-3 CAPLUS

CN Benzonitrile, 4-[5,6,7,8-tetrahydro-7-[(4-methylphenyl)methyl]-6-oxoimidazo[1,5-a]pyrazin-5-yl]- (CA INDEX NAME)



RN 660854-28-4 CAPLUS


CN Benzonitrile, 4-[7-[(4-chlorophenyl)methyl]-5,6,7,8-tetrahydro-6-oxoimidazo[1,5-a]pyrazin-5-yl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 660854-29-5 CAPLUS


CN Benzonitrile, 4-[5,6,7,8-tetrahydro-6-oxo-7-[[4-(trifluoromethyl)phenyl]methyl]imidazo[1,5-a]pyrazin-5-yl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 660854-30-8 CAPLUS


CN Benzonitrile, 4-[5,6,7,8-tetrahydro-7-[(3-methylphenyl)methyl]-6-oxoimidazo[1,5-a]pyrazin-5-yl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 660854-31-9 CAPLUS


CN Benzonitrile, 4-[7-[(4-fluorophenyl)methyl]-5,6,7,8-tetrahydro-6-oxoimidazo[1,5-a]pyrazin-5-yl]- (CA INDEX NAME)



RN 660854-32-0 CAPLUS

CN Benzonitrile, 4-[5,6,7,8-tetrahydro-6-oxo-7-[[3-


(trifluoromethyl)phenyl)methylimidazo[1,5-a]pyrazin-5-yl]-,
monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 660854-33-1 CAPLUS

CN Benzonitrile, 4-[7-[(3,4-dichlorophenyl)methyl]-5,6,7,8-tetrahydro-6-oxoimidazo[1,5-a]pyrazin-5-yl]- (CA INDEX NAME)




RN 660854-37-5 CAPLUS

CN Benzonitrile, 4-[5,6,7,8-tetrahydro-7-(2-methoxyethyl)-6-oxoimidazo[1,5-a]pyrazin-5-yl]- (CA INDEX NAME)




RN 660854-38-6 CAPLUS

CN Benzonitrile, 4-[5,6,7,8-tetrahydro-7-(3-methoxypropyl)-6-oxoimidazo[1,5-a]pyrazin-5-yl]- (CA INDEX NAME)




RN 660854-39-7 CAPLUS

CN Benzonitrile, 4-[5,6,7,8-tetrahydro-6-oxo-7-(4-pyridinylmethyl)imidazo[1,5-a]pyrazin-5-yl]- (CA INDEX NAME)




RN 660854-40-0 CAPLUS

CN Imidazo[1,5-a]pyrazin-6(5H)-one, 7-[(4-fluorophenyl)methyl]-7,8-dihydro-5-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 660854-41-1 CAPLUS

CN Imidazo[1,5-a]pyrazin-6(5H)-one, 7-(cyclopropylmethyl)-7,8-dihydro-5-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 660854-42-2 CAPLUS

CN Imidazo[1,5-a]pyrazin-6(5H)-one, 7-[(4-fluorophenyl)methyl]-7,8-dihydro-5-(4-methoxyphenyl)- (CA INDEX NAME)




RN 660854-43-3 CAPLUS

CN Imidazo[1,5-a]pyrazin-6(5H)-one, 7-[(4-fluorophenyl)methyl]-7,8-dihydro-5-(2-methoxyphenyl)- (CA INDEX NAME)




RN 660854-44-4 CAPLUS

CN Imidazo[1,5-a]pyrazin-6(5H)-one, 5-(2-chlorophenyl)-7-[(4-fluorophenyl)methyl]-7,8-dihydro- (CA INDEX NAME)




RN 660854-45-5 CAPLUS

CN Imidazo[1,5-a]pyrazin-6(5H)-one, 7-[(4-fluorophenyl)methyl]-7,8-dihydro-5-(1-naphthalenyl)- (CA INDEX NAME)




RN 660854-46-6 CAPLUS

CN Imidazo[1,5-a]pyrazin-6(5H)-one, 7-[(4-fluorophenyl)methyl]-7,8-dihydro-5-(2-naphthalenyl)- (CA INDEX NAME)




RN 660854-47-7 CAPLUS

CN Imidazo[1,5-a]pyrazin-6(5H)-one, 7-[(4-fluorophenyl)methyl]-7,8-dihydro-5-(2-thienyl)- (CA INDEX NAME)




RN 660854-48-8 CAPLUS

CN Imidazo[1,5-a]pyrazin-6(5H)-one, 7-[(4-fluorophenyl)methyl]-7,8-dihydro-5-(3-thienyl)- (CA INDEX NAME)



RN 660854-49-9 CAPLUS


CN Imidazo[1,5-a]pyrazin-6(5H)-one, 7,8-dihydro-5-phenyl-7-(phenylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 660854-50-2 CAPLUS


CN Imidazo[1,5-a]pyrazin-6(5H)-one, 7,8-dihydro-7-methyl-5-phenyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 660854-51-3 CAPLUS

CN Imidazo[1,5-a]pyrazin-6(5H)-one, 5-(4-bromophenyl)-7,8-dihydro-7-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



RN 660854-53-5 CAPLUS


CN Imidazo[1,5-a]pyrazin-6(5H)-one, 5-(4-bromophenyl)-7-(cyclopropylmethyl)-7,8-dihydro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 660854-54-6 CAPLUS


CN Imidazo[1,5-a]pyrazin-6(5H)-one, 5-(4-bromophenyl)-7,8-dihydro-7-(phenylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 660854-55-7 CAPLUS


CN Imidazo[1,5-a]pyrazin-6(5H)-one, 5-(4-bromophenyl)-7-[(4-chlorophenyl)methyl]-7,8-dihydro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 660854-56-8 CAPLUS


CN Imidazo[1,5-a]pyrazin-6(5H)-one, 5-(4-bromophenyl)-7,8-dihydro-7-[[4-(trifluoromethyl)phenyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 660854-58-0 CAPLUS


CN Imidazo[1,5-a]pyrazin-6(5H)-one, 5-(4-bromophenyl)-7-[[2-(4-fluorophenyl)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 660854-59-1 CAPLUS


CN Imidazo[1,5-a]pyrazin-6(5H)-one, 5-(4-bromophenyl)-7-[(4-fluorophenyl)methyl]-7,8-dihydro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 660854-60-4 CAPLUS


CN Imidazo[1,5-a]pyrazin-6(5H)-one, 5-(3-bromophenyl)-7,8-dihydro-7-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 660854-71-7 CAPLUS


CN Imidazo[1,5-a]pyrazin-6(5H)-one, 5-(3-bromophenyl)-7-[(4-methoxyphenyl)methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 660854-72-8 CAPLUS


CN Imidazo[1,5-a]pyrazin-6(5H)-one, 5-(3-bromophenyl)-7-[(4-fluorophenyl)methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 660854-73-9 CAPLUS


CN Imidazo[1,5-a]pyrazin-6(5H)-one, 5-(3-bromophenyl)-7-[(4-chlorophenyl)methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 660854-74-0 CAPLUS


CN Imidazo[1,5-a]pyrazin-6(5H)-one, 5-(3-bromophenyl)-7,8-dihydro-7-[(4-methylphenyl)methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 660854-75-1 CAPLUS

CN Imidazo[1,5-a]pyrazin-6(5H)-one, 5-(3-bromophenyl)-7,8-dihydro-7-[[4-(trifluoromethyl)phenyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 660854-76-2 CAPLUS
 CN Imidazo[1,5-a]pyrazin-6(5H)-one, 5-(3-bromophenyl)-7,8-dihydro-7-[(3-(trifluoromethyl)phenyl)methyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 660854-77-3 CAPLUS
 CN Imidazo[1,5-a]pyrazin-6(5H)-one, 5-(3-bromophenyl)-7-[(3-fluorophenyl)methyl]-7,8-dihydro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 660854-78-4 CAPLUS
 CN Imidazo[1,5-a]pyrazin-6(5H)-one, 5-(3-bromophenyl)-7,8-dihydro-7-[(3-methylphenyl)methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 660854-79-5 CAPLUS


CN Imidazo[1,5-a]pyrazin-6(5H)-one, 5-(3-bromophenyl)-7,8-dihydro-7-(2-phenylethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 660854-80-8 CAPLUS


CN Imidazo[1,5-a]pyrazin-6(5H)-one, 5-(3-bromophenyl)-7,8-dihydro-7-[2-(4-methoxyphenyl)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 660854-81-9 CAPLUS

CN Imidazo[1,5-a]pyrazin-6(5H)-one, 5-(3-bromophenyl)-7-[2-(4-chlorophenyl)ethyl]-7,8-dihydro-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 660854-82-0 CAPLUS
 CN Imidazo[1,5-a]pyrazin-6(5H)-one, 5-(3-bromophenyl)-7-[2-(3-chlorophenyl)ethyl]-7,8-dihydro-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 660854-83-1 CAPLUS
 CN Imidazo[1,5-a]pyrazin-6(5H)-one, 5-(3-bromophenyl)-7,8-dihydro-7-[2-(4-methylphenyl)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 660854-84-2 CAPLUS
 CN Imidazo[1,5-a]pyrazin-6(5H)-one, 5-(3-bromophenyl)-7-[2-(4-fluorophenyl)ethyl]-7,8-dihydro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 660854-85-3 CAPLUS


CN Imidazo[1,5-a]pyrazin-6(5H)-one, 5-(3-bromophenyl)-7,8-dihydro-7-(2-thienylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 660854-86-4 CAPLUS


CN Imidazo[1,5-a]pyrazin-6(5H)-one, 5-(3-bromophenyl)-7-(2-furanylmethyl)-7,8-dihydro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 660854-87-5 CAPLUS

CN Imidazo[1,5-a]pyrazin-6(5H)-one, 5-(3-bromophenyl)-7,8-dihydro-7-(3-thienylmethyl)- (CA INDEX NAME)




RN 660854-88-6 CAPLUS

CN Imidazo[1,5-a]pyrazin-6(5H)-one, 5-(3-bromophenyl)-7-(3-furanylmethyl)-7,8-dihydro- (CA INDEX NAME)




RN 660854-89-7 CAPLUS

CN Imidazo[1,5-a]pyrazin-6(5H)-one, 5-(3-bromophenyl)-7,8-dihydro-7-(3-pyridinylmethyl)- (CA INDEX NAME)




RN 660854-90-0 CAPLUS

CN Imidazo[1,5-a]pyrazin-6(5H)-one, 5-(3-bromophenyl)-7,8-dihydro-7-(2-pyridinylmethyl)- (CA INDEX NAME)




RN 660854-91-1 CAPLUS

CN Imidazo[1,5-a]pyrazin-6(5H)-one, 5-(3-bromophenyl)-7,8-dihydro-7-(4-pyridinylmethyl)- (CA INDEX NAME)




RN 660854-92-2 CAPLUS

CN Imidazo[1,5-a]pyrazin-6(5H)-one, 5-(3-bromophenyl)-7-(cyclohexylmethyl)-7,8-dihydro- (CA INDEX NAME)




RN 660854-93-3 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[5-(3-bromophenyl)-5,6-dihydro-6-oxoimidazo[1,5-a]pyrazin-7(8H)-yl]methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 660854-94-4 CAPLUS

CN Imidazo[1,5-a]pyrazin-6(5H)-one, 5-(3-bromophenyl)-7,8-dihydro-7-(4-piperidinylmethyl)-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 660854-95-5 CAPLUS

CN Imidazo[1,5-a]pyrazin-6(5H)-one, 5-(3-bromophenyl)-7,8-dihydro-7-[(1R)-1-phenylethyl]-, (5S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 660854-96-6 CAPLUS

CN Imidazo[1,5-a]pyrazin-6(5H)-one, 5-(3-bromophenyl)-7,8-dihydro-7-[(1R)-1-phenylethyl]-, (5R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 660854-97-7 CAPLUS

CN Imidazo[1,5-a]pyrazin-6(5H)-one, 5-(3-bromophenyl)-7,8-dihydro-7-[(1S)-1-phenylethyl]-, (5S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 660854-98-8 CAPLUS

CN Imidazo[1,5-a]pyrazin-6(5H)-one, 5-(3-bromophenyl)-7,8-dihydro-7-[(1S)-1-phenylethyl]-, (5R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 660854-99-9 CAPLUS

CN Imidazo[1,5-a]pyrazin-6(5H)-one, 5-(4-bromophenyl)-7,8-dihydro-7-[(1R)-1-phenylethyl]-, (5S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 660855-00-5 CAPLUS

CN Imidazo[1,5-a]pyrazin-6(5H)-one, 5-(4-bromophenyl)-7,8-dihydro-7-[(1R)-1-phenylethyl]-, (5R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 660855-01-6 CAPLUS

CN Imidazo[1,5-a]pyrazin-6(5H)-one, 5-(4-bromophenyl)-7,8-dihydro-7-[(1S)-1-phenylethyl]-, (5S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 660855-02-7 CAPLUS

CN Imidazo[1,5-a]pyrazin-6(5H)-one, 5-(4-bromophenyl)-7,8-dihydro-7-[(1S)-1-phenylethyl]-, (5R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 660855-03-8 CAPLUS

CN Benzonitrile, 4-[(5S)-5,6,7,8-tetrahydro-6-oxo-7-[(1S)-1-phenylethyl]imidazo[1,5-a]pyrazin-5-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 660855-04-9 CAPLUS


CN Benzonitrile, 4-[(5R)-5,6,7,8-tetrahydro-6-oxo-7-[(1S)-1-phenylethyl]imidazo[1,5-a]pyrazin-5-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 660855-05-0 CAPLUS


CN Imidazo[1,5-a]pyrazin-6(5H)-one, 7,8-dihydro-7-(phenylmethyl)-,
monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 660855-06-1 CAPLUS

CN Imidazo[1,5-a]pyrazin-6(5H)-one, 7,8-dihydro-7-[(4-methylphenyl)methyl]-
(CA INDEX NAME)



RN 660855-07-2 CAPLUS


CN Imidazo[1,5-a]pyrazin-6(5H)-one, 7-[(4-fluorophenyl)methyl]-7,8-dihydro-
(CA INDEX NAME)



RN 660855-08-3 CAPLUS


CN Benzonitrile, 3-[5,6,7,8-tetrahydro-6-oxo-7-(phenylmethyl)imidazo[1,5-

a]pyrazin-5-yl]- (CA INDEX NAME)



RN 660855-09-4 CAPLUS


CN Benzonitrile, 3-[5,6,7,8-tetrahydro-7-[(4-methylphenyl)methyl]-6-oxoimidazo[1,5-a]pyrazin-5-yl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 660855-10-7 CAPLUS


CN Benzonitrile, 3-[7-[(4-fluorophenyl)methyl]-5,6,7,8-tetrahydro-6-oxoimidazo[1,5-a]pyrazin-5-yl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 660855-11-8 CAPLUS


CN Benzonitrile, 3-[7-[(4-chlorophenyl)methyl]-5,6,7,8-tetrahydro-6-oxoimidazo[1,5-a]pyrazin-5-yl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 660855-12-9 CAPLUS


CN Benzonitrile, 3-[5,6,7,8-tetrahydro-7-[(4-methoxyphenyl)methyl]-6-oxoimidazo[1,5-a]pyrazin-5-yl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 660855-13-0 CAPLUS


CN Benzonitrile, 3-[7-[2-(4-fluorophenyl)ethyl]-5,6,7,8-tetrahydro-6-oxoimidazo[1,5-a]pyrazin-5-yl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 660855-14-1 CAPLUS


CN Benzonitrile, 3-[5,6,7,8-tetrahydro-6-oxo-7-(2-phenylethyl)imidazo[1,5-a]pyrazin-5-yl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 660855-15-2 CAPLUS


CN Benzonitrile, 3-[7-(cyclopropylmethyl)-5,6,7,8-tetrahydro-6-oxoimidazo[1,5-a]pyrazin-5-yl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 660855-16-3 CAPLUS

CN Imidazo[1,5-a]pyrazin-6(5H)-one, 5-(4'-chloro[1,1'-biphenyl]-4-yl)-7,8-dihydro-7-[(4-methoxyphenyl)methyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 660855-17-4 CAPLUS
 CN Imidazo[1,5-a]pyrazin-6(5H)-one, 7,8-dihydro-7-[(4-methoxyphenyl)methyl]-5-
 [(4-(3-thienyl)phenyl)- (CA INDEX NAME)




RN 660855-18-5 CAPLUS
 CN Imidazo[1,5-a]pyrazin-6(5H)-one, 7-(cyclopropylmethyl)-7,8-dihydro-5-[4-(3-
 thienyl)phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 660855-19-6 CAPLUS


CN Imidazo[1,5-a]pyrazin-6(5H)-one, 5-(4'-(4-(cyclopropylmethyl)thiophen-2-yl)-7,8-dihydro-7-(phenylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 660855-20-9 CAPLUS

CN Imidazo[1,5-a]pyrazin-6(5H)-one, 5-[1,1'-biphenyl]-4-yl-7-[(4-fluorophenyl)methyl]-7,8-dihydro- (CA INDEX NAME)



RN 660855-21-0 CAPLUS


CN Imidazo[1,5-a]pyrazin-6(5H)-one, 5-[1,1'-biphenyl]-3-yl-7-(4-fluorophenylmethyl)-7,8-dihydro- (9CI) (CA INDEX NAME)



● HCl

RN 660855-22-1 CAPLUS


CN Benzoic acid, 4-[5,6,7,8-tetrahydro-6-oxo-7-(phenylmethyl)imidazo[1,5-a]pyrazin-5-yl]-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 660855-23-2 CAPLUS


CN Benzonitrile, 4-[5,6,7,8-tetrahydro-5-methyl-6-oxo-7-(phenylmethyl)imidazo[1,5-a]pyrazin-5-yl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 660855-24-3 CAPLUS


CN Imidazo[1,5-a]pyrazin-6(5H)-one, 5-(4-bromophenyl)-7-(cyclopropylmethyl)-7,8-dihydro-5-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 660855-25-4 CAPLUS

CN Imidazo[1,5-a]pyrazin-6(5H)-one, 5-(3-bromophenyl)-7-(cyclopropylmethyl)-7,8-dihydro-5-methyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 660855-26-5 CAPLUS


CN Imidazo[1,5-a]pyrazin-6(5H)-one, 5-(4-bromophenyl)-7-[(4-

fluorophenyl)methyl]-7,8-dihydro-5-methyl-, monohydrochloride (9CI) (CA
INDEX NAME)




● HCl

RN 660855-27-6 CAPLUS
CN Benzonitrile, 4-[7-[(4-fluorophenyl)methyl]-5,6,7,8-tetrahydro-5-methyl-6-oxoimidazo[1,5-a]pyrazin-5-yl]- (CA INDEX NAME)



RN 660855-28-7 CAPLUS
CN Benzonitrile, 4-[(5S)-7-[(1S)-1-(4-fluorophenyl)ethyl]-5,6,7,8-tetrahydro-5-methyl-6-oxoimidazo[1,5-a]pyrazin-5-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 660855-29-8 CAPLUS


CN Benzonitrile, 4-[(1S)-7-[(1S)-1-(4-fluorophenyl)ethyl]-5,6,7,8-tetrahydro-5-methyl-6-oxoimidazo[1,5-a]pyrazin-5-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 660855-30-1 CAPLUS


CN Imidazo[1,5-a]pyrazin-6(5H)-one, 5-(4-bromophenyl)-7-[(4-fluorophenyl)methyl]-7,8-dihydro-5-(phenylmethyl)- (CA INDEX NAME)



RN 660855-31-2 CAPLUS


CN Benzonitrile, 4-[5,6,7,8-tetrahydro-6-oxo-5,7-bis(phenylmethyl)imidazo[1,5-

a]pyrazin-5-yl]- (CA INDEX NAME)




RN 660855-32-3 CAPLUS

CN Benzonitrile, 4-[7-(cyclopropylmethyl)-5,6,7,8-tetrahydro-6-oxo-5-(phenylmethyl)imidazo[1,5-a]pyrazin-5-yl]- (CA INDEX NAME)



RN 660855-33-4 CAPLUS


CN Imidazo[1,5-a]pyrazine, 5-(4-bromophenyl)-5,6,7,8-tetrahydro-7-[(4-methoxyphenyl)methyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 660855-34-5 CAPLUS


CN Imidazo[1,5-a]pyrazine, 5-(4-bromophenyl)-5,6,7,8-tetrahydro-7-[(4-methoxyphenyl)methyl]- (CA INDEX NAME)



RN 660855-35-6 CAPLUS
 CN Imidazo[1,5-a]pyrazine, 5-(4-bromophenyl)-5,6,7,8-tetrahydro-7-[(4-methoxyphenyl)methyl]-, mono(4-methylbenzenesulfonate) (9CI) (CA INDEX NAME)


CM 1

CRN 660855-34-5
 CMF C20 H20 Br N3 O




CM 2

CRN 104-15-4
 CMF C7 H8 O3 S




RN 660855-54-9 CAPLUS
 CN Benzonitrile, 4-(5,6,7,8-tetrahydro-7-methyl-6-oxoimidazo[1,5-a]pyrazin-5-yl)- (CA INDEX NAME)




RN 660855-55-0 CAPLUS

CN Benzonitrile, 4-[7-(2-(4-fluorophenyl)ethyl)-5,6,7,8-tetrahydro-6-oxoimidazo[1,5-a]pyrazin-5-yl]- (CA INDEX NAME)




RN 660855-56-1 CAPLUS

CN Benzonitrile, 4-[5,6,7,8-tetrahydro-7-[3-(4-morpholinyl)propyl]-6-oxoimidazo[1,5-a]pyrazin-5-yl]- (CA INDEX NAME)




RN 660855-57-2 CAPLUS

CN Benzonitrile, 4-[7-[(4-chlorophenyl)methyl]-5,6,7,8-tetrahydro-6-oxoimidazo[1,5-a]pyrazin-5-yl]- (CA INDEX NAME)




RN 660855-58-3 CAPLUS

CN Benzonitrile, 4-[5,6,7,8-tetrahydro-6-oxo-7-[[4-(trifluoromethyl)phenyl]methyl]imidazo[1,5-a]pyrazin-5-yl]- (CA INDEX NAME)




RN 660855-59-4 CAPLUS

CN Benzonitrile, 4-[5,6,7,8-tetrahydro-7-[(3-methylphenyl)methyl]-6-oxoimidazo[1,5-a]pyrazin-5-yl]- (CA INDEX NAME)




RN 660855-60-7 CAPLUS

CN Benzonitrile, 4-[5,6,7,8-tetrahydro-6-oxo-7-[[3-(trifluoromethyl)phenyl]methyl]imidazo[1,5-a]pyrazin-5-yl]- (CA INDEX NAME)




RN 660855-61-8 CAPLUS

CN Imidazo[1,5-a]pyrazin-6(5H)-one, 7,8-dihydro-5-phenyl-7-(phenylmethyl)-
(CA INDEX NAME)




RN 660855-62-9 CAPLUS

CN Imidazo[1,5-a]pyrazin-6(5H)-one, 7,8-dihydro-7-methyl-5-phenyl- (CA INDEX NAME)




RN 660855-63-0 CAPLUS

CN Imidazo[1,5-a]pyrazin-6(5H)-one, 5-(4-bromophenyl)-7-(cyclopropylmethyl)-
7,8-dihydro- (CA INDEX NAME)




RN 660855-64-1 CAPLUS

CN Imidazo[1,5-a]pyrazin-6(5H)-one, 5-(4-bromophenyl)-7-[(4-chlorophenyl)methyl]-7,8-dihydro- (CA INDEX NAME)




RN 660855-65-2 CAPLUS

CN Imidazo[1,5-a]pyrazin-6(5H)-one, 5-(4-bromophenyl)-7-[(4-(trifluoromethyl)phenyl)methyl]-7,8-dihydro- (CA INDEX NAME)




RN 660855-67-4 CAPLUS

CN Imidazo[1,5-a]pyrazin-6(5H)-one, 5-(4-bromophenyl)-7-[2-(4-fluorophenyl)ethyl]-7,8-dihydro- (CA INDEX NAME)




RN 660855-68-5 CAPLUS

CN Imidazo[1,5-a]pyrazin-6(5H)-one, 5-(4-bromophenyl)-7-[(4-fluorophenyl)methyl]-7,8-dihydro- (CA INDEX NAME)




RN 660855-69-6 CAPLUS

CN Imidazo[1,5-a]pyrazin-6(5H)-one, 5-(3-bromophenyl)-7,8-dihydro-7-methyl-
(CA INDEX NAME)




RN 660855-70-9 CAPLUS

CN Imidazo[1,5-a]pyrazin-6(5H)-one, 5-(3-bromophenyl)-7-(cyclopropylmethyl)-
7,8-dihydro- (CA INDEX NAME)




RN 660855-71-0 CAPLUS

CN Imidazo[1,5-a]pyrazin-6(5H)-one, 5-(3-bromophenyl)-7,8-dihydro-7-[(4-
methoxyphenyl)methyl]- (CA INDEX NAME)




RN 660855-72-1 CAPLUS

CN Imidazo[1,5-a]pyrazin-6(5H)-one, 5-(3-bromophenyl)-7-[(4-fluorophenyl)methyl]-7,8-dihydro- (CA INDEX NAME)




RN 660855-73-2 CAPLUS

CN Imidazo[1,5-a]pyrazin-6(5H)-one, 5-(3-bromophenyl)-7-[(4-chlorophenyl)methyl]-7,8-dihydro- (CA INDEX NAME)




RN 660855-74-3 CAPLUS

CN Imidazo[1,5-a]pyrazin-6(5H)-one, 5-(3-bromophenyl)-7,8-dihydro-7-[(4-methylphenyl)methyl]- (CA INDEX NAME)




RN 660855-75-4 CAPLUS

CN Imidazo[1,5-a]pyrazin-6(5H)-one, 5-(3-bromophenyl)-7,8-dihydro-7-[[4-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)




RN 660855-76-5 CAPLUS

CN Imidazo[1,5-a]pyrazin-6(5H)-one, 5-(3-bromophenyl)-7,8-dihydro-7-[[3-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)




RN 660855-77-6 CAPLUS

CN Imidazo[1,5-a]pyrazin-6(5H)-one, 5-(3-bromophenyl)-7-[(3-fluorophenyl)methyl]-7,8-dihydro- (CA INDEX NAME)




RN 660855-78-7 CAPLUS

CN Imidazo[1,5-a]pyrazin-6(5H)-one, 5-(3-bromophenyl)-7,8-dihydro-7-[(3-methylphenyl)methyl]- (CA INDEX NAME)




RN 660855-79-8 CAPLUS

CN Imidazo[1,5-a]pyrazin-6(5H)-one, 5-(3-bromophenyl)-7,8-dihydro-7-(2-phenylethyl)- (CA INDEX NAME)




RN 660855-80-1 CAPLUS

CN Imidazo[1,5-a]pyrazin-6(5H)-one, 5-(3-bromophenyl)-7,8-dihydro-7-[2-(4-methoxyphenyl)ethyl]- (CA INDEX NAME)




RN 660855-81-2 CAPLUS

CN Imidazo[1,5-a]pyrazin-6(5H)-one, 5-(3-bromophenyl)-7-[2-(4-chlorophenyl)ethyl]-7,8-dihydro- (CA INDEX NAME)




RN 660855-82-3 CAPLUS

CN Imidazo[1,5-a]pyrazin-6(5H)-one, 5-(3-bromophenyl)-7-[2-(3-chlorophenyl)ethyl]-7,8-dihydro- (CA INDEX NAME)




RN 660855-83-4 CAPLUS

CN Imidazo[1,5-a]pyrazin-6(5H)-one, 5-(3-bromophenyl)-7,8-dihydro-7-[2-(4-methylphenyl)ethyl]- (CA INDEX NAME)




RN 660855-84-5 CAPLUS

CN Imidazo[1,5-a]pyrazin-6(5H)-one, 5-(3-bromophenyl)-7-[2-(4-fluorophenyl)ethyl]-7,8-dihydro- (CA INDEX NAME)




RN 660855-85-6 CAPLUS

CN Imidazo[1,5-a]pyrazin-6(5H)-one, 5-(3-bromophenyl)-7,8-dihydro-7-(2-thienylmethyl)- (CA INDEX NAME)




RN 660855-86-7 CAPLUS

CN Imidazo[1,5-a]pyrazin-6(5H)-one, 5-(3-bromophenyl)-7-(2-furanylmethyl)-7,8-dihydro- (CA INDEX NAME)




RN 660855-87-8 CAPLUS

CN Imidazo[1,5-a]pyrazin-6(5H)-one, 5-(3-bromophenyl)-7,8-dihydro-7-(4-piperidinylmethyl)- (CA INDEX NAME)




RN 660855-88-9 CAPLUS

CN Imidazo[1,5-a]pyrazin-6(5H)-one, 7,8-dihydro-7-(phenylmethyl)- (CA INDEX NAME)




RN 660855-89-0 CAPLUS

CN Benzonitrile, 3-[5,6,7,8-tetrahydro-7-[(4-methylphenyl)methyl]-6-oxoimidazo[1,5-a]pyrazin-5-yl]- (CA INDEX NAME)




RN 660855-90-3 CAPLUS

CN Benzonitrile, 3-[7-[(4-fluorophenyl)methyl]-5,6,7,8-tetrahydro-6-oxoimidazo[1,5-a]pyrazin-5-yl]- (CA INDEX NAME)




RN 660855-91-4 CAPLUS

CN Benzonitrile, 3-[7-[(4-chlorophenyl)methyl]-5,6,7,8-tetrahydro-6-oxoimidazo[1,5-a]pyrazin-5-yl]- (CA INDEX NAME)




RN 660855-92-5 CAPLUS

CN Benzonitrile, 3-[5,6,7,8-tetrahydro-7-[(4-methoxyphenyl)methyl]-6-oxoimidazo[1,5-a]pyrazin-5-yl]- (CA INDEX NAME)




RN 660855-93-6 CAPLUS

CN Benzonitrile, 3-[7-(2-(4-fluorophenyl)ethyl)-5,6,7,8-tetrahydro-6-oxoimidazo[1,5-a]pyrazin-5-yl]- (CA INDEX NAME)




RN 660855-94-7 CAPLUS

CN Benzonitrile, 3-[5,6,7,8-tetrahydro-6-oxo-7-(2-phenylethyl)imidazo[1,5-a]pyrazin-5-yl]- (CA INDEX NAME)




RN 660855-95-8 CAPLUS

CN Benzonitrile, 3-[7-(cyclopropylmethyl)-5,6,7,8-tetrahydro-6-oxoimidazo[1,5-a]pyrazin-5-yl]- (CA INDEX NAME)




RN 660855-96-9 CAPLUS

CN Imidazo[1,5-a]pyrazin-6(5H)-one, 5-(4'-chloro[1,1'-biphenyl]-4-yl)-7,8-dihydro-7-[(4-methoxyphenyl)methyl]- (CA INDEX NAME)




RN 660855-97-0 CAPLUS

CN Imidazo[1,5-a]pyrazin-6(5H)-one, 7-(cyclopropylmethyl)-7,8-dihydro-5-[4-(3-thienyl)phenyl]- (CA INDEX NAME)




RN 660855-98-1 CAPLUS

CN Imidazo[1,5-a]pyrazin-6(5H)-one, 5-(4'-fluoro[1,1'-biphenyl]-3-yl)-7,8-dihydro-7-(phenylmethyl)- (CA INDEX NAME)




RN 660855-99-2 CAPLUS

CN Benzoic acid, 4-[5,6,7,8-tetrahydro-6-oxo-7-(phenylmethyl)imidazo[1,5-a]pyrazin-5-yl]-, methyl ester (CA INDEX NAME)




RN 660856-00-8 CAPLUS

CN Benzonitrile, 4-[5,6,7,8-tetrahydro-5-methyl-6-oxo-7-(phenylmethyl)imidazo[1,5-a]pyrazin-5-yl]- (CA INDEX NAME)




RN 660856-01-9 CAPLUS

CN Imidazo[1,5-a]pyrazin-6(5H)-one, 5-(4-bromophenyl)-7-(cyclopropylmethyl)-7,8-dihydro-5-methyl- (CA INDEX NAME)




RN 660856-02-0 CAPLUS

CN Imidazo[1,5-a]pyrazin-6(5H)-one, 5-(3-bromophenyl)-7-(cyclopropylmethyl)-7,8-dihydro-5-methyl- (CA INDEX NAME)



RN 660856-03-1 CAPLUS
 CN Imidazo[1,5-a]pyrazin-6(5H)-one, 5-(4-bromophenyl)-7-[(4-fluorophenyl)methyl]-7,8-dihydro-5-methyl- (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 4 OF 70 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2003:980226 CAPLUS

DOCUMENT NUMBER: 140:428816

TITLE: Quantitative Biopharmaceutics Classification System: The Central Role of Dose/Solubility Ratio

AUTHOR(S): Rinaki, Eleni; Valsami, Georgia; Macheras, Panos

CORPORATE SOURCE: School of Pharmacy, Laboratory of Biopharmaceutics and Pharmacokinetics, University of Athens, Athens, 15771, Greece

SOURCE: Pharmaceutical Research (2003), 20(12), 1917-1925

CODEN: PHREEB; ISSN: 0724-8741

PUBLISHER: Kluwer Academic/Plenum Publishers

DOCUMENT TYPE: Journal

LANGUAGE: English


IT 124423-84-3, Panadiplon

RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(role of dose/solubility ratio)

RN 124423-84-3 CAPLUS


CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-5-(1-methylethyl)- (CA INDEX NAME)



REFERENCE COUNT: 44 THERE ARE 44 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L5 ANSWER 5 OF 70 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2003:738720 CAPLUS
 DOCUMENT NUMBER: 139:350706
 TITLE: Novel Synthetic Approach to 6,7-Dihydro-5H-imidazo[1,5-a]pyrazin-8-ones
 AUTHOR(S): Gopalsamy, Ariamala; Shi, Mengxiao
 CORPORATE SOURCE: Chemical and Screening Sciences, Wyeth Research, Pearl River, NY, 10965, USA
 SOURCE: Organic Letters (2003), 5(21), 3907-3909
 CODEN: ORLEF7; ISSN: 1523-7060
 PUBLISHER: American Chemical Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 139:350706
 IT 618905-37-6P 618905-38-7P 618905-39-8P
 618905-40-1P 618905-41-2P 618905-42-3P
 618905-43-4P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of dihydroimidazo[1,5-a]pyrazinones)
 RN 618905-37-6 CAPLUS
 CN Imidazo[1,5-a]pyrazin-8(5H)-one, 6,7-dihydro-3-(4-methoxyphenyl)-7-methyl-1-phenyl-6-(phenylmethyl)-, (6S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 618905-38-7 CAPLUS
 CN Imidazo[1,5-a]pyrazin-8(5H)-one, 6,7-dihydro-3-(4-methoxyphenyl)-1-phenyl-6,7-bis(phenylmethyl)-, (6S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 618905-39-8 CAPLUS

CN Imidazo[1,5-a]pyrazin-8(5H)-one, 6,7-dihydro-3-(4-methoxyphenyl)-1-phenyl-6-(phenylmethyl)-7-(2-propenyl)-, (6S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 618905-40-1 CAPLUS

CN Imidazo[1,5-a]pyrazin-8(5H)-one, 3-(4-chlorophenyl)-6,7-dihydro-7-methyl-1-phenyl-6-(phenylmethyl)-, (6S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 618905-41-2 CAPLUS

CN Imidazo[1,5-a]pyrazin-8(5H)-one, 3-(4-chlorophenyl)-6,7-dihydro-1-phenyl-6,7-bis(phenylmethyl)-, (6S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 618905-42-3 CAPLUS

CN Imidazo[1,5-a]pyrazin-8(5H)-one, 3-(4-chlorophenyl)-6,7-dihydro-1-phenyl-6-(phenylmethyl)-7-(2-propenyl)-, (6S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 618905-43-4 CAPLUS

CN Imidazo[1,5-a]pyrazin-8(5H)-one, 6,7-dihydro-3-(4-methylphenyl)-1-phenyl-6-(phenylmethyl)-7-(2-propenyl)-, (6S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 6 OF 70 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2003:737747 CAPLUS

DOCUMENT NUMBER: 139:261314

TITLE: Preparation of alkoxy quinazolinone compounds as
all adrenoceptors antagonists useful in therapy
INVENTOR(S): Blagg, Julian; Fray, Michael Jonathan; Lewis, Mark
Llewellyn; Mathias, John Paul; Stefaniak, Mark Henryk;
Stobie, Alan

PATENT ASSIGNEE(S): Pfizer Limited, UK; Pfizer Inc.

SOURCE: PCT Int. Appl., 247 pp.

DOCUMENT TYPE: CODEN: PIXXD2
 LANGUAGE: Patent
 FAMILY ACC. NUM. COUNT: English
 PATENT INFORMATION: 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003076427	A1	20030918	WO 2003-IB998	20030305 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2479016	A1	20030918	CA 2003-2479016	20030305 <--
AU 2003209594	A1	20030922	AU 2003-209594	20030305 <--
EP 1483257	A1	20041208	EP 2003-743965	20030305 <--
EP 1483257	B1	20060913		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003008407	A	20050111	BR 2003-8407	20030305 <--
JP 2005532275	T	20051027	JP 2003-574644	20030305 <--
AT 339414	T	20061015	AT 2003-743965	20030305 <--
ES 2271618	T3	20070416	ES 2003-743965	20030305 <--
US 20040029859	A1	20040212	US 2003-387106	20030312 <--
US 6936619	B2	20050830		
MX 2004PA08939	A	20041126	MX 2004-PA8939	20040914 <--
PRIORITY APPLN. INFO.:				
			GB 2002-6033	A 20020314 <--
			US 2002-374894P	P 20020423 <--
			WO 2003-IB998	W 20030305 <--

OTHER SOURCE(S): MARPAT 139:261314


IT 165894-09-7P, 7-Benzyl-5,6,7,8-tetrahydroimidazo[1,5-a]pyrazine 601515-08-6P, 7-Benzyl-3-bromo-5,6,7,8-tetrahydroimidazo[1,5-a]pyrazine 601515-59-7P, 7-Benzyl-3-(4-methoxypiperidin-1-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyrazine 601515-83-7P, 7-Benzyl-3-(4-morpholinyl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyrazine

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of alkoxy quinazolinone compds. as α 1L adrenoceptors antagonists useful in therapy)


RN 165894-09-7 CAPLUS

CN Imidazo[1,5-a]pyrazine, 5,6,7,8-tetrahydro-7-(phenylmethyl)- (CA INDEX NAME)




RN 601515-08-6 CAPLUS


CN Imidazo[1,5-a]pyrazine, 3-bromo-5,6,7,8-tetrahydro-7-(phenylmethyl)- (CA INDEX NAME)



RN 601515-59-7 CAPLUS
 CN Imidazo[1,5-a]pyrazine, 5,6,7,8-tetrahydro-3-(4-methoxy-1-piperidinyl)-7-(phenylmethyl)- (CA INDEX NAME)




RN 601515-83-7 CAPLUS
 CN Imidazo[1,5-a]pyrazine, 5,6,7,8-tetrahydro-3-(4-morpholinyl)-7-(phenylmethyl)- (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 7 OF 70 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2003:175840 CAPLUS
 DOCUMENT NUMBER: 139:296678
 TITLE: The Mean Dissolution Time Depends on the Dose/Solubility Ratio
 AUTHOR(S): Rinaki, Eleni; Dokoumetzidis, Aristides; Macheras, Panos
 CORPORATE SOURCE: School of Pharmacy, Laboratory of Biopharmaceutics and Pharmacokinetics, University of Athens, Athens, 15771, Greece
 SOURCE: Pharmaceutical Research (2003), 20(3), 406-408
 CODEN: PHREEB; ISSN: 0724-8741
 PUBLISHER: Kluwer Academic/Plenum Publishers
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 IT 124423-84-3, Panadiplon
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (mean dissoln. time depends on drug dose/solubility ratio)
 RN 124423-84-3 CAPLUS
 CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-5-(1-methylethyl)- (CA INDEX NAME)



REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 8 OF 70 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2002:497626 CAPLUS

DOCUMENT NUMBER: 137:352994

TITLE: Synthesis of a new series of imidazo-[1,5-a]pyrido[2,3-e]pyrazines as potential ligands for the GABA receptor complex

AUTHOR(S): Weber, Manuela; Bartsch, Herbert; Erker, Thomas
CORPORATE SOURCE: Institute of Pharmaceutical Chemistry, University of Vienna, Vienna, A-1090, Austria

SOURCE: Monatshefte fuer Chemie (2002), 133(5), 653-659

CODEN: MOCMB7; ISSN: 0026-9247

PUBLISHER: Springer-Verlag Wien

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 137:352994

IT 474977-04-3P 474977-05-4P 474977-06-5P


474977-07-6P 474977-08-7P 474977-09-8P

RL: SPN (Synthetic preparation); PREP (Preparation)

(synthesis of imidazoapyridopyrazines as potential ligands for the GABA receptor complex via cyclization reaction)


RN 474977-04-3 CAPLUS

CN Imidazo[1,5-a]pyrido[2,3-e]pyrazin-4(5H)-one, 3-(5-ethyl-1,2,4-oxadiazol-3-yl)-5-(1-methylethyl)- (CA INDEX NAME)




RN 474977-05-4 CAPLUS

CN Imidazo[1,5-a]pyrido[2,3-e]pyrazin-4(5H)-one, 5-(1-methylethyl)-3-[5-(1-methylethyl)-1,2,4-oxadiazol-3-yl]- (CA INDEX NAME)




RN 474977-06-5 CAPLUS

CN Imidazo[1,5-a]pyrido[2,3-e]pyrazin-4(5H)-one, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-5-(1-methylethyl)- (CA INDEX NAME)




RN 474977-07-6 CAPLUS

CN Imidazo[1,5-a]pyrido[2,3-e]pyrazin-4(5H)-one, 3-[5-(1,1-dimethylethyl)-1,2,4-oxadiazol-3-yl]-5-(1-methylethyl)- (CA INDEX NAME)




RN 474977-08-7 CAPLUS

CN Imidazo[1,5-a]pyrido[2,3-e]pyrazin-4(5H)-one, 3-(5-cyclohexyl-1,2,4-oxadiazol-3-yl)-5-(1-methylethyl)- (CA INDEX NAME)




RN 474977-09-8 CAPLUS

CN Imidazo[1,5-a]pyrido[2,3-e]pyrazin-4(5H)-one, 5-(1-methylethyl)-3-(5-phenyl-1,2,4-oxadiazol-3-yl)- (CA INDEX NAME)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 9 OF 70 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2002:325872 CAPLUS
 DOCUMENT NUMBER: 137:257545
 TITLE: Molecular determinants of recognition and activation at GABAA/benzodiazepine receptors
 AUTHOR(S): Filizola, Marta; Harris, Danni L.
 CORPORATE SOURCE: Molecular Research Institute, Mountain View, CA, 94043, USA
 SOURCE: International Journal of Quantum Chemistry (2002), 88(1), 56-64
 CODEN: IJQCB2; ISSN: 0020-7608
 PUBLISHER: John Wiley & Sons, Inc.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 IT 124423-84-3, U78875
 RL: PAC (Pharmacological activity); PRP (Properties); BIOL (Biological study)
 (mol. determinants of recognition and activation at GABAA/benzodiazepine receptors)
 RN 124423-84-3 CAPLUS
 CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-5-(1-methylethyl)- (CA INDEX NAME)




REFERENCE COUNT: 47 THERE ARE 47 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 10 OF 70 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2001:851115 CAPLUS
 DOCUMENT NUMBER: 136:5907
 TITLE: Synthesis of aryl-amido-cyclohexane derivatives and their use as NK-1 receptor antagonists
 INVENTOR(S): Castro Pineiro, Jose Luis; Dinnell, Kevin; Elliott, Jason Matthew; Hollingworth, Gregory John; Shaw, Duncan Edward; Swain, Christopher John
 PATENT ASSIGNEE(S): Merck Sharp & Dohme Limited, UK
 SOURCE: PCT Int. Appl., 199 pp.
 CODEN: PIXXD2

DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001087838	A1	20011122	WO 2001-GB2145	20010516 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2408849	A1	20011122	CA 2001-2408849	20010516 <--
EP 1286967	A1	20030305	EP 2001-929829	20010516 <--
EP 1286967	B1	20060927		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003533509	T	20031111	JP 2001-584234	20010516 <--
AT 340781	T	20061015	AT 2001-929829	20010516 <--
ES 2273837	T3	20070516	ES 2001-929829	20010516 <--
US 20030236250	A1	20031225	US 2002-276127	20021113 <--
US 7105507	B2	20060912		
PRIORITY APPLN. INFO.:			GB 2000-12240	A 20000519 <--
			WO 2001-GB2145	W 20010516 <--
OTHER SOURCE(S): MARPAT 136:5907				
IT 374795-76-3P				
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (intermediate; synthesis of aryl-amido-cyclohexane derivs. and use as NK-1 receptor antagonists)				
RN 374795-76-3 CAPLUS				
CN Imidazo[1,5-a]pyrazine-7(8H)-carboxylic acid, 5,6-dihydro-, 1,1-dimethylethyl ester (CA INDEX NAME)				



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L5 ANSWER 11 OF 70 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2001:775298 CAPLUS
 DOCUMENT NUMBER: 136:134734
 TITLE: Synthesis of 1,2,4-oxadiazolylimidazo[1,5-a]thieno[2,3-e]pyrazines as ligands for the γ -aminobutyric acid A/benzodiazepine receptor complex
 AUTHOR(S): Erker, Thomas; Trinkl, Karin
 CORPORATE SOURCE: Institute of Pharmaceutical Chemistry, University of Vienna, Vienna, A-1090, Austria
 SOURCE: Heterocycles (2001), 55(10), 1963-1969
 CODEN: HTCYAM; ISSN: 0385-5414

PUBLISHER: Japan Institute of Heterocyclic Chemistry
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 136:134734
 IT 124423-84-3DP, Panadiplon, analogs
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of
 2-(1,2,4-oxadiazol-3-yl)imidazo[1,5-a]thieno[2,3-e]pyrazin-4-
 one derivs. (panadiplon analogs))
 RN 124423-84-3 CAPLUS
 CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-
 5-(1-methylethyl)- (CA INDEX NAME)




REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 12 OF 70 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2001:429266 CAPLUS
 DOCUMENT NUMBER: 135:283056
 TITLE: Characterization of novel benzodiazepine ligands in Spodoptera frugiperda (Sf-9) insect cells
 AUTHOR(S): Lameh, J.; Keohane, A.; Clark, D. J.; Loew, G. H.
 CORPORATE SOURCE: Molecular Research Institute, Mountain View, CA, USA
 SOURCE: Neuroscience Letters (2001), 306(1-2), 25-28
 CODEN: NELED5; ISSN: 0304-3940
 PUBLISHER: Elsevier Science Ireland Ltd.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 IT 124423-84-3, U78875
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
 (characterization of novel benzodiazepine ligands in Spodoptera frugiperda (Sf-9) insect cells and rat cerebellum expressing GABAA receptors containing $\alpha 1$ and $\alpha 6$ subunits)
 RN 124423-84-3 CAPLUS
 CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-5-(1-methylethyl)- (CA INDEX NAME)




REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L5 ANSWER 13 OF 70 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2001:426071 CAPLUS
 DOCUMENT NUMBER: 135:211011
 TITLE: Reaction of quinoxalin-2-ones with TosMIC reagent:
 synthesis of imidazo[1,5-a]quinoxalin-4-ones
 AUTHOR(S): Chen, P.; Barrish, J. C.; Iwanowicz, E.; Lin, J.;
 Bednarz, M. S.; Chen, B.-C.
 CORPORATE SOURCE: Discovery Chemistry, Bristol-Myers Squibb
 Pharmaceutical Research Institute, Princeton, NJ,
 08543-4000, USA
 SOURCE: Tetrahedron Letters (2001), 42(26),
 4293-4295
 CODEN: TELEAY; ISSN: 0040-4039
 PUBLISHER: Elsevier Science Ltd.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 135:211011
 IT 221025-37-2P 357637-50-4P 357637-52-6P
 357637-54-8P 357637-58-2P 357637-76-4P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of imidazo[1,5-a]quinoxalin-4-ones via reaction of
 quinoxalinones with TosMIC reagent)
 RN 221025-37-2 CAPLUS
 CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 5-[(4-methoxyphenyl)methyl]- (CA
 INDEX NAME)



RN 357637-50-4 CAPLUS
 CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 7-methoxy-5-[(4-methoxyphenyl)methyl]-
 (CA INDEX NAME)




RN 357637-52-6 CAPLUS
 CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 7,8-dimethoxy-5-[(4-
 methoxyphenyl)methyl]- (CA INDEX NAME)




RN 357637-54-8 CAPLUS

CN Imidazo[1,5-a]quinoxaline-7-carboxylic acid, 4,5-dihydro-5-[(4-methoxyphenyl)methyl]-4-oxo-, methyl ester (CA INDEX NAME)




RN 357637-58-2 CAPLUS

CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 5-[(4-methoxyphenyl)methyl]-9-nitro- (CA INDEX NAME)




RN 357637-76-4 CAPLUS

CN Imidazo[1,5-a]quinoxaline-8-carboxylic acid, 4,5-dihydro-5-[(4-methoxyphenyl)methyl]-4-oxo-, methyl ester (CA INDEX NAME)



REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L5 ANSWER 14 OF 70 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2001:314869 CAPLUS
 DOCUMENT NUMBER: 135:189620
 TITLE: Metabolic, idiosyncratic toxicity of drugs: overview of the hepatic toxicity induced by the anxiolytic, panadiplon
 AUTHOR(S): Ulrich, R. G.; Bacon, J. A.; Brass, E. P.; Cramer, C. T.; Petrella, D. K.; Sun, E. L.
 CORPORATE SOURCE: Department 463, Cellular and Molecular Toxicology, Abbott Laboratories, Abbott Park, IL, USA
 SOURCE: Chemico-Biological Interactions (2001), 134(3), 251-270
 CODEN: CBINA8; ISSN: 0009-2797
 PUBLISHER: Elsevier Science Ireland Ltd.
 DOCUMENT TYPE: Journal; General Review
 LANGUAGE: English
 IT 124423-84-3, Panadiplon
 RL: ADV (Adverse effect, including toxicity); BIOL (Biological study) (metabolic, idiosyncratic toxicity of drugs: anxiolytic panadiplon-induced hepatic toxicity)
 RN 124423-84-3 CAPLUS
 CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-5-(1-methylethyl)- (CA INDEX NAME)



REFERENCE COUNT: 73 THERE ARE 73 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L5 ANSWER 15 OF 70 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2001:74652 CAPLUS
 DOCUMENT NUMBER: 135:118023
 TITLE: Discriminative stimulus effects of Panadiplon (U-78875), a partial agonist at the benzodiazepine site, in pentobarbital-trained rhesus monkeys

AUTHOR(S): Rowlett, J. K.; Woolverton, W. L.
 CORPORATE SOURCE: Department of Psychiatry and Human Behavior,
 University of Mississippi Medical Center, Jackson, MS,
 39216, USA
 SOURCE: Drug and Alcohol Dependence (2001), 61(3),
 229-236
 CODEN: DADEDV; ISSN: 0376-8716
 PUBLISHER: Elsevier Science Ireland Ltd.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 IT 124423-84-3, U-78875
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological
 study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES
 (Uses)
 (discriminative stimulus effects of Panadiplon in pentobarbital-trained
 rhesus monkeys)
 RN 124423-84-3 CAPLUS
 CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-
 5-(1-methylethyl)- (CA INDEX NAME)



REFERENCE COUNT: 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 16 OF 70 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2000:840662 CAPLUS
 DOCUMENT NUMBER: 134:95133
 TITLE: Development and assessment of a 3D pharmacophore for
 ligand recognition of BDZR/GABAA receptors initiating
 the anxiolytic response
 AUTHOR(S): Harris, Danni L.; Loew, Gilda
 CORPORATE SOURCE: Molecular Research Institute, Mountain View, CA,
 94043, USA
 SOURCE: Bioorganic & Medicinal Chemistry (2000),
 8(11), 2527-2538
 CODEN: BMECEP; ISSN: 0968-0896
 PUBLISHER: Elsevier Science Ltd.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 IT 124423-84-3, U 78875
 RL: BPR (Biological process); BSU (Biological study, unclassified); PRP
 (Properties); BIOL (Biological study); PROC (Process)
 (development and assessment of a 3D pharmacophore for ligand
 recognition of BDZR/GABAA receptors initiating the anxiolytic response)
 RN 124423-84-3 CAPLUS
 CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-
 5-(1-methylethyl)- (CA INDEX NAME)



REFERENCE COUNT: 41 THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 17 OF 70 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2000:688232 CAPLUS

DOCUMENT NUMBER: 133:266729

TITLE: Preparation of novel substituted tetrahydropyrans as neurokinin 1 (NK-1) receptor antagonists

INVENTOR(S): Owen, Simon Neil; Seward, Eileen Mary; Swain, Christopher John; Williams, Brian John

PATENT ASSIGNEE(S): Merck Sharp & Dohme Limited, UK

SOURCE: PCT Int. Appl., 149 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000056727	A1	20000928	WO 2000-GB974	20000316 <--
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JF, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
CA 2367985	A1	20000928	CA 2000-2367985	20000316 <--
EP 1165540	A1	20020102	EP 2000-911045	20000316 <--
EP 1165540	B1	20030813		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
AU 746251	B2	20020418	AU 2000-33042	20000316 <--
HU 2002000441	A2	20020729	HU 2002-441	20000316 <--
HU 2002000441	A3	20020930		
JP 2002540107	T	20021126	JP 2000-606588	20000316 <--
AT 247096	T	20030815	AT 2000-911045	20000316 <--
ES 2203434	T3	20040416	ES 2000-911045	20000316 <--
ZA 2001006844	A	20020820	ZA 2001-6844	20010820 <--
IN 2001CN01225	A	20050304	IN 2001-CN1225	20010903 <--
US 6458830	B1	20021001	US 2001-936343	20010910 <--
PRIORITY APPLN. INFO.:			GB 1999-6480	A 19990319 <--
			GB 1999-24616	A 19991018 <--
			WO 2000-GB974	W 20000316 <--

OTHER SOURCE(S): MARPAT 133:266729

IT 297169-97-2P 297170-65-1P 297170-86-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(target compound; preparation of substituted tetrahydropyrans as neurokinin


1

(NK-1) receptor antagonists)

RN 297169-97-2 CAPLUS

CN Imidazo[1,5-a]pyrazine, 7-[2-[(2R,3S,4S)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]tetrahydro-3-phenyl-2H-pyran-4-yl]ethyl]-5,6,7,8-tetrahydro- (CA INDEX NAME)


Absolute stereochemistry.



RN 297170-65-1 CAPLUS

CN Imidazo[1,5-a]pyrazine, 7-[[(2R,3R,4R)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]tetrahydro-3-phenyl-2H-pyran-4-yl]methyl]-5,6,7,8-tetrahydro- (CA INDEX NAME)


Absolute stereochemistry.



RN 297170-86-6 CAPLUS

CN Imidazo[1,5-a]pyrazine, 7-[2-[(2R,3R,4R)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]tetrahydro-3-phenyl-2H-pyran-4-yl]ethyl]-5,6,7,8-tetrahydro- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 18 OF 70 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2000:554355 CAPLUS

DOCUMENT NUMBER: 133:275846

TITLE: Determinants of recognition of ligands binding to benzodiazepine receptor/GABAA receptors initiating sedation

AUTHOR(S): Harris, D. L.; DeLorey, T. M.; He, X.; Cook, J. M.; Loew, G. H.

CORPORATE SOURCE: Molecular Research Institute, Mountain View, CA, 94043, USA

SOURCE: European Journal of Pharmacology (2000), 401(3), 271-287

PUBLISHER: Elsevier Science B.V.


DOCUMENT TYPE: Journal

LANGUAGE: English

IT 124423-84-3, U78875
 RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); PROC (Process)
 (determinants of recognition of ligands binding to benzodiazepine receptor/GABAA receptors initiating sedation)

RN 124423-84-3 CAPLUS

CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-5-(1-methylethyl)- (CA INDEX NAME)



REFERENCE COUNT: 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 19 OF 70 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2000:286494 CAPLUS

DOCUMENT NUMBER: 133:68365

TITLE: Benzodiazepine-induced hyperphagia: development and assessment of a 3D pharmacophore by computational methods

AUTHOR(S): Filizola, Marta; Harris, Danni L.; Loew, Gilda H.

CORPORATE SOURCE: Molecular Research Institute, Mountain View, CA, 94043, USA

SOURCE: Journal of Biomolecular Structure & Dynamics (2000), 17(5), 769-778
CODEN: JBSDD6; ISSN: 0739-1102

PUBLISHER: Adenine Press


DOCUMENT TYPE: Journal

LANGUAGE: English

IT 124423-84-3, u78875
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(benzodiazepine-induced hyperphagia: development and assessment of 3D pharmacophore by computational method)

RN 124423-84-3 CAPLUS

CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-5-(1-methylethyl)- (CA INDEX NAME)



REFERENCE COUNT: 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 20 OF 70 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2000:42344 CAPLUS

DOCUMENT NUMBER: 132:185328

TITLE: An integrated model for determining causes of poor oral drug absorption

AUTHOR(S): Yu, Lawrence X.

CORPORATE SOURCE: Glaxo Wellcome. Inc., Research Triangle Park, NC, 27709, USA

SOURCE: Pharmaceutical Research (1999), 16(12), 1883-1887
CODEN: PHREEB; ISSN: 0724-8741

PUBLISHER: Kluwer Academic/Plenum Publishers


DOCUMENT TYPE: Journal

LANGUAGE: English

IT 124423-84-3, Panadiplon
RL: BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(an integrated model for determining causes of poor oral drug absorption)

RN 124423-84-3 CAPLUS

CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-5-(1-methylethyl)- (CA INDEX NAME)



REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 21 OF 70 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1999:576928 CAPLUS

DOCUMENT NUMBER: 131:199711

TITLE: Preparation of heterocyclo-substituted imidazopyridopyrazine as protein tyrosine kinase inhibitors

INVENTOR(S): Chen, Ping; Norris, Derek J.; Barrish, Joel C.; Iwanowicz, Edwin J.; Gu, Henry H.; Schieven, Gary L.

PATENT ASSIGNEE(S): Bristol-Myers Squibb Co., USA

SOURCE: PCT Int. Appl., 112 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9945009	A1	19990910	WO 1999-US4499	19990301 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2322311	A1	19990910	CA 1999-2322311	19990301 <--
AU 9933137	A	19990920	AU 1999-33137	19990301 <--
AU 756838	B2	20030123		
EP 1066286	A1	20010110	EP 1999-937929	19990301 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2002505330	T	20020219	JP 2000-534551	19990301 <--
ZA 9901721	A	20001010	ZA 1999-1721	19990303 <--
US 5990109	A	19991123	US 1999-262525	19990304 <--
PRIORITY APPLN. INFO.:			US 1998-76789P	P 19980304 <--
			WO 1999-US4499	W 19990301 <--


OTHER SOURCE(S): MARPAT 131:199711

IT 240815-60-5P 240815-65-0P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of imidazopyridopyrazines as protein tyrosine kinase inhibitors)

RN 240815-60-5 CAPLUS

CN Imidazo[1,5-a]pyrido[2,3-e]pyrazin-4(5H)-one, 5-[(2,4-dimethoxyphenyl)methyl]- (CA INDEX NAME)



RN 240815-65-0 CAPLUS
 CN Pyrido[3,4-e]imidazo[1,5-a]pyrazin-4(5H)-one, 5-[(4-methoxyphenyl)methyl]-
 (9CI) (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 22 OF 70 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1999:335428 CAPLUS

DOCUMENT NUMBER: 131:111335

TITLE: Drug discrimination analysis of partial agonists at
 the benzodiazepine site. I. Differential effects of
 U-78875 across training conditions in baboons and rats

AUTHOR(S): Ator, Nancy A.; Griffiths, Roland R.

CORPORATE SOURCE: Behavioral Biology Research Center, Department of
 Psychiatry and Behavioral Sciences, Johns Hopkins
 School of Medicine, Baltimore, MD, USA

SOURCE: Journal of Pharmacology and Experimental Therapeutics
 (1999), 289(3), 1434-1446

CODEN: JPETAB; ISSN: 0022-3565

PUBLISHER: American Society for Pharmacology and Experimental
 Therapeutics

DOCUMENT TYPE: Journal

LANGUAGE: English


IT 124423-84-3, U-78875

RL: BAC (Biological activity or effector, except adverse); BSU (Biological
 study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES
 (Uses)

(drug discrimination anal. of partial benzodiazepine agonists: U-78875
 differential effect in baboon and rat)

RN 124423-84-3 CAPLUS

CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-
 5-(1-methylethyl)- (CA INDEX NAME)



REFERENCE COUNT: 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 23 OF 70 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1999:189985 CAPLUS

DOCUMENT NUMBER: 131:13351

TITLE: Piperazine Imidazo[1,5-a]quinoxaline Ureas as High-Affinity GABAA Ligands of Dual Functionality
 AUTHOR(S): Jacobsen, E. Jon; Stelzer, Lindsay S.; TenBrink, Ruth E.; Belonga, Kenneth L.; Carter, Donald B.; Im, Haesook K.; Im, Wha Bin; Sethy, Vimala H.; Tang, Andy H.; VonVoigtlander, Philip F.; Petke, James D.; Zhong, Wei-Zhu; Mickelson, John W.

CORPORATE SOURCE: Departments of Structural Analytical and Medicinal Chemistry Central Nervous System Diseases Research Computer Aided Drug Discovery and Pharmacokinetics and Bioanalysis Research Upjohn Laboratories, Pharmacia Upjohn Inc., Kalamazoo, MI, 49001, USA

SOURCE: Journal of Medicinal Chemistry (1999), 42(7), 1123-1144

CODEN: JMCMAR; ISSN: 0022-2623

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English


IT 124423-84-3, PNU 78875 148011-51-2, PNU 91571

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(piperazine imidazo[1,5-a]quinoxaline ureas as high-affinity GABAA ligands of dual functionality)


RN 124423-84-3 CAPLUS

CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-5-(1-methylethyl)- (CA INDEX NAME)



RN 148011-51-2 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxamide, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-N,N-dimethyl- (CA INDEX NAME)




REFERENCE COUNT: 77 THERE ARE 77 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 24 OF 70 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1999:166611 CAPLUS
 DOCUMENT NUMBER: 130:223296
 TITLE: Preparation of imidazoquinoxaline protein tyrosine kinase inhibitors
 INVENTOR(S): Barrish, Joel C.; Spergel, Steven H.
 PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
 SOURCE: PCT Int. Appl., 64 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9910341	A1	19990304	WO 1998-US16026	19980803 <--
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
US 6635626	B1	20031021	US 1998-94797	19980615 <--
AU 9886816	A	19990316	AU 1998-86816	19980803 <--
US 6239133	B1	20010529	US 2000-566002	20000505 <--
PRIORITY APPLN. INFO.:			US 1997-56797P	P 19970825 <--
			US 1998-94297	A1 19980615 <--
			WO 1998-US16026	W 19980803 <--

OTHER SOURCE(S): MARPAT 130:223296
 IT 221025-37-2P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of imidazoquinoxaline protein tyrosine kinase inhibitors)
 RN 221025-37-2 CAPLUS
 CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 5-[(4-methoxyphenyl)methyl]- (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 25 OF 70 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1999:166498 CAPLUS

DOCUMENT NUMBER: 130:223295

TITLE: Preparation of imidazoquinoxaline protein tyrosine kinase inhibitors

INVENTOR(S): Barrish, Joel C.; Chen, Ping; Das, Jagabandhu; Iwanowicz, Edwin J.; Norris, Derek J.; Padmanabha, Ramesh; Roberge, Jacques Y.; Schieven, Gary L.

PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA

SOURCE: PCT Int. Appl., 315 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9909845	A1	19990304	WO 1998-US16027	19980803 <--
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
US 6235740	B1	20010522	US 1998-97338	19980615 <--
AU 9886817	A	19990316	AU 1998-86817	19980803 <--
ZA 9807649	A	20000224	ZA 1998-7649	19980824 <--
PRIORITY APPLN. INFO.:			US 1997-56770P	P 19970825 <--
			US 1997-69159P	P 19971209 <--
			WO 1998-US16027	W 19980803 <--

OTHER SOURCE(S): MARPAT 130:223295

IT 221025-37-2P 221068-01-5P 221068-80-0P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of imidazoquinoxalines as protein tyrosine kinase inhibitors)


RN 221025-37-2 CAPLUS

CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 5-[(4-methoxyphenyl)methyl]- (CA


INDEX NAME)



RN 221068-01-5 CAPLUS
 CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 5-[(4-methoxyphenyl)methyl]-8-nitro-
 (CA INDEX NAME)



RN 221068-80-0 CAPLUS
 CN Imidazo[1,5-a]quinoxaline-5,7(4H)-dicarboxylic acid, 4-oxo-,
 5-(1,1-dimethylethyl) 7-methyl ester (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 26 OF 70 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1999:36260 CAPLUS

DOCUMENT NUMBER: 130:218173

TITLE: Disruption of mitochondrial activities in rabbit and
 human hepatocytes by a quinoxalinone anxiolytic and
 its carboxylic acid metabolite


AUTHOR(S): Ulrich, Roger G.; Bacon, James A.; Cramer, Clay T.;
 Petrella, Diane K.; Sun, Elena L.; Meglasson, Martin
 D.; Holmuhamedov, Ekhsan

CORPORATE SOURCE: Pharmacia and Upjohn, Inc, Kalamazoo, MI, 49007, USA
 SOURCE: Toxicology (1998), 131(1), 33-47

CODEN: TXCYAC; ISSN: 0300-483X

PUBLISHER: Elsevier Science Ireland Ltd.


DOCUMENT TYPE: Journal
 LANGUAGE: English
 IT 124423-84-3, Panadiplon
 RL: ADV (Adverse effect, including toxicity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (disruption of mitochondrial activities in rabbit and human hepatocytes
 by a quinoxalinone anxiolytic and its carboxylic acid metabolite)
 RN 124423-84-3 CAPLUS
 CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-
 5-(1-methylethyl)- (CA INDEX NAME)




REFERENCE COUNT: 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 27 OF 70 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1997:124496 CAPLUS
 DOCUMENT NUMBER: 126:131462
 TITLE: Preparation of fused imidazole derivatives as drugs
 INVENTOR(S): Yoden, Toru; Okada, Minoru; Ishihara, Tsukasa;
 Kinoyama, Isao; Sakuda, Shuichi; Ideyama, Yukitaka;
 Kudoh, Masafumi
 PATENT ASSIGNEE(S): Yamanouchi Pharmaceutical Co., Ltd., Japan
 SOURCE: PCT Int. Appl., 46 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9700257	A1	19970103	WO 1996-JP1610	19960613 <--
W: AL, AM, AU, AZ, BB, BG, BR, BY, CA, CN, CZ, EE, GE, HU, IL, IS, JP, KE, KG, KR, KZ, LK, LR, LS, LT, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9660157	A	19970115	AU 1996-60157	19960613 <--
PRIORITY APPLN. INFO.:			JP 1995-147920	A 19950614 <--
			WO 1996-JP1610	W 19960613 <--
OTHER SOURCE(S):		MARPAT 126:131462		
IT 186422-04-8P				
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of fused imidazole derivs. as drugs)				
RN 186422-04-8 CAPLUS				
CN Imidazo[1,5-a]pyrazine, 5-(9H-fluoren-2-yl)-5,6,7,8-tetrahydro-7-methyl- (CA INDEX NAME)				



IT 186422-27-5P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of fused imidazole derivs. as drugs)
 RN 186422-27-5 CAPLUS
 CN Imidazo[1,5-a]pyrazine, 5-(9H-fluoren-2-yl)-5,6,7,8-tetrahydro-7-
 (phenylmethyl)- (CA INDEX NAME)




L5 ANSWER 28 OF 70 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1996:628622 CAPLUS
 DOCUMENT NUMBER: 126:8073
 TITLE: High-Affinity α -Aminobutyric Acid
 A/Benzodiazepine Ligands: Synthesis and
 Structure-Activity Relationship Studies of a New
 Series of Tetracyclic Imidazoquininoxalines
 AUTHOR(S): Mickelson, John W.; Jacobsen, E. Jon; Carter, Donald
 B.; Im, Haesook K.; Im, Wha Bin; Schreur, Peggy J. K.
 D.; Sethy, Vimala H.; Tang, Andy H.; McGee, James E.;
 Petke, James D.
 CORPORATE SOURCE: Department of Structural and Medicinal Chemistry,
 Upjohn Company, Kalamazoo, MI, 49001, USA
 SOURCE: Journal of Medicinal Chemistry (1996),
 39(23), 4654-4666
 CODEN: JMCMAR; ISSN: 0022-2623
 PUBLISHER: American Chemical Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 IT 124423-84-3DP, U-78875, analogs 148011-51-2DP, U 91571,
 analogs
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological
 study, unclassified); PNU (Preparation, unclassified); BIOL (Biological
 study); PREP (Preparation)
 (synthesis and structure-activity relationship studies of tetracyclic
 imidazoquininoxalines)
 RN 124423-84-3 CAPLUS
 CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-
 5-(1-methylethyl)- (CA INDEX NAME)



RN 148011-51-2 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxamide, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-N,N-dimethyl- (CA INDEX NAME)




IT 176790-89-9P 183802-01-9P 183802-21-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(synthesis and structure-activity relationship studies of tetracyclic imidazoquinoxalines)


RN 176790-89-9 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxamide, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-N-methoxy- (CA INDEX NAME)




RN 183802-01-9 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-4,5-dihydro-5-(3-methyl-1-oxo-2-butenyl)- (9CI) (CA INDEX NAME)



RN 183802-21-3 CAPLUS
CN Imidazo[1,5-a]quinoxaline, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-4,5-dihydro-5-(1-oxo-3-phenyl-2-propenyl)-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT: 52 THERE ARE 52 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 29 OF 70 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1996:513739 CAPLUS

DOCUMENT NUMBER: 125:157765

TITLE: 3-Phenyl-Substituted Imidazo[1,5-a]quinoxalin-4-ones and Imidazo[1,5-a]quinoxaline Ureas That Have High Affinity at the GABAA/Benzodiazepine Receptor Complex

AUTHOR(S): Jacobsen, E. Jon; Stelzer, Lindsay S.; Belonga, Kenneth L.; Carter, Donald B.; Im, Wha Bin; Sethy, Vimala H.; Tang, Andrew H.; VonVoigtlander, Philip F.; Petke, James D.

CORPORATE SOURCE: Department of Structural and Medicinal Chemistry, Pharmacia Upjohn, Kalamazoo, MI, 49001, USA

SOURCE: Journal of Medicinal Chemistry (1996), 39(19), 3820-3836

CODEN: JMCMAR; ISSN: 0022-2623

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 125:157765

IT 148858-14-4P 180207-87-8P 180207-89-0P


180207-96-9P 180208-00-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of 3-phenyl-substituted imidazo[1,5-a]quinoxalin-4-ones and imidazo[1,5-a]quinoxaline ureas with high affinity at the GABAA/benzodiazepine receptor complex)


RN 148858-14-4 CAPLUS

CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 5-(1,1-dimethylethyl)-3-(4-fluorophenyl)- (CA INDEX NAME)




RN 180207-87-8 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 5-(1,1-dimethylethyl)-3-(4-fluorophenyl)-4,5-dihydro- (CA INDEX NAME)




RN 180207-89-0 CAPLUS

CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 5-(1,1-dimethylethyl)-3-(4-methylphenyl)- (CA INDEX NAME)




RN 180207-96-9 CAPLUS

CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 7-chloro-5-[(3,4-dimethoxyphenyl)methyl]-3-(4-fluorophenyl)- (CA INDEX NAME)



RN 180208-00-8 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carbonyl chloride, 6-chloro-3-(4-fluorophenyl)- (CA INDEX NAME)



IT 148012-34-4P 148012-35-5P 148012-56-0P


148012-57-1P 148012-59-3P 148858-63-3P

148858-64-4P 148858-65-5P 148858-66-6P
 148858-68-8P 148858-69-9P 148859-27-2P
 148859-29-4P 148859-30-7P 148891-00-3P
 148891-02-5P 148891-10-5P 148891-12-7P
 152805-98-6P 152805-99-7P 152806-00-3P
 152806-01-4P 152806-02-5P 152806-04-7P
 152806-06-9P 152806-20-7P 152806-23-0P
 152806-24-1P 152806-27-4P 152806-28-5P
 152806-29-6P 152806-36-5P 180207-64-1P
 180207-65-2P 180207-66-3P 180207-67-4P
 180207-68-5P 180207-69-6P 180207-70-9P
 180207-71-0P 180207-72-1P 180207-73-2P
 180207-74-3P 180207-75-4P 180207-76-5P
 180207-77-6P 180207-78-7P 180207-79-8P
 180207-80-1P 180207-81-2P

RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
 (preparation of 3-phenyl-substituted imidazo[1,5-a]quinoxalin-4-ones and imidazo[1,5-a]quinoxaline ureas with high affinity at the GABAA/benzodiazepine receptor complex)


RN 148012-34-4 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxamide, 3-(4-fluorophenyl)-N,N-dimethyl- (CA INDEX NAME)




RN 148012-35-5 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 4,5-dihydro-3-phenyl-5-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 148012-56-0 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(4-fluorophenyl)-4,5-dihydro-5-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 148012-57-1 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxamide, N,N-dimethyl-3-phenyl- (CA INDEX NAME)




RN 148012-59-3 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 4,5-dihydro-3-(4-methylphenyl)-5-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 148858-63-3 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(4-fluorophenyl)-4,5-dihydro-5-(4-morpholinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 148858-64-4 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 5-(3-fluorobenzoyl)-3-(4-fluorophenyl)-4,5-dihydro- (9CI) (CA INDEX NAME)




RN 148858-65-5 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxylic acid, 3-(4-fluorophenyl)-, methyl ester (CA INDEX NAME)




RN 148858-66-6 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxamide, N-(1,1-dimethylethyl)-3-(4-fluorophenyl)- (CA INDEX NAME)




RN 148858-68-8 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxamide, 3-(4-fluorophenyl)- (CA INDEX NAME)




RN 148858-69-9 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxamide, N-ethyl-3-(4-fluorophenyl)- (CA INDEX NAME)




RN 148859-27-2 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 5-(2-fluorobenzoyl)-3-(4-fluorophenyl)-4,5-dihydro- (9CI) (CA INDEX NAME)




RN 148859-29-4 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 7-fluoro-3-(4-fluorophenyl)-4,5-dihydro-5-(4-morpholinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 148859-30-7 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 7-chloro-3-(4-fluorophenyl)-4,5-dihydro-5-(4-morpholinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 148891-00-3 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(4-fluorophenyl)-4,5-dihydro-5-[(3,4,5-trimethyl-1-piperazinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 148891-02-5 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 7-fluoro-3-(4-fluorophenyl)-4,5-dihydro-5-[(3,4,5-trimethyl-1-piperazinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 148891-10-5 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 5-[(3,5-dimethyl-1-piperazinyl)carbonyl]-3-(4-fluorophenyl)-4,5-dihydro- (9CI) (CA INDEX NAME)




RN 148891-12-7 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 5-[(3,5-dimethyl-1-piperazinyl)carbonyl]-7-fluoro-3-(4-fluorophenyl)-4,5-dihydro- (9CI) (CA INDEX NAME)




RN 152805-98-6 CAPLUS

CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 3-(4-methoxyphenyl)-5-(1-methylethyl)- (CA INDEX NAME)




RN 152805-99-7 CAPLUS

CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 7-fluoro-5-(1-methylethyl)-3-phenyl- (CA INDEX NAME)




RN 152806-00-3 CAPLUS

CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 3-(4-fluorophenyl)-5-(1-methylethyl)-
(CA INDEX NAME)




RN 152806-01-4 CAPLUS

CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 7-fluoro-3-(4-fluorophenyl)-5-(1-methylethyl)- (CA INDEX NAME)




RN 152806-02-5 CAPLUS

CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 6-chloro-3-(4-fluorophenyl)-5-(1-methylethyl)- (CA INDEX NAME)




RN 152806-04-7 CAPLUS

CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 5-(1-methylethyl)-3-phenyl- (CA INDEX NAME)




RN 152806-06-9 CAPLUS

CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 5-(1-methylethyl)-3-(4-methylphenyl)-
(CA INDEX NAME)




RN 152806-20-7 CAPLUS

CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 3-(3-fluorophenyl)-5-(1-methylethyl)-
(CA INDEX NAME)




RN 152806-23-0 CAPLUS

CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 7-fluoro-3-(4-methoxyphenyl)-5-(1-methylethyl)- (CA INDEX NAME)




RN 152806-24-1 CAPLUS

CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 6-chloro-3-(4-methoxyphenyl)-5-(1-methylethyl)- (CA INDEX NAME)




RN 152806-27-4 CAPLUS

CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 5-(1-methylethyl)-3-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 152806-28-5 CAPLUS

CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 3-(4-methoxyphenyl)-6-methyl-5-(1-methylethyl)- (CA INDEX NAME)




RN 152806-29-6 CAPLUS

CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 3-(4-fluorophenyl)-6-methyl-5-(1-methylethyl)- (CA INDEX NAME)




RN 152806-36-5 CAPLUS

CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 3-(3-methoxyphenyl)-5-(1-methylethyl)- (CA INDEX NAME)




RN 180207-64-1 CAPLUS

CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 3-(4-chlorophenyl)-5-(1-methylethyl)-
(CA INDEX NAME)




RN 180207-65-2 CAPLUS

CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 5-(1-methylethyl)-3-[4-(trifluoromethyl)phenyl]-
(CA INDEX NAME)




RN 180207-66-3 CAPLUS

CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 3-(2-methoxyphenyl)-5-(1-methylethyl)-
(CA INDEX NAME)




RN 180207-67-4 CAPLUS


CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 7-chloro-3-(4-fluorophenyl)-5-(1-methylethyl)-
(CA INDEX NAME)




RN 180207-68-5 CAPLUS
 CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxamide, N,N-dimethyl-3-(4-fluorophenyl)- (CA INDEX NAME)




RN 180207-69-6 CAPLUS
 CN Imidazo[1,5-a]quinoxaline, 4,5-dihydro-3-phenyl-5-(1-piperidinylcarbonyl)- (9CI) (CA INDEX NAME)



RN 180207-70-9 CAPLUS
 CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxamide, N,N,4-trimethyl-3-phenyl- (CA INDEX NAME)




RN 180207-71-0 CAPLUS
 CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxamide, 3-(4-fluorophenyl)-N,N,4-trimethyl- (CA INDEX NAME)




RN 180207-72-1 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxamide, N,N,4-trimethyl-3-(4-methylphenyl)- (CA INDEX NAME)




RN 180207-73-2 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(4-fluorophenyl)-4,5-dihydro-4-methyl-5-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 180207-74-3 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 4,5-dihydro-4-methyl-3-(4-methylphenyl)-5-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 180207-75-4 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxylic acid, 3-(4-fluorophenyl)-, 1-methylethyl ester (CA INDEX NAME)




RN 180207-76-5 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 5-(4-fluorobenzoyl)-3-(4-fluorophenyl)-4,5-dihydro- (9CI) (CA INDEX NAME)




RN 180207-77-6 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 6-chloro-3-(4-fluorophenyl)-4,5-dihydro-5-(4-morpholinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 180207-78-7 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 5-[(3,5-dimethyl-1-piperazinyl)carbonyl]-4,5-dihydro-3-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 180207-79-8 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 4,5-dihydro-3-(4-methoxyphenyl)-5-[(3,4,5-trimethyl-1-piperazinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 180207-80-1 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 6-chloro-5-[(3,5-dimethyl-1-piperazinyl)carbonyl]-3-(4-fluorophenyl)-4,5-dihydro- (9CI) (CA INDEX NAME)



RN 180207-81-2 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 6-chloro-3-(4-fluorophenyl)-4,5-dihydro-5-[(3,4,5-trimethyl-1-piperazinyl)carbonyl]- (9CI) (CA INDEX NAME)




IT 124423-84-3, U-78875 148011-51-2, U 91571

RL: BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); PROC (Process)

(preparation of 3-phenyl-substituted imidazo[1,5-a]quinoxalin-4-ones and imidazo[1,5-a]quinoxaline ureas with high affinity at the GABAA/benzodiazepine receptor complex)


RN 124423-84-3 CAPLUS

CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-5-(1-methylethyl)- (CA INDEX NAME)



RN 148011-51-2 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxamide, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-N,N-dimethyl- (CA INDEX NAME)



L5 ANSWER 30 OF 70 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1996:494757 CAPLUS

DOCUMENT NUMBER: 125:195687

TITLE: Imidazo[1,5-a]quinoxalines useful as anxiolytic and sedative/hypnotic agents

INVENTOR(S): Tenbrink, Ruth E.; Jacobsen, E. Jon; Gammill, Ronald B.

PATENT ASSIGNEE(S): Upjohn Co., USA

SOURCE: U.S., 85 pp., Cont.-in-part of U.S. Ser. No. 843,650, abandoned.

CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5541324	A	19960730	US 1993-166037	19931213 <--
CA 2110942	A1	19921223	CA 1992-2110942	19920601 <--
US 5574038	A	19961112	US 1995-466959	19950606 <--
US 5668282	A	19970916	US 1995-469719	19950606 <--
PRIORITY APPLN. INFO.:			US 1991-715930	B2 19910614 <--
			US 1992-843650	B2 19920228 <--
			US 1993-166037	A3 19931213 <--

OTHER SOURCE(S): MARPAT 125:195687

IT 148010-51-9P 148010-52-0P 148010-53-1P
 148010-54-2P 148010-55-3P 148010-56-4P
 148010-57-5P 148010-58-6P 148010-59-7P
 148010-62-2P 148010-73-5P 148010-75-7P
 148010-76-8P 148010-77-9P 148010-78-0P
 148010-79-1P 148010-80-4P 148010-81-5P
 148010-82-6P 148010-84-8P 148010-85-9P


148010-86-0P 148010-87-1P 148010-90-6P
148010-91-7P 148010-92-8P 148010-93-9P
148010-95-1P 148010-97-3P 148010-99-5P
148011-00-1P 148011-01-2P 148011-02-3P
148011-03-4P 148011-04-5P 148011-05-6P
148011-06-7P 148011-07-8P 148011-11-4P
148011-12-5P 148011-14-7P 148011-15-8P
148011-16-9P 148011-18-1P 148011-20-5P
148011-21-6P 148011-23-8P 148011-24-9P
148011-25-0P 148011-26-1P 148011-27-2P
148011-28-3P 148011-29-4P 148011-30-7P
148011-31-8P 148011-32-9P 148011-33-0P
148011-34-1P 148011-35-2P 148011-36-3P
148011-37-4P 148011-38-5P 148011-39-6P
148011-40-9P 148011-41-0P 148011-42-1P
148011-43-2P 148011-44-3P 148011-45-4P
148011-46-5P 148011-47-6P 148011-48-7P
148011-50-1P 148011-51-2P 148011-52-3P
148011-53-4P 148011-54-5P 148011-55-6P
148011-56-7P 148011-57-8P 148011-58-9P
148011-59-0P 148011-60-3P 148011-61-4P
148011-62-5P 148011-63-6P 148011-64-7P
148011-65-8P 148011-69-2P 148011-72-7P
148011-73-8P 148011-74-9P 148011-79-4P
148011-80-7P 148011-81-8P 148011-85-2P
148011-86-3P 148011-95-4P 148011-99-8P
148012-02-6P 148012-03-7P 148012-04-8P
148012-05-9P 148012-06-0P 148012-07-1P
148012-08-2P 148012-10-6P 148012-11-7P
148012-21-9P 148012-22-0P 148012-23-1P
148012-26-4P 148012-27-5P 148012-30-0P
148012-31-1P 148012-32-2P 148012-33-3P
148012-34-4P 148012-35-5P 148012-36-6P
148012-37-7P 148012-38-8P 148012-39-9P
148012-40-2P 148012-41-3P 148012-42-4P
148012-44-6P 148012-46-8P 148012-47-9P
148012-48-0P 148012-49-1P 148012-50-4P
148012-51-5P 148012-52-6P 148012-53-7P
148012-54-8P 148012-55-9P 148012-56-0P
148012-57-1P 148012-59-3P 148012-60-6P
148012-61-7P 148012-62-8P 148012-63-9P
148012-64-0P 148012-65-1P 148012-69-5P
148012-72-0P 148012-73-1P 148012-76-4P
148012-77-5P 148012-80-0P 148012-82-2P
148012-83-3P 148858-22-4P 148858-23-5P
148858-28-0P 148858-30-4P 148858-34-8P
148858-39-3P 148858-43-9P 148858-44-0P
148858-45-1P 148858-48-4P 148858-51-9P
148858-53-1P 148858-54-2P 148858-55-3P
148858-56-4P 148858-57-5P 148858-59-7P
148858-60-0P 148858-63-3P 148858-64-4P
148858-65-5P 148858-66-6P 148858-67-7P
148858-68-8P 148858-69-9P 148858-95-1P
148858-96-2P 148858-97-3P 148858-99-5P
148859-00-1P 148859-08-9P 148859-09-0P
148859-10-3P 148859-11-4P 148859-12-5P
148859-13-6P 148859-14-7P 148859-16-9P
148859-17-0P 148859-18-1P 148859-19-2P
148859-20-5P 148859-21-6P 148859-22-7P
148859-23-8P 148859-24-9P 148859-25-0P
148859-26-1P 148859-27-2P 148859-28-3P
148859-29-4P 148859-30-7P 148859-31-8P

148859-35-2P 148859-37-4P 148890-50-0P
 148890-81-7P 148890-82-8P 148890-83-9P
 148890-85-1P 148890-86-2P 148890-87-3P
 148890-88-4P 148890-89-5P 148890-90-8P
 148890-91-9P 148890-92-0P 148890-93-1P
 148890-94-2P 148890-95-3P 148890-96-4P
 148890-97-5P 148890-98-6P 148891-00-3P
 148891-01-4P 148891-02-5P 148891-03-6P
 148891-04-7P 148891-05-8P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (imidazo[1,5-a]quinoxalines useful as anxiolytic and sedative/hypnotic agents)


RN 148010-51-9 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxamide, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-N,N,4,4-tetramethyl- (CA INDEX NAME)




RN 148010-52-0 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carbothioic acid, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-4,4-dimethyl-, S-phenyl ester (CA INDEX NAME)




RN 148010-53-1 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxamide, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-4,4-dimethyl- (CA INDEX NAME)




RN 148010-54-2 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxamide, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-N,N-diethyl-4,4-dimethyl- (CA INDEX NAME)




RN 148010-55-3 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxamide, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-N,N,4,4-trimethyl- (CA INDEX NAME)




RN 148010-56-4 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxamide, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-N-ethyl-4,4-dimethyl- (CA INDEX NAME)




RN 148010-57-5 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carbothioic acid, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-4,4-dimethyl-, S-methyl ester (CA INDEX NAME)




RN 148010-58-6 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carbothioic acid, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-4,4-dimethyl-, S-ethyl ester (CA INDEX NAME)




RN 148010-59-7 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxaldehyde, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-4,4-dimethyl- (CA INDEX NAME)




RN 148010-62-2 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 7-chloro-3-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-4,5-dihydro-5-[(2,4,6-trimethyl-1-piperazinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 148010-73-5 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 7-fluoro-4,4-dimethyl-3-[5-(1-methylethyl)-1,2,4-oxadiazol-3-yl]-5-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 148010-75-7 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxylic acid, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 148010-76-8 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 5-benzoyl-3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-4,5-dihydro- (9CI) (CA INDEX NAME)




RN 148010-77-9 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 5-acetyl-3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-4,5-dihydro- (9CI) (CA INDEX NAME)




RN 148010-78-0 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-5-(2-furanylcarbonyl)-4,5-dihydro- (9CI) (CA INDEX NAME)




RN 148010-79-1 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxylic acid, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-6-methyl-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 148010-80-4 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 7-chloro-3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-4,5-dihydro-5-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 148010-81-5 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxamide, 7-chloro-3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-N,N-dimethyl- (CA INDEX NAME)




RN 148010-82-6 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxylic acid, 7-chloro-3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 148010-84-8 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 5-benzoyl-7-chloro-3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-4,5-dihydro- (9CI) (CA INDEX NAME)




RN 148010-85-9 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxylic acid, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-6-fluoro-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 148010-86-0 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 5-acetyl-7-chloro-3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-4,5-dihydro- (9CI) (CA INDEX NAME)




RN 148010-87-1 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 7-chloro-3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-4,5-dihydro-5-(1-oxopropyl)- (9CI) (CA INDEX NAME)




RN 148010-90-6 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 7-chloro-4,5-dihydro-3-[5-(1-methylethyl)-1,2,4-oxadiazol-3-yl]-5-(1-pyrrolidinylicarbonyl)- (9CI) (CA INDEX NAME)




RN 148010-91-7 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxamide, 7-chloro-N,N-dimethyl-3-[5-(1-methylethyl)-1,2,4-oxadiazol-3-yl]- (CA INDEX NAME)




RN 148010-92-8 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 7-chloro-3-(5-ethyl-1,2,4-oxadiazol-3-yl)-4,5-dihydro-5-(1-pyrrolidinylicarbonyl)- (9CI) (CA INDEX NAME)




RN 148010-93-9 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxamide, 7-chloro-3-(5-ethyl-1,2,4-oxadiazol-3-yl)-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 148010-95-1 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 7-fluoro-4,5-dihydro-3-[5-(1-methylethyl)-1,2,4-oxadiazol-3-yl]-5-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 148010-97-3 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 6-chloro-4,5-dihydro-3-[5-(1-methylethyl)-1,2,4-oxadiazol-3-yl]-5-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 148010-99-5 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 6-chloro-3-(5-ethyl-1,2,4-oxadiazol-3-yl)-4,5-dihydro-5-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 148011-00-1 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxamide, 6-chloro-N,N-dimethyl-3-[5-(1-methylethyl)-1,2,4-oxadiazol-3-yl]- (CA INDEX NAME)




RN 148011-01-2 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 6-chloro-4,5-dihydro-3-[3-(1-methylethyl)-1,2,4-oxadiazol-5-yl]-5-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 148011-02-3 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxamide, 6-chloro-3-(5-ethyl-1,2,4-oxadiazol-3-yl)-N,N-dimethyl- (CA INDEX NAME)




RN 148011-03-4 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxamide, 6-chloro-N,N-dimethyl-3-[3-(1-methylethyl)-1,2,4-oxadiazol-5-yl]- (CA INDEX NAME)




RN 148011-04-5 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 7-chloro-3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-4,5-dihydro-4,4-dimethyl-5-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 148011-05-6 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxamide, 7-chloro-3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-N,N,4,4-tetramethyl- (CA INDEX NAME)




RN 148011-06-7 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 7-chloro-4,5-dihydro-4,4-dimethyl-3-[5-(1-methylethyl)-1,2,4-oxadiazol-3-yl]-5-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 148011-07-8 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxamide, 7-chloro-N,N,4,4-tetramethyl-3-[5-(1-methylethyl)-1,2,4-oxadiazol-3-yl]- (CA INDEX NAME)




RN 148011-11-4 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 7-chloro-3-(5-ethyl-1,2,4-oxadiazol-3-yl)-4,5-dihydro-4,4-dimethyl-5-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 148011-12-5 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxamide, 7-chloro-3-(5-ethyl-1,2,4-oxadiazol-3-yl)-N,N,4,4-tetramethyl- (CA INDEX NAME)




RN 148011-14-7 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 6-chloro-4,5-dihydro-4,4-dimethyl-3-[5-(1-methylethyl)-1,2,4-oxadiazol-3-yl]-5-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 148011-15-8 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxamide, 6-chloro-N,N,4,4-tetramethyl-3-[5-(1-methylethyl)-1,2,4-oxadiazol-3-yl]- (CA INDEX NAME)




RN 148011-16-9 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 6-chloro-3-(5-ethyl-1,2,4-oxadiazol-3-yl)-4,5-dihydro-4,4-dimethyl-5-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 148011-18-1 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxamide, 6-chloro-3-(5-ethyl-1,2,4-oxadiazol-3-yl)-N,N,4,4-tetramethyl- (CA INDEX NAME)




RN 148011-20-5 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-4,5-dihydro-5-(1-oxopropyl)- (9CI) (CA INDEX NAME)




RN 148011-21-6 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-acetic acid, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)- α -oxo-, ethyl ester (CA INDEX NAME)




RN 148011-23-8 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-4,5-dihydro-5-(4-morpholinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 148011-24-9 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-5-[(3,5-dimethyl-1H-pyrazol-1-yl)carbonyl]-4,5-dihydro- (9CI) (CA INDEX NAME)




RN 148011-25-0 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 5-acetyl-3-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-4,5-dihydro-4,4-dimethyl- (9CI) (CA INDEX NAME)




RN 148011-26-1 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 5-acetyl-3-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-4,5-dihydro- (9CI) (CA INDEX NAME)




RN 148011-27-2 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxamide, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-6-fluoro-N,N-dimethyl- (CA INDEX NAME)




RN 148011-28-3 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-6-fluoro-4,5-dihydro-5-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 148011-29-4 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 5-acetyl-3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-6-fluoro-4,5-dihydro- (9CI) (CA INDEX NAME)




RN 148011-30-7 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 5-benzoyl-3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-6-fluoro-4,5-dihydro- (9CI) (CA INDEX NAME)




RN 148011-31-8 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 5-acetyl-3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-7-fluoro-4,5-dihydro- (9CI) (CA INDEX NAME)




RN 148011-32-9 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxamide, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-7-fluoro-N,N-dimethyl- (CA INDEX NAME)




RN 148011-33-0 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-7-fluoro-4,5-dihydro-5-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 148011-34-1 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 5-benzoyl-3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-7-fluoro-4,5-dihydro- (9CI) (CA INDEX NAME)




RN 148011-35-2 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-7-fluoro-4,5-dihydro-5-(1H-imidazol-1-ylcarbonyl)- (9CI) (CA INDEX NAME)




RN 148011-36-3 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-7-fluoro-4,5-dihydro-5-(4-morpholinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 148011-37-4 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 5-acetyl-3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-4,5-dihydro-4,4-dimethyl- (9CI) (CA INDEX NAME)




RN 148011-38-5 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxylic acid, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-4,4-dimethyl-, methyl ester (CA INDEX NAME)




RN 148011-39-6 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxylic acid, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-4,4-dimethyl-, 1-methylethyl ester (CA INDEX NAME)




RN 148011-40-9 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-acetic acid, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-4,4-dimethyl-α-oxo-, ethyl ester (CA INDEX NAME)




RN 148011-41-0 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxylic acid, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-4,4-dimethyl-, phenyl ester (CA INDEX NAME)




RN 148011-42-1 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-4,5-dihydro-4,4-dimethyl-5-(oxo-1-pyrrolidinylacetyl)- (9CI) (CA INDEX NAME)




RN 148011-43-2 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 6-chloro-3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-4,5-dihydro-5-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 148011-44-3 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxamide, 6-chloro-3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-N,N-dimethyl- (CA INDEX NAME)




RN 148011-45-4 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carbothioic acid, 6-chloro-3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-, S-methyl ester (CA INDEX NAME)




RN 148011-46-5 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-4,5-dihydro-5-(trifluoroacetyl)- (9CI) (CA INDEX NAME)




RN 148011-47-6 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-4,5-dihydro-5-(1H-imidazol-1-ylcarbonyl)- (9CI) (CA INDEX NAME)




RN 148011-48-7 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-4,5-dihydro-5-(2-pyridinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 148011-50-1 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxamide, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-N-phenyl- (CA INDEX NAME)




RN 148011-51-2 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxamide, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-N,N-dimethyl- (CA INDEX NAME)




RN 148011-52-3 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxamide, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-N-methyl- (CA INDEX NAME)




RN 148011-53-4 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxamide, N-(2-chlorophenyl)-3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)- (CA INDEX NAME)




RN 148011-54-5 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxamide, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-N-(1-methylethyl)- (CA INDEX NAME)




RN 148011-55-6 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxamide, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-N,N-diethyl- (CA INDEX NAME)




RN 148011-56-7 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-4,5-dihydro-5-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 148011-57-8 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carbothioic acid, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-, S-phenyl ester (CA INDEX NAME)




RN 148011-58-9 CAPLUS


CN Imidazo[1,5-a]quinoxaline-5(4H)-carbothioic acid, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-, S-ethyl ester (CA INDEX NAME)




RN 148011-59-0 CAPLUS
 CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxamide, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-N-ethyl- (CA INDEX NAME)



RN 148011-60-3 CAPLUS
 CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxamide, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)- (CA INDEX NAME)




RN 148011-61-4 CAPLUS
 CN Imidazo[1,5-a]quinoxaline-5(4H)-carbothioic acid, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-, S-methyl ester (CA INDEX NAME)




RN 148011-62-5 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-4,5-dihydro-4,4-dimethyl-5-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 148011-63-6 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(5-cyclopentyl-1,2,4-oxadiazol-3-yl)-4,5-dihydro-5-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 148011-64-7 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 4,5-dihydro-4,4-dimethyl-3-[3-(1-methylethyl)-1,2,4-oxadiazol-5-yl]-5-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)



RN 148011-65-8 CAPLUS


CN Imidazo[1,5-a]quinoxaline, 7-chloro-4,5-dihydro-4,4-dimethyl-3-[3-(1-methylethyl)-1,2,4-oxadiazol-5-yl]-5-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)



RN 148011-69-2 CAPLUS


CN Imidazo[1,5-a]quinoxaline, 4,5-dihydro-4-methyl-3-[3-(1-methylethyl)-1,2,4-oxadiazol-5-yl]-5-(1-pyrrolidinylcarbonyl)-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 148011-72-7 CAPLUS

CN Spiro[cyclopentane-1,4'-(5'H)-imidazo[1,5-a]quinoxaline], 3'-[3-(1-methylethyl)-1,2,4-oxadiazol-5-yl]-5'-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 148011-73-8 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 7-chloro-4,5-dihydro-3-[3-(1-methylethyl)-1,2,4-oxadiazol-5-yl]-5-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 148011-74-9 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 7-fluoro-4,5-dihydro-3-[3-(1-methylethyl)-1,2,4-oxadiazol-5-yl]-5-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)



RN 148011-79-4 CAPLUS


CN Spiro[cyclopentane-1,4'-(5'H)-imidazo[1,5-a]quinoxaline], 3'-[5-(1-methylethyl)-1,2,4-oxadiazol-3-yl]-5'-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)



RN 148011-80-7 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 7-fluoro-4,5-dihydro-4-methyl-3-[3-(1-methylethyl)-1,2,4-oxadiazol-5-yl]-5-(1-pyrrolidinylcarbonyl)-, (S)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 148011-81-8 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 7-fluoro-4,5-dihydro-4-methyl-3-[5-(1-methylethyl)-1,2,4-oxadiazol-3-yl]-5-(1-pyrrolidinylcarbonyl)-, (S)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 148011-85-2 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 4-ethyl-4,5-dihydro-3-[5-(1-methylethyl)-1,2,4-oxadiazol-3-yl]-5-(1-pyrrolidinylcarbonyl)-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 148011-86-3 CAPLUS


CN Imidazo[1,5-a]quinoxaline, 4-ethyl-4,5-dihydro-3-[3-(1-methylethyl)-1,2,4-oxadiazol-5-yl]-5-(1-pyrrolidinylcarbonyl)-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 148011-95-4 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(2-benzoxazolyl)-7-fluoro-4,5-dihydro-5-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 148011-99-8 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 7-fluoro-4,5-dihydro-3-phenyl-5-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 148012-02-6 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(2-benzoxazolyl)-4,5-dihydro-5-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 148012-03-7 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 7-fluoro-3-(4-fluorophenyl)-4,5-dihydro-4,4-dimethyl-5-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 148012-04-8 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-[5-(1,1-dimethylethyl)-1,2,4-oxadiazol-3-yl]-7-fluoro-4,5-dihydro-5-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 148012-05-9 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-[5-(1,1-dimethylethyl)-1,2,4-oxadiazol-3-yl]-4,5-dihydro-5-(4-morpholinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 148012-06-0 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-[5-(1,1-dimethylethyl)-1,2,4-oxadiazol-3-yl]-7-fluoro-4,5-dihydro-4,4-dimethyl-5-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 148012-07-1 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-[5-(1,1-dimethylethyl)-1,2,4-oxadiazol-3-yl]-6-fluoro-4,5-dihydro-5-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 148012-08-2 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxamide, 3-(5-ethyl-1,2,4-oxadiazol-3-yl)-N,N-dimethyl- (CA INDEX NAME)




RN 148012-10-6 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(5-ethyl-1,2,4-oxadiazol-3-yl)-4,5-dihydro-4,4-dimethyl-5-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 148012-11-7 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(5-ethyl-1,2,4-oxadiazol-3-yl)-4,5-dihydro-5-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 148012-21-9 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 4,5-dihydro-7-methyl-3-[5-(1-methylethyl)-1,2,4-oxadiazol-3-yl]-5-(1-pyrrolidinylicarbonyl)- (9CI) (CA INDEX NAME)




RN 148012-22-0 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxamide, 3-[5-(1,1-dimethylethyl)-1,2,4-oxadiazol-3-yl]-N,N-dimethyl- (CA INDEX NAME)




RN 148012-23-1 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxamide, 3-[5-(1,1-dimethylethyl)-1,2,4-oxadiazol-3-yl]-N,N,4,4-tetramethyl- (CA INDEX NAME)




RN 148012-26-4 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 4,5-dihydro-4,4-dimethyl-3-[5-(1-methylethyl)-1,2,4-oxadiazol-3-yl]-5-(1-pyrrolidinylicarbonyl)- (9CI) (CA INDEX NAME)




RN 148012-27-5 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxamide, N,N,4,4-tetramethyl-3-[5-(1-methylethyl)-1,2,4-oxadiazol-3-yl]- (CA INDEX NAME)




RN 148012-30-0 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxamide, N,N-dimethyl-3-[5-(1-methylethyl)-1,2,4-oxadiazol-3-yl]- (CA INDEX NAME)




RN 148012-31-1 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 4,5-dihydro-4,4-dimethyl-3-(4-methylphenyl)-5-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 148012-32-2 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxamide, N,N,4,4-tetramethyl-3-(4-methylphenyl)- (CA INDEX NAME)




RN 148012-33-3 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(4-fluorophenyl)-4,5-dihydro-4,4-dimethyl-5-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 148012-34-4 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxamide, 3-(4-fluorophenyl)-N,N-dimethyl- (CA INDEX NAME)




RN 148012-35-5 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 4,5-dihydro-3-phenyl-5-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 148012-36-6 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 4,5-dihydro-3-[5-(1-methylethyl)-1,2,4-oxadiazol-3-yl]-5-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 148012-37-7 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxamide, N,N-dimethyl-3-[3-(1-methylethyl)-1,2,4-oxadiazol-5-yl]- (CA INDEX NAME)




RN 148012-38-8 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxamide, N,N,4,4-tetramethyl-3-[3-(1-methylethyl)-1,2,4-oxadiazol-5-yl]- (CA INDEX NAME)




RN 148012-39-9 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxamide, N,N,4,4-tetramethyl-3-phenyl- (CA INDEX NAME)




RN 148012-40-2 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxamide, 6-chloro-N,N,4,4-tetramethyl-3-phenyl- (CA INDEX NAME)




RN 148012-41-3 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 7-chloro-4,5-dihydro-4,4-dimethyl-3-phenyl-5-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 148012-42-4 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxamide, 7-chloro-N,N,4,4-tetramethyl-3-phenyl- (CA INDEX NAME)




RN 148012-44-6 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 4,5-dihydro-6-methyl-3-[5-(1-methylethyl)-1,2,4-oxadiazol-3-yl]-5-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 148012-46-8 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxamide, N,N,6-trimethyl-3-[5-(1-methylethyl)-1,2,4-oxadiazol-3-yl]- (CA INDEX NAME)




RN 148012-47-9 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-[5-(1,1-dimethylethyl)-1,2,4-oxadiazol-3-yl]-4,5-dihydro-5-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 148012-48-0 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-[5-(1,1-dimethylethyl)-1,2,4-oxadiazol-3-yl]-4,5-dihydro-4,4-dimethyl-5-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 148012-49-1 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 7-chloro-3-[5-(1,1-dimethylethyl)-1,2,4-oxadiazol-3-yl]-4,5-dihydro-5-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 148012-50-4 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxamide, 7-chloro-3-[5-(1,1-dimethylethyl)-1,2,4-oxadiazol-3-yl]-N,N-dimethyl- (CA INDEX NAME)




RN 148012-51-5 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxamide, 7-chloro-3-[5-(1,1-dimethylethyl)-1,2,4-oxadiazol-3-yl]-N,N,4,4-tetramethyl- (CA INDEX NAME)




RN 148012-52-6 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 6-chloro-3-[5-(1,1-dimethylethyl)-1,2,4-oxadiazol-3-yl]-4,5-dihydro-4,4-dimethyl-5-(1-pyrrolidinylcarbonyl)- (9CI)
(CA INDEX NAME)




RN 148012-53-7 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxamide, 6-chloro-3-[5-(1,1-dimethylethyl)-1,2,4-oxadiazol-3-yl]-N,N,4,4-tetramethyl- (CA INDEX NAME)




RN 148012-54-8 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 6-chloro-3-[5-(1,1-dimethylethyl)-1,2,4-oxadiazol-3-yl]-4,5-dihydro-5-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 148012-55-9 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxamide, 6-chloro-3-[5-(1,1-dimethylethyl)-1,2,4-oxadiazol-3-yl]-N,N-dimethyl- (CA INDEX NAME)




RN 148012-56-0 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(4-fluorophenyl)-4,5-dihydro-5-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 148012-57-1 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxamide, N,N-dimethyl-3-phenyl- (CA INDEX NAME)




RN 148012-59-3 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 4,5-dihydro-3-(4-methylphenyl)-5-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 148012-60-6 CAPLUS


CN Imidazo[1,5-a]quinoxaline, 5-benzoyl-3-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-4,5-dihydro- (9CI) (CA INDEX NAME)




RN 148012-61-7 CAPLUS
 CN Imidazo[1,5-a]quinoxaline, 3-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-4,5-dihydro-5-(1-oxopropyl)- (9CI) (CA INDEX NAME)



RN 148012-62-8 CAPLUS
 CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxylic acid, 3-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-, phenyl ester (CA INDEX NAME)




RN 148012-63-9 CAPLUS
 CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxylic acid, 3-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-, ethyl ester (CA INDEX NAME)




RN 148012-64-0 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxamide, 3-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-N,N-diethyl- (CA INDEX NAME)




RN 148012-65-1 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-5-(2-furanylcarbonyl)-4,5-dihydro- (9CI) (CA INDEX NAME)




RN 148012-69-5 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 4,5-dihydro-5-(1-pyrrolidinylcarbonyl)-3-[5-(3,3,3-trifluoropropyl)-1,2,4-oxadiazol-3-yl]- (9CI) (CA INDEX NAME)




RN 148012-72-0 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 7-fluoro-4,5-dihydro-5-(1-pyrrolidinylcarbonyl)-3-[5-(3,3,3-trifluoro-2-methylpropyl)-1,2,4-oxadiazol-3-yl]- (9CI) (CA INDEX NAME)



RN 148012-73-1 CAPLUS


CN Imidazo[1,5-a]quinoxaline, 4,5-dihydro-5-(1-pyrrolidinylcarbonyl)-3-[5-(3,3,3-trifluoro-2-methylpropyl)-1,2,4-oxadiazol-3-yl]- (9CI) (CA INDEX NAME)



RN 148012-76-4 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 7-fluoro-4,5-dihydro-4-methyl-3-[5-(1-methylethyl)-1,2,4-oxadiazol-3-yl]-5-(1-pyrrolidinylcarbonyl)-, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 148012-77-5 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(5-cyclopentyl-1,2,4-oxadiazol-3-yl)-7-fluoro-4,5-dihydro-4-methyl-5-(4-morpholinylacetyl)-, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 148012-80-0 CAPLUS


CN Imidazo[1,5-a]quinoxaline, 3-(5-cyclopentyl-1,2,4-oxadiazol-3-yl)-7-fluoro-4,5-dihydro-4-methyl-5-(1-pyrrolidinylacetyl)-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 148012-82-2 CAPLUS
 CN Pyrrolidine, 1-[[3-(5-cyclopentyl-1,2,4-oxadiazol-3-yl)-7-fluoro-4-methylimidazo[1,5-a]quinoxalin-5(4H)-yl]acetyl]-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 148012-83-3 CAPLUS
 CN Imidazo[1,5-a]quinoxaline, 7-fluoro-4,5-dihydro-4-methyl-3-[5-(1-methylcyclopropyl)-1,2,4-oxadiazol-3-yl]-5-(2-pyridinylmethyl)-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 148858-22-4 CAPLUS
 CN Imidazo[1,5-a]quinoxaline, 5-benzoyl-3-[5-(1,1-dimethylethyl)-1,2,4-oxadiazol-3-yl]-4,5-dihydro- (9CI) (CA INDEX NAME)




RN 148858-23-5 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 5-benzoyl-3-[5-(1,1-dimethylethyl)-1,2,4-oxadiazol-3-yl]-7-fluoro-4,5-dihydro- (9CI) (CA INDEX NAME)




RN 148858-28-0 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxylic acid, 3-[5-(1,1-dimethylethyl)-1,2,4-oxadiazol-3-yl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 148858-30-4 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxylic acid, 3-(2-benzoxazolyl)-, methyl ester (CA INDEX NAME)




RN 148858-34-8 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[[3-(1,1-dimethylethyl)-1,2,4-oxadiazol-3-yl]imidazo[1,5-a]quinoxalin-5(4H)-yl]carbonyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 148858-39-3 CAPLUS


CN Imidazo[1,5-a]quinoxaline, 4,5-dihydro-3-(2-oxazolyl)-5-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)



RN 148858-43-9 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-7-fluoro-4,5-dihydro-4-methyl-5-(1-pyrrolidinylcarbonyl)-, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 148858-44-0 CAPLUS


CN Imidazo[1,5-a]quinoxaline, 7-fluoro-4,5-dihydro-4-methyl-3-[5-(1-methylcyclopropyl)-1,2,4-oxadiazol-3-yl]-5-(1-pyrrolidinylcarbonyl)-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 148858-45-1 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-7-fluoro-4,5-dihydro-5-(4-morpholinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 148858-48-4 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(5-(1-methylcyclopropyl)-1,2,4-oxadiazol-3-yl)-6-fluoro-4,5-dihydro-5-(4-morpholinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 148858-51-9 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-[5-(1,1-dimethylethyl)-1,2,4-oxadiazol-3-yl]-4,5-dihydro-6-methyl-5-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 148858-53-1 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-[5-(1,1-dimethylethyl)-1,2,4-oxadiazol-3-yl]-5-(3-fluorobenzoyl)-4,5-dihydro- (9CI) (CA INDEX NAME)




RN 148858-54-2 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxylic acid, 3-[5-(1,1-dimethylethyl)-1,2,4-oxadiazol-3-yl]-, methyl ester (CA INDEX NAME)




RN 148858-55-3 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxylic acid, 7-chloro-3-[5-(1,1-dimethylethyl)-1,2,4-oxadiazol-3-yl]-, methyl ester (CA INDEX NAME)




RN 148858-56-4 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxylic acid, 7-chloro-3-[5-(1,1-dimethylethyl)-1,2,4-oxadiazol-3-yl]-4,4-dimethyl-, methyl ester (CA INDEX NAME)




RN 148858-57-5 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 7-chloro-3-[5-(1,1-dimethylethyl)-1,2,4-oxadiazol-3-yl]-4,5-dihydro-4,4-dimethyl-5-(4-morpholinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 148858-59-7 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-[5-(1,1-dimethylethyl)-1,2,4-oxadiazol-3-yl]-4,5-dihydro-5-(4-nitrobenzoyl)- (9CI) (CA INDEX NAME)




RN 148858-60-0 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 5-(3-chlorobenzoyl)-3-[5-(1,1-dimethylethyl)-1,2,4-oxadiazol-3-yl]-4,5-dihydro- (9CI) (CA INDEX NAME)




RN 148858-63-3 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(4-fluorophenyl)-4,5-dihydro-5-(4-morpholinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 148858-64-4 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 5-(3-fluorobenzoyl)-3-(4-fluorophenyl)-4,5-dihydro- (9CI) (CA INDEX NAME)




RN 148858-65-5 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxylic acid, 3-(4-fluorophenyl)-, methyl ester (CA INDEX NAME)




RN 148858-66-6 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxamide, N-(1,1-dimethylethyl)-3-(4-fluorophenyl)- (CA INDEX NAME)




RN 148858-67-7 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(4-fluorophenyl)-4,5-dihydro-5-[4-(trifluoromethyl)benzoyl]- (9CI) (CA INDEX NAME)




RN 148858-68-8 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxamide, 3-(4-fluorophenyl)- (CA INDEX NAME)




RN 148858-69-9 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxamide, N-ethyl-3-(4-fluorophenyl)- (CA INDEX NAME)




RN 148858-95-1 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 7-chloro-3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-4,5-dihydro-5-[(4-morpholinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 148858-96-2 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 7-chloro-3-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-4,5-dihydro-5-[(4-morpholinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 148858-97-3 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 7-chloro-3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-4,5-dihydro-5-[(4-methyl-1-piperazinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 148858-99-5 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 7-chloro-3-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-4,5-dihydro-5-[(4-methyl-1-piperazinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 148859-00-1 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxylic acid, 7-chloro-3-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-, 1-methylethyl ester (CA INDEX NAME)




RN 148859-08-9 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxamide, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-N-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)




RN 148859-09-0 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxamide, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-N-[2-(diethylamino)ethyl]- (CA INDEX NAME)




RN 148859-10-3 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxamide, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-N-(2-methoxyethyl)- (CA INDEX NAME)




RN 148859-11-4 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-5-[(3,5-dimethyl-1-piperazinyl)carbonyl]-4,5-dihydro- (9CI) (CA INDEX NAME)




RN 148859-12-5 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxylic acid, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-, 2-methoxyethyl ester (CA INDEX NAME)




RN 148859-13-6 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxamide, 7-chloro-3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-N-ethyl- (CA INDEX NAME)




RN 148859-14-7 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxamide, 7-chloro-3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)- (CA INDEX NAME)




RN 148859-16-9 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-4,5-dihydro-7-methyl-5-(4-morpholinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 148859-17-0 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-5-[(3,5-dimethyl-1-piperazinyl)carbonyl]-4,5-dihydro-7-methyl- (9CI) (CA INDEX NAME)




RN 148859-18-1 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxamide, 3-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-7-methyl- (CA INDEX NAME)




RN 148859-19-2 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-4,5-dihydro-5-[(3,4,5-trimethyl-1-piperazinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 148859-20-5 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxylic acid, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-, 2-(dimethylamino)ethyl ester (CA INDEX NAME)




RN 148859-21-6 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxamide, 3-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-N-ethyl-7-methyl- (CA INDEX NAME)




RN 148859-22-7 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-4,5-dihydro-7-methyl-5-[(4-methyl-1-piperazinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 148859-23-8 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 7-chloro-3-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-5-[(3,5-dimethyl-1-piperazinyl)carbonyl]-4,5-dihydro- (9CI) (CA INDEX NAME)




RN 148859-24-9 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-4,5-dihydro-6-methyl-5-(4-morpholinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 148859-25-0 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-4,5-dihydro-6-methyl-5-[(4-methyl-1-piperazinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 148859-26-1 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 7-chloro-3-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-4,5-dihydro-5-[(3,4,5-trimethyl-1-piperazinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 148859-27-2 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 5-(2-fluorobenzoyl)-3-(4-fluorophenyl)-4,5-dihydro- (9CI) (CA INDEX NAME)




RN 148859-28-3 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(4-fluorophenyl)-4,5-dihydro-5-[3-(trifluoromethyl)benzoyl]- (9CI) (CA INDEX NAME)




RN 148859-29-4 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 7-fluoro-3-(4-fluorophenyl)-4,5-dihydro-5-(4-morpholinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 148859-30-7 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 7-chloro-3-(4-fluorophenyl)-4,5-dihydro-5-(4-morpholinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 148859-31-8 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxamide, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-7-fluoro-N,N-bis(2-methoxyethyl)- (CA INDEX NAME)




RN 148859-35-2 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxylic acid, 3-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-7-fluoro-, 1-methylethyl ester (CA INDEX NAME)




RN 148859-37-4 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-6-fluoro-4,5-dihydro-5-(1-piperazinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 148890-50-0 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-[5-(1,1-dimethylethyl)-1,2,4-oxadiazol-3-yl]-5-(4-fluorobenzoyl)-4,5-dihydro- (9CI) (CA INDEX NAME)



RN 148890-81-7 CAPLUS


CN Imidazo[1,5-a]quinoxaline, 3-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-4,5-dihydro-5-[(4-methyl-1-piperazinyl)carbonyl]- (9CI) (CA INDEX NAME)



RN 148890-82-8 CAPLUS


CN Imidazo[1,5-a]quinoxaline, 3-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-7-fluoro-

4,5-dihydro-5-[(4-methyl-1-piperazinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 148890-83-9 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-6-fluoro-4,5-dihydro-5-[(4-methyl-1-piperazinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 148890-85-1 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-7-fluoro-4,5-dihydro-5-[(4-methyl-1-piperazinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 148890-86-2 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-6-fluoro-4,5-dihydro-5-[(4-methyl-1-piperazinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 148890-87-3 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-4,5-dihydro-7-methyl-5-[(4-methyl-1-piperazinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 148890-88-4 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(4-fluorophenyl)-4,5-dihydro-5-[(4-methyl-1-piperazinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 148890-89-5 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 7-chloro-3-(4-fluorophenyl)-4,5-dihydro-5-[(4-methyl-1-piperazinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 148890-90-8 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 7-fluoro-3-(4-fluorophenyl)-4,5-dihydro-5-[(4-methyl-1-piperazinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 148890-91-9 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(4-fluorophenyl)-4,5-dihydro-7-methyl-5-[(4-methyl-1-piperazinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 148890-92-0 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(4-cyclopropyl-2-thiazolyl)-4,5-dihydro-5-[(4-methyl-1-piperazinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 148890-93-1 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(4-cyclopropyl-2-thiazolyl)-7-fluoro-4,5-dihydro-5-[(4-methyl-1-piperazinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 148890-94-2 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(4-cyclopropyl-2-thiazolyl)-6-fluoro-4,5-dihydro-5-[(4-methyl-1-piperazinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 148890-95-3 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(4-cyclopropyl-2-thiazolyl)-4,5-dihydro-7-methyl-5-[(4-methyl-1-piperazinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 148890-96-4 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-7-fluoro-4,5-dihydro-5-[(3,4,5-trimethyl-1-piperazinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 148890-97-5 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-6-fluoro-4,5-dihydro-5-[(3,4,5-trimethyl-1-piperazinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 148890-98-6 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-4,5-dihydro-7-methyl-5-[(3,4,5-trimethyl-1-piperazinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 148891-00-3 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(4-fluorophenyl)-4,5-dihydro-5-[(3,4,5-trimethyl-1-piperazinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 148891-01-4 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 7-chloro-3-(4-fluorophenyl)-4,5-dihydro-5-[(3,4,5-trimethyl-1-piperazinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 148891-02-5 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 7-fluoro-3-(4-fluorophenyl)-4,5-dihydro-5-[(3,4,5-trimethyl-1-piperazinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 148891-03-6 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(4-fluorophenyl)-4,5-dihydro-7-methyl-5-[(3,4,5-trimethyl-1-piperazinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 148891-04-7 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(4-cyclopropyl-2-thiazolyl)-4,5-dihydro-5-[(3,4,5-trimethyl-1-piperazinyl)carbonyl]- (9CI) (CA INDEX NAME)



RN 148891-05-8 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 7-chloro-3-(4-cyclopropyl-2-thiazolyl)-4,5-dihydro-5-[(3,4,5-trimethyl-1-piperazinyl)carbonyl]- (9CI) (CA INDEX NAME)




IT 148891-06-9P 148891-07-0P 148891-08-1P
 148891-10-5P 148891-11-6P 148891-12-7P
 148891-13-8P 148891-14-9P 148891-15-0P
 148891-16-1P 148891-17-2P 148891-18-3P
 148891-19-4P 148891-20-7P 148891-21-8P
 148891-22-9P 148891-23-0P 148891-24-1P
 148891-25-2P 148891-26-3P 148891-27-4P
 148891-28-5P 148891-29-6P 148891-30-9P
 148891-31-0P 148891-32-1P 148891-33-2P
 148891-34-3P 148891-35-4P 148891-36-5P
 148891-37-6P 148891-38-7P 148891-39-8P
 148891-40-1P 148891-41-2P 148912-78-1P
 148912-79-2P 148912-80-5P 148912-81-6P
 148912-82-7P 148912-83-8P 148912-84-9P
 148912-85-0P 148912-86-1P 148912-87-2P
 148912-88-3P 148912-89-4P 173165-48-5P
 180207-68-5P 180207-69-6P 180207-75-4P
 180207-76-5P 180989-53-1P 180989-54-2P
 180989-56-4P 180989-57-5P 180989-58-6P
 180989-59-7P 180989-60-0P 180989-63-3P
 180989-71-3P 180989-72-4P 180989-73-5P

180989-74-6P 180989-75-7P 180989-77-9P
 180989-78-0P 180989-79-1P 180989-80-4P
 180989-81-5P 180989-82-6P 180989-84-8P
 180989-92-8P 180989-95-1P 180989-96-2P
 180989-98-4P 180989-99-5P 180990-00-5P
 180990-01-6P 180990-02-7P 180990-07-2P
 180990-09-4P 180990-10-7P 180990-13-0P
 180990-14-1P 180990-16-3P 180990-17-4P
 180990-18-5P 180990-19-6P 180990-20-9P
 180990-21-0P 180990-22-1P 180990-23-2P
 180990-24-3P 180990-26-5P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (imidazo[1,5-a]quinoxalines useful as anxiolytic and sedative/hypnotic agents)


RN 148891-06-9 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(4-cyclopropyl-2-thiazolyl)-7-fluoro-4,5-dihydro-5-[(3,4,5-trimethyl-1-piperazinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 148891-07-0 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-5-[(3,5-dimethyl-1-piperazinyl)carbonyl]-7-fluoro-4,5-dihydro- (9CI) (CA INDEX NAME)




RN 148891-08-1 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-5-[(3,5-dimethyl-1-piperazinyl)carbonyl]-6-fluoro-4,5-dihydro- (9CI) (CA INDEX NAME)




RN 148891-10-5 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 5-[(3,5-dimethyl-1-piperazinyl)carbonyl]-3-(4-fluorophenyl)-4,5-dihydro- (9CI) (CA INDEX NAME)




RN 148891-11-6 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 7-chloro-5-[(3,5-dimethyl-1-piperazinyl)carbonyl]-3-(4-fluorophenyl)-4,5-dihydro- (9CI) (CA INDEX NAME)




RN 148891-12-7 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 5-[(3,5-dimethyl-1-piperazinyl)carbonyl]-7-fluoro-3-(4-fluorophenyl)-4,5-dihydro- (9CI) (CA INDEX NAME)




RN 148891-13-8 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 5-[(3,5-dimethyl-1-piperazinyl)carbonyl]-3-(4-fluorophenyl)-4,5-dihydro-7-methyl- (9CI) (CA INDEX NAME)




RN 148891-14-9 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(4-cyclopropyl-2-thiazolyl)-5-[(3,5-dimethyl-1-piperazinyl)carbonyl]-4,5-dihydro- (9CI) (CA INDEX NAME)




RN 148891-15-0 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 7-chloro-3-(4-cyclopropyl-2-thiazolyl)-5-[(3,5-dimethyl-1-piperazinyl)carbonyl]-4,5-dihydro- (9CI) (CA INDEX NAME)




RN 148891-16-1 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(4-cyclopropyl-2-thiazolyl)-5-[(3,5-dimethyl-1-piperazinyl)carbonyl]-7-fluoro-4,5-dihydro- (9CI) (CA INDEX NAME)




RN 148891-17-2 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(4-cyclopropyl-2-thiazolyl)-5-[(3,5-dimethyl-1-piperazinyl)carbonyl]-6-fluoro-4,5-dihydro- (9CI) (CA INDEX NAME)




RN 148891-18-3 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(4-cyclopropyl-2-thiazolyl)-5-[(3,5-dimethyl-1-piperazinyl)carbonyl]-4,5-dihydro-7-methyl- (9CI) (CA INDEX NAME)




RN 148891-19-4 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-7-fluoro-4,5-dihydro-5-[(2,4,6-trimethyl-1-piperazinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 148891-20-7 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-4,5-dihydro-7-methyl-5-[(2,4,6-trimethyl-1-piperazinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 148891-21-8 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-4,5-dihydro-5-[(2,4,6-trimethyl-1-piperazinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 148891-22-9 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-6-fluoro-4,5-dihydro-5-[(2,4,6-trimethyl-1-piperazinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 148891-23-0 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(4-fluorophenyl)-4,5-dihydro-5-[(2,4,6-trimethyl-1-piperazinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 148891-24-1 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 7-chloro-3-(4-fluorophenyl)-4,5-dihydro-5-[(2,4,6-trimethyl-1-piperazinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 148891-25-2 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 7-fluoro-3-(4-fluorophenyl)-4,5-dihydro-5-[(2,4,6-trimethyl-1-piperazinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 148891-26-3 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(4-fluorophenyl)-4,5-dihydro-7-methyl-5-[(2,4,6-trimethyl-1-piperazinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 148891-27-4 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(4-cyclopropyl-2-thiazolyl)-4,5-dihydro-5-[(2,4,6-trimethyl-1-piperazinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 148891-28-5 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 7-chloro-3-(4-cyclopropyl-2-thiazolyl)-4,5-dihydro-5-[(2,4,6-trimethyl-1-piperazinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 148891-29-6 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(4-cyclopropyl-2-thiazolyl)-7-fluoro-4,5-dihydro-5-[(2,4,6-trimethyl-1-piperazinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 148891-30-9 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(4-cyclopropyl-2-thiazolyl)-6-fluoro-4,5-dihydro-5-[(2,4,6-trimethyl-1-piperazinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 148891-31-0 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(4-cyclopropyl-2-thiazolyl)-4,5-dihydro-7-methyl-5-[(2,4,6-trimethyl-1-piperazinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 148891-32-1 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-5-[(2,6-dimethyl-1-piperazinyl)carbonyl]-4,5-dihydro- (9CI) (CA INDEX NAME)




RN 148891-33-2 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 7-chloro-3-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-5-[(2,6-dimethyl-1-piperazinyl)carbonyl]-4,5-dihydro- (9CI) (CA INDEX NAME)




RN 148891-34-3 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-5-[(2,6-dimethyl-1-piperazinyl)carbonyl]-7-fluoro-4,5-dihydro- (9CI) (CA INDEX NAME)




RN 148891-35-4 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-5-[(2,6-dimethyl-1-piperazinyl)carbonyl]-6-fluoro-4,5-dihydro- (9CI) (CA INDEX NAME)




RN 148891-36-5 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-5-[(2,6-dimethyl-1-piperazinyl)carbonyl]-4,5-dihydro-7-methyl- (9CI) (CA INDEX NAME)




RN 148891-37-6 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-5-[(2,6-dimethyl-1-piperazinyl)carbonyl]-4,5-dihydro- (9CI) (CA INDEX NAME)




RN 148891-38-7 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 7-chloro-3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-5-[(2,6-dimethyl-1-piperazinyl)carbonyl]-4,5-dihydro- (9CI) (CA INDEX NAME)




RN 148891-39-8 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-5-[(2,6-dimethyl-1-piperazinyl)carbonyl]-7-fluoro-4,5-dihydro- (9CI) (CA INDEX NAME)




RN 148891-40-1 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-5-[(2,6-dimethyl-1-piperazinyl)carbonyl]-6-fluoro-4,5-dihydro- (9CI) (CA INDEX NAME)




RN 148891-41-2 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-5-[(2,6-dimethyl-1-piperazinyl)carbonyl]-4,5-dihydro-7-methyl- (9CI) (CA INDEX NAME)




RN 148912-78-1 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 7-chloro-3-(4-cyclopropyl-2-thiazolyl)-4,5-dihydro-5-[(4-methyl-1-piperazinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 148912-79-2 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(4-cyclopropyl-2-thiazolyl)-6-fluoro-4,5-dihydro-5-[(3,4,5-trimethyl-1-piperazinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 148912-80-5 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(4-cyclopropyl-2-thiazolyl)-4,5-dihydro-7-methyl-5-[(3,4,5-trimethyl-1-piperazinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 148912-81-6 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 5-[(2,6-dimethyl-1-piperazinyl)carbonyl]-3-(4-fluorophenyl)-4,5-dihydro- (9CI) (CA INDEX NAME)




RN 148912-82-7 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 7-chloro-5-[(2,6-dimethyl-1-piperazinyl)carbonyl]-3-(4-fluorophenyl)-4,5-dihydro- (9CI) (CA INDEX NAME)




RN 148912-83-8 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 5-[(2,6-dimethyl-1-piperazinyl)carbonyl]-7-fluoro-3-(4-fluorophenyl)-4,5-dihydro- (9CI) (CA INDEX NAME)




RN 148912-84-9 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 5-[(2,6-dimethyl-1-piperazinyl)carbonyl]-3-(4-fluorophenyl)-4,5-dihydro-7-methyl- (9CI) (CA INDEX NAME)




RN 148912-85-0 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(4-cyclopropyl-2-thiazolyl)-5-[(2,6-dimethyl-1-piperazinyl)carbonyl]-4,5-dihydro- (9CI) (CA INDEX NAME)




RN 148912-86-1 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 7-chloro-3-(4-cyclopropyl-2-thiazolyl)-5-[(2,6-dimethyl-1-piperazinyl)carbonyl]-4,5-dihydro- (9CI) (CA INDEX NAME)




RN 148912-87-2 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(4-cyclopropyl-2-thiazolyl)-5-[(2,6-dimethyl-1-piperazinyl)carbonyl]-7-fluoro-4,5-dihydro- (9CI) (CA INDEX NAME)




RN 148912-88-3 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(4-cyclopropyl-2-thiazolyl)-5-[(2,6-dimethyl-1-piperazinyl)carbonyl]-6-fluoro-4,5-dihydro- (9CI) (CA INDEX NAME)




RN 148912-89-4 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(4-cyclopropyl-2-thiazolyl)-5-[(2,6-dimethyl-1-piperazinyl)carbonyl]-4,5-dihydro-7-methyl- (9CI) (CA INDEX NAME)




RN 173165-48-5 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-4,5-dihydro-5-(1H-pyrrol-2-ylcarbonyl)- (9CI) (CA INDEX NAME)




RN 180207-68-5 CAPLUS


CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxamide, N,N-dimethyl-3-(4-methylphenyl)- (CA INDEX NAME)




RN 180207-69-6 CAPLUS
 CN Imidazo[1,5-a]quinoxaline, 4,5-dihydro-3-phenyl-5-(1-piperidinylcarbonyl)-
 (9CI) (CA INDEX NAME)




RN 180207-75-4 CAPLUS
 CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxylic acid, 3-(4-fluorophenyl)-,
 1-methylethyl ester (CA INDEX NAME)



RN 180207-76-5 CAPLUS
 CN Imidazo[1,5-a]quinoxaline, 5-(4-fluorobenzoyl)-3-(4-fluorophenyl)-4,5-dihydro- (9CI) (CA INDEX NAME)




RN 180989-53-1 CAPLUS
 CN Imidazo[1,5-a]quinoxaline-4-carboxylic acid, 6-fluoro-4,5-dihydro-5-(1-pyrrolidinylcarbonyl)-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 180989-54-2 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 6-fluoro-4,5-dihydro-4-[5-(1-methylethyl)-1,2,4-oxadiazol-3-yl]-5-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 180989-56-4 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 7-chloro-3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-5-(2-furanylcarbonyl)-4,5-dihydro- (9CI) (CA INDEX NAME)




RN 180989-57-5 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxamide, 7-chloro-N,N-dimethyl-3-[3-(1-methylethyl)-1,2,4-oxadiazol-5-yl]- (CA INDEX NAME)




RN 180989-58-6 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 6-chloro-4,5-dihydro-4,4-dimethyl-3-[3-(1-methylethyl)-1,2,4-oxadiazol-5-yl]-5-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 180989-59-7 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxamide, 6-chloro-N,N,4,4-tetramethyl-3-[3-(1-methylethyl)-1,2,4-oxadiazol-5-yl]- (CA INDEX NAME)



RN 180989-60-0 CAPLUS


CN Imidazo[1,5-a]quinoxaline, 5-(2-chlorobenzoyl)-3-(5-cyclopentyl-1,2,4-oxadiazol-3-yl)-4,5-dihydro- (9CI) (CA INDEX NAME)



RN 180989-63-3 CAPLUS


CN Imidazo[1,5-a]quinoxaline, 6-chloro-4,5-dihydro-4-methyl-3-[5-(1-methylethyl)-1,2,4-oxadiazol-3-yl]-5-(1-pyrrolidinylcarbonyl)-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 180989-71-3 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 4,5-dihydro-3-[5-(1-methylethyl)-1,2,4-oxadiazol-3-yl]-5-(4-morpholinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 180989-72-4 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxamide, 3-[5-(1-methylethyl)-1,2,4-oxadiazol-3-yl]-N,N-dipropyl- (CA INDEX NAME)




RN 180989-73-5 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 4,5-dihydro-3-[5-(1-methylethyl)-1,2,4-oxadiazol-3-yl]-5-(1-piperidinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 180989-74-6 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 4,5-dihydro-3-[3-(1-methylethyl)-1,2,4-oxadiazol-5-yl]-5-(1-piperidinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 180989-75-7 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(5-ethyl-1,2,4-oxadiazol-3-yl)-4,5-dihydro-5-(1-piperidinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 180989-77-9 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 4,5-dihydro-4,4-dimethyl-3-[5-(1-methylethyl)-1,2,4-oxadiazol-3-yl]-5-(1-piperidinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 180989-78-0 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxamide, N,N,7-trimethyl-3-[5-(1-methylethyl)-1,2,4-oxadiazol-3-yl]- (CA INDEX NAME)




RN 180989-79-1 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxamide, 3-(4-fluorophenyl)-N,N,4,4-tetramethyl- (CA INDEX NAME)



RN 180989-80-4 CAPLUS


CN Morpholine, 4-[3-[5-(3,3,3-trifluoro-2-methylpropyl)-1,2,4-oxadiazol-3-yl]imidazo[1,5-a]quinoxalin-5(4H)-yl]acetyl)- (9CI) (CA INDEX NAME)



RN 180989-81-5 CAPLUS

CN Morpholine, 4-[[3-(5-cyclopentyl-1,2,4-oxadiazol-3-yl)-7-fluoro-4-methylimidazo[1,5-a]quinoxalin-5(4H)-yl]acetyl]-, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 180989-82-6 CAPLUS


CN Piperidine, 1-[3-(5-cyclopentyl-1,2,4-oxadiazol-3-yl)-7-fluoro-4-methylimidazo[1,5-a]quinoxalin-5(4H)-yl]acetyl-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 180989-84-8 CAPLUS
 CN Imidazo[1,5-a]quinoxaline, 3-[5-(cyclopropylmethyl)-1,2,4-oxadiazol-3-yl]-7-fluoro-4,5-dihydro-4-methyl-5-(2-pyridinylmethyl)-, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 180989-92-8 CAPLUS
 CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxylic acid, 3-[5-(1,1-dimethylethyl)-1,2,4-oxadiazol-3-yl]-6-fluoro-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 180989-95-1 CAPLUS
 CN Imidazo[1,5-a]quinoxaline, 3-(4-cyclopropyl-2-thiazolyl)-4,5-dihydro-5-(4-morpholinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 180989-96-2 CAPLUS
 CN Imidazo[1,5-a]quinoxaline, 3-(2-benzoxazolyl)-4,5-dihydro-5-(4-morpholinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 180989-98-4 CAPLUS
 CN Imidazo[1,5-a]quinoxaline, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-5-[(3,5-dimethyl-4-morpholinyl)carbonyl]-7-fluoro-4,5-dihydro- (9CI) (CA INDEX NAME)



RN 180989-99-5 CAPLUS
 CN Imidazo[1,5-a]quinoxaline, 3-[5-(1,1-dimethylethyl)-1,2,4-oxadiazol-3-yl]-4,5-dihydro-5-(1-piperidinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 180990-00-5 CAPLUS
 CN Imidazo[1,5-a]quinoxaline, 6-chloro-3-[5-(1,1-dimethylethyl)-1,2,4-oxadiazol-3-yl]-4,5-dihydro-4,4-dimethyl-5-(4-morpholinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 180990-01-6 CAPLUS
 CN Imidazo[1,5-a]quinoxaline, 3-[3-(1,1-dimethylethyl)-1,2,4-oxadiazol-5-yl]-

4,5-dihydro-5-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 180990-02-7 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 5-(2-chlorobenzoyl)-3-[5-(1,1-dimethylethyl)-1,2,4-oxadiazol-3-yl]-4,5-dihydro- (9CI) (CA INDEX NAME)




RN 180990-07-2 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-[3-(1,1-dimethylethyl)-5-isoxazolyl]-4,5-dihydro-5-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 180990-09-4 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 7-chloro-3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-5-[(3,5-dimethyl-4-morpholinyl)carbonyl]-4,5-dihydro- (9CI) (CA INDEX NAME)




RN 180990-10-7 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxylic acid, 3-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-, 1-methylethyl ester (CA INDEX NAME)



RN 180990-13-0 CAPLUS


CN Imidazo[1,5-a]quinoxaline, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-7-fluoro-4,5-dihydro-5-(1-piperazinylcarbonyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 180990-14-1 CAPLUS


CN Imidazo[1,5-a]quinoxaline, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-6-fluoro-4,5-dihydro-5-(1-piperazinylcarbonyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 180990-16-3 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-7-fluoro-4,5-dihydro-5-[(3,4,5-trimethyl-1-piperazinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 180990-17-4 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-6-fluoro-4,5-dihydro-5-[(3,4,5-trimethyl-1-piperazinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 180990-18-5 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-5-[(3,5-dimethyl-1-piperazinyl)carbonyl]-7-fluoro-4,5-dihydro- (9CI) (CA INDEX NAME)



RN 180990-19-6 CAPLUS


CN Imidazo[1,5-a]quinoxaline, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-5-[(3,5-dimethyl-1-piperazinyl)carbonyl]-6-fluoro-4,5-dihydro- (9CI) (CA INDEX NAME)



RN 180990-20-9 CAPLUS


CN Imidazo[1,5-a]quinoxaline, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-4,5-dihydro-5-[(2,4,6-trimethyl-1-piperazinyl)carbonyl]- (9CI) (CA INDEX NAME)

NAME)




RN 180990-21-0 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 7-chloro-3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-4,5-dihydro-5-[(2,4,6-trimethyl-1-piperazinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 180990-22-1 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-7-fluoro-4,5-dihydro-5-[(2,4,6-trimethyl-1-piperazinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 180990-23-2 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-6-fluoro-4,5-dihydro-5-[(2,4,6-trimethyl-1-piperazinyl)carbonyl]- (9CI) (CA INDEX NAME)



RN 180990-24-3 CAPLUS


CN Imidazo[1,5-a]quinoxaline, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-4,5-dihydro-7-methyl-5-[(2,4,6-trimethyl-1-piperazinyl)carbonyl]- (9CI) (CA INDEX NAME)



RN 180990-26-5 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 8-fluoro-4,5-dihydro-4-methyl-3-[5-(1-methylcyclopropyl)-1,2,4-oxadiazol-3-yl]-5-(1-pyrrolidinylcarbonyl)-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 148858-14-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(imidazo[1,5-a]quinoxalines useful as anxiolytic and sedative/hypnotic agents)

RN 148858-14-4 CAPLUS

CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 5-(1,1-dimethylethyl)-3-(4-fluorophenyl)- (CA INDEX NAME)



L5 ANSWER 31 OF 70 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1996:216358 CAPLUS

DOCUMENT NUMBER: 124:306537

TITLE: Quantitative structure - activity relationship studies on benzodiazepine receptor binding of some nonbenzodiazepine series of ligands

AUTHOR(S): Gupta, S. P.; Paleti, Anitha

CORPORATE SOURCE: Dep. Chemistry, Birla Institute of Technology and Science, Pilani, 333031, India

SOURCE: Quantitative Structure-Activity Relationships (1996), 15(1), 12-16
CODEN: QSARDI; ISSN: 0931-8771

PUBLISHER: VCH


DOCUMENT TYPE: Journal

LANGUAGE: English

IT 148010-75-7 148010-76-8 148010-77-9
148011-22-7 148011-26-1 148011-29-4
148011-30-7 148011-31-8 148011-34-1
148011-37-4 148011-38-5 148011-39-6
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); FRP (Properties); BIOL (Biological study)
(QSAR studies on benzodiazepine receptor binding of some nonbenzodiazepine series of ligands)


RN 148010-75-7 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxylic acid, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 148010-76-8 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 5-benzoyl-3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-4,5-dihydro- (9CI) (CA INDEX NAME)




RN 148010-77-9 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 5-acetyl-3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-4,5-dihydro- (9CI) (CA INDEX NAME)




RN 148011-22-7 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 5-(2-chlorobenzoyl)-3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-4,5-dihydro- (9CI) (CA INDEX NAME)




RN 148011-26-1 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 5-acetyl-3-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-4,5-dihydro- (9CI) (CA INDEX NAME)



RN 148011-29-4 CAPLUS


CN Imidazo[1,5-a]quinoxaline, 5-acetyl-3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-6-fluoro-4,5-dihydro- (9CI) (CA INDEX NAME)



RN 148011-30-7 CAPLUS


CN Imidazo[1,5-a]quinoxaline, 5-benzoyl-3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-4,5-dihydro- (9CI) (CA INDEX NAME)

yl)-6-fluoro-4,5-dihydro- (9CI) (CA INDEX NAME)




RN 148011-31-8 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 5-acetyl-3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-7-fluoro-4,5-dihydro- (9CI) (CA INDEX NAME)




RN 148011-34-1 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 5-benzoyl-3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-7-fluoro-4,5-dihydro- (9CI) (CA INDEX NAME)




RN 148011-37-4 CAPLUS


CN Imidazo[1,5-a]quinoxaline, 5-benzoyl-3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-4,5-dihydro-4,4-dimethyl- (9CI) (CA INDEX NAME)



RN 148011-38-5 CAPLUS
 CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxylic acid, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-4,4-dimethyl-, methyl ester (CA INDEX NAME)



RN 148011-39-6 CAPLUS
 CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxylic acid, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-4,4-dimethyl-, 1-methylethyl ester (CA INDEX NAME)



L5 ANSWER 32 OF 70 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1996:213416 CAPLUS

DOCUMENT NUMBER: 124:343186

TITLE: Oxidative cyclization of acyclic ureas with bis(trifluoroacetoxy)iodobenzene to generate N-substituted 2-benzimidazolinones

AUTHOR(S): Romero, Arthur G.; Darlington, William H.; Jacobsen, E. Jon; Mickelson, John W.

CORPORATE SOURCE: Med. Chem. Res., Pharmacia, Upjohn, Inc., Kalamazoo, MI, 49001, USA

SOURCE: Tetrahedron Letters (1996), 37(14), 2361-4
 CODEN: TELEAY; ISSN: 0040-4039

PUBLISHER: Elsevier

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 124:343186


IT 176790-89-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(oxidative cyclization of acyclic ureas with bis(trifluoroacetoxy)iodobenzene to generate N-substituted 2-benzimidazolinones)

RN 176790-89-9 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxamide, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-N-methoxy- (CA INDEX NAME)



L5 ANSWER 33 OF 70 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1996:173925 CAPLUS
 DOCUMENT NUMBER: 124:250522
 TITLE: Potentiation of hypoxic injury in cultured rabbit
 hepatocytes by the quinoxalinone anxiolytic,
 panadiplon
 AUTHOR(S): Bacon, James A.; Cramer, Clay T.; Petrella, Diane K.;
 Sun, Elena L.; Ulrich, Roger G.
 CORPORATE SOURCE: Investigative Toxicology, Upjohn Laboratories,
 Kalamazoo, MI, 49007, USA
 SOURCE: Toxicology (1996), 108(1,2), 9-16
 CODEN: TXCYAC; ISSN: 0300-483X
 PUBLISHER: Elsevier
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 IT 124423-84-3, Panadiplon
 RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or
 effector, except adverse); BSU (Biological study, unclassified); THU
 (Therapeutic use); BIOL (Biological study); USES (Uses)
 (panadiplon potentiation of hypoxic injury in cultured rabbit
 hepatocytes)
 RN 124423-84-3 CAPLUS
 CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-
 5-(1-methylethyl)- (CA INDEX NAME)




L5 ANSWER 34 OF 70 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1996:10861 CAPLUS
 DOCUMENT NUMBER: 124:106400
 TITLE: Putative benzodiazepine partial agonists demonstrate
 receptor heterogeneity
 AUTHOR(S): Chen, Shu-Wen; Chen, Henry A.; Davies, M. Frances;
 Loew, Gilda H.
 CORPORATE SOURCE: Mol. Res. Inst., Palo Alto, CA, 94304, USA
 SOURCE: Pharmacology, Biochemistry and Behavior (1996)
), 53(1), 87-97
 CODEN: PBBHAU; ISSN: 0091-3057
 PUBLISHER: Elsevier
 DOCUMENT TYPE: Journal
 LANGUAGE: English

IT 124423-84-3, U78875

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(putative benzodiazepine partial agonists demonstrate receptor heterogeneity)

RN 124423-84-3 CAPLUS

CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-5-(1-methylethyl)- (CA INDEX NAME)



L5 ANSWER 35 OF 70 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1995:982965 CAPLUS

DOCUMENT NUMBER: 124:117265

TITLE: High-Affinity Partial Agonist Imidazo[1,5-a]quinoxaline Amides, Carbamates, and Ureas at the γ -Aminobutyric Acid A/Benzodiazepine Receptor Complex

AUTHOR(S): Jacobsen, E. Jon; TenBrink, Ruth E.; Stelzer, Lindsay S.; Belonga, Kenneth L.; Carter, Donald B.; Im, Haesook K.; Im, Wha Bin; Sethy, Vimala H.; Tang, Andy H.; et al.

CORPORATE SOURCE: Upjohn Laboratories, Upjohn Company, Kalamazoo, MI, 49001, USA

SOURCE: Journal of Medicinal Chemistry (1996), 39(1), 158-75

PUBLISHER: CODEN: JMCMAR; ISSN: 0022-2623

DOCUMENT TYPE: American Chemical Society

LANGUAGE: Journal


OTHER SOURCE(S): English

IT 148010-77-9 CASREACT 124:117265

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(preparation and activity of imidazoquinoxaline derivs. at γ -aminobutyric acid A/benzodiazepine receptor)

RN 148010-77-9 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 5-acetyl-3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-4,5-dihydro- (9CI) (CA INDEX NAME)




IT 148010-51-9P 148010-53-1P 148010-55-3P

148010-57-5P 148010-75-7P 148010-76-8P
 148010-78-0P 148010-80-4P 148010-81-5P
 148011-04-5P 148011-05-6P 148011-23-8P
 148011-27-2P 148011-28-3P 148011-32-9P
 148011-33-0P 148011-36-3P 148011-37-4P
 148011-38-5P 148011-43-2P 148011-44-3P
 148011-46-5P 148011-48-7P 148011-50-1P
 148011-51-2P 148011-52-3P 148011-54-5P
 148011-55-6P 148011-56-7P 148011-57-8P
 148011-58-9P 148011-59-0P 148011-60-3P
 148011-61-4P 148011-62-5P 148012-11-7P
 148012-36-6P 148012-47-9P 148858-48-4P
 148858-95-1P 148859-24-9P 173165-48-5P
 173165-49-6P 173165-50-9P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (preparation and activity of imidazoquinoxaline derivs. at γ -aminobutyric acid A/benzodiazepine receptor)


RN 148010-51-9 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxamide, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-N,N,4,4-tetramethyl- (CA INDEX NAME)




RN 148010-53-1 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxamide, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-4,4-dimethyl- (CA INDEX NAME)




RN 148010-55-3 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxamide, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-N,4,4-trimethyl- (CA INDEX NAME)




RN 148010-57-5 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carbothioic acid, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-4,4-dimethyl-, S-methyl ester (CA INDEX NAME)




RN 148010-75-7 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxylic acid, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 148010-76-8 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 5-benzoyl-3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-4,5-dihydro- (9CI) (CA INDEX NAME)




RN 148010-78-0 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-5-(2-furanylcarbonyl)-4,5-dihydro- (9CI) (CA INDEX NAME)




RN 148010-80-4 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 7-chloro-3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-4,5-dihydro-5-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 148010-81-5 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxamide, 7-chloro-3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-N,N-dimethyl- (CA INDEX NAME)




RN 148011-04-5 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 7-chloro-3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-4,5-dihydro-4,4-dimethyl-5-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 148011-05-6 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxamide, 7-chloro-3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-N,N,4,4-tetramethyl- (CA INDEX NAME)




RN 148011-23-8 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-4,5-dihydro-5-(4-morpholinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 148011-27-2 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxamide, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-6-fluoro-N,N-dimethyl- (CA INDEX NAME)




RN 148011-28-3 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-6-fluoro-4,5-dihydro-5-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 148011-32-9 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxamide, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-7-fluoro-N,N-dimethyl- (CA INDEX NAME)




RN 148011-33-0 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-7-fluoro-4,5-dihydro-5-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 148011-36-3 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-7-fluoro-4,5-dihydro-5-(4-morpholinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 148011-37-4 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 5-acetyl-3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-4,5-dihydro-4,4-dimethyl- (9CI) (CA INDEX NAME)




RN 148011-38-5 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxylic acid, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-4,4-dimethyl-, methyl ester (CA INDEX NAME)




RN 148011-43-2 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 6-chloro-3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-4,5-dihydro-5-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 148011-44-3 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxamide, 6-chloro-3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-N,N-dimethyl- (CA INDEX NAME)




RN 148011-46-5 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-4,5-dihydro-5-(trifluoroacetyl)- (9CI) (CA INDEX NAME)




RN 148011-48-7 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-4,5-dihydro-5-(2-pyridinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 148011-50-1 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxamide, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-N-phenyl- (CA INDEX NAME)




RN 148011-51-2 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxamide, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-N,N-dimethyl- (CA INDEX NAME)




RN 148011-52-3 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxamide, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-N-methyl- (CA INDEX NAME)




RN 148011-54-5 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxamide, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-N-(1-methylethyl)- (CA INDEX NAME)




RN 148011-55-6 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxamide, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-N,N-diethyl- (CA INDEX NAME)




RN 148011-56-7 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-4,5-dihydro-5-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 148011-57-8 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carbothioic acid, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-, S-phenyl ester (CA INDEX NAME)




RN 148011-58-9 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carbothioic acid, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-, S-ethyl ester (CA INDEX NAME)




RN 148011-59-0 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxamide, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-N-ethyl- (CA INDEX NAME)




RN 148011-60-3 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxamide, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)- (CA INDEX NAME)




RN 148011-61-4 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carbothioic acid, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-, S-methyl ester (CA INDEX NAME)




RN 148011-62-5 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-4,5-dihydro-4,4-dimethyl-5-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 148012-11-7 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(5-ethyl-1,2,4-oxadiazol-3-yl)-4,5-dihydro-5-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 148012-36-6 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 4,5-dihydro-3-[5-(1-methylethyl)-1,2,4-oxadiazol-3-yl]-5-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 148012-47-9 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-[5-(1,1-dimethylethyl)-1,2,4-oxadiazol-3-yl]-4,5-dihydro-5-(1-pyrrolidinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 148858-48-4 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-6-fluoro-4,5-dihydro-5-(4-morpholinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 148858-95-1 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 7-chloro-3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-4,5-dihydro-5-(4-morpholinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 148859-24-9 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-4,5-dihydro-6-methyl-5-(4-morpholinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 173165-48-5 CAPLUS

CN Imidazo[1,5-a]quinoxaline, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-4,5-dihydro-5-(1H-pyrrol-2-ylcarbonyl)- (9CI) (CA INDEX NAME)




RN 173165-49-6 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxylic acid, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-, methyl ester (CA INDEX NAME)



RN 173165-50-9 CAPLUS

CN Imidazo[1,5-a]quinoxaline-5(4H)-carboxylic acid, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-, 1-methylethyl ester (CA INDEX NAME)




IT 173165-54-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and activity of imidazoquinoxaline derivs. at γ -aminobutyric acid A/benzodiazepine receptor)

RN 173165-54-3 CAPLUS


CN Imidazo[1,5-a]quinoxaline-5(4H)-carbonyl chloride, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)- (CA INDEX NAME)



ACCESSION NUMBER: 1995:721205 CAPLUS
 DOCUMENT NUMBER: 123:111747
 TITLE: Preparation of antibacterial 1-methylcarbapenem derivatives
 INVENTOR(S): Oida, Sadao; Tanaka, Teruo; Konosu, Toshuki; Mori, Makoto; Myaoka, Takeo; Tajima, Kazu
 PATENT ASSIGNEE(S): Sankyo Co, Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 55 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 07101959	A	19950418	JP 1993-244299	19930930 <--
JP 1993-244299			JP 1993-244299	19930930 <--

PRIORITY APPLN. INFO.:
 OTHER SOURCE(S): MARPAT 123:111747
 IT 165894-09-7P 165894-11-1P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of antibacterial 1-methylcarbapenem derivs.)
 RN 165894-09-7 CAPLUS
 CN Imidazo[1,5-a]pyrazine, 5,6,7,8-tetrahydro-7-(phenylmethyl)- (CA INDEX NAME)



RN 165894-11-1 CAPLUS
 CN 1-Pyrrolidinecarboxylic acid, 4-(acetylthio)-2-[(5,6-dihydroimidazo[1,5-a]pyrazin-7(8H)-yl)carbonyl]-, (4-nitrophenyl)methyl ester, (2S-cis)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



IT 156263-93-3P
 RL: RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of antibacterial 1-methylcarbapenem derivs.)
 RN 156263-93-3 CAPLUS
 CN 1-Azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, 3-[[5-[(5,6-

dihydroimidazo[1,5-a]pyrazin-7(8H)-yl)carbonyl]-1-[[4-(4-nitrophenyl)methoxy]carbonyl]-3-pyrrolidinyl]thio]-6-(1-hydroxyethyl)-4-methyl-7-oxo-, (4-nitrophenyl)methyl ester, [4R-[3(3S*,5S*),4 α ,5 β ,6 β (R*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 165893-71-0P 165893-72-1P 165893-73-2P


RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of antibacterial 1-methylcarbapenem derivs.)

RN 165893-71-0 CAPLUS

CN 1-Azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, 3-[[5-[[5,6-dihydroimidazo[1,5-a]pyrazin-7(8H)-yl)carbonyl]-3-pyrrolidinyl]thio]-6-(1-hydroxyethyl)-4-methyl-7-oxo-, [4R-[3(3S*,5S*),4 α ,5 β ,6 β (R*)]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 165893-72-1 CAPLUS

CN Imidazo[1,5-a]pyrazinium, 7-[[4-[[2-carboxy-6-(1-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-en-3-yl]thio]-2-pyrrolidinyl]carbonyl]-5,6,7,8-tetrahydro-2-methyl-, chloride, [4R-[3(2S*,4S*),4 α ,5 β ,6 β (R*)]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● Cl⁻

RN 165893-73-2 CAPLUS
 CN Imidazo[1,5-a]pyrazinium, 7-[[4-[[2-carboxy-6-(1-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-en-3-yl]thio]-2-pyrrolidinyl]carbonyl]-5,6,7,8-tetrahydro-2-(2-hydroxyethyl)-, chloride, [4R-[3(2S*,4S*), 4α,5β,6β(R*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● Cl⁻

L5 ANSWER 37 OF 70 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1995:556019 CAPLUS
 DOCUMENT NUMBER: 122:306417
 TITLE: Induction of a hepatic toxic syndrome in the Dutch-belted rabbit by a quinoxalinone anxiolytic
 AUTHOR(S): Ulrich, Roger G.; Bacon, James A.; Branstetter, Daniel G.; Cramer, Clay T.; Michael Funk, G; Hunt, Charles E.; Petrella, Diane K.; Sun, Elena L.
 CORPORATE SOURCE: Investigative Toxicology and Drug Development Toxicology Units, Upjohn Laboratories, Kalamazoo, MI, 49001, USA
 SOURCE: Toxicology (1995), 98(1-3), 187-98
 CODEN: TXCYAC; ISSN: 0300-483X
 PUBLISHER: Elsevier
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 IT 124423-84-3, Panadiplon
 RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
 (quinoxalinone anxiolytic panadiplon induction of hepatic toxic syndrome and steatosis)

RN 124423-84-3 CAPLUS

CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-5-(1-methylethyl)- (CA INDEX NAME)



L5 ANSWER 38 OF 70 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1995:521047 CAPLUS

DOCUMENT NUMBER: 122:305875

TITLE: Characterization of novel ligands for wild-type and natural mutant diazepam-insensitive benzodiazepine receptors

AUTHOR(S): Wong, Garry; Uusi-Oukari, Mikko; Hansen, Holger C.; Suzdak, Peter D.; Korpi, Esa R.

CORPORATE SOURCE: Biomedical Research Center, Alko Group Ltd., Helsinki, Finland

SOURCE: European Journal of Pharmacology, Molecular Pharmacology Section (1995), 289(2), 335-42
CODEN: EJPPET; ISSN: 0922-4106

PUBLISHER: Elsevier

DOCUMENT TYPE: Journal

LANGUAGE: English

IT 124423-85-4, NNC 14-0578 126990-93-0, NNC 14-0687

126991-09-1, NNC 14-0712 129799-94-6, NNC 14-0695


163436-66-6, NNC 14-0756 163436-67-7, NNC 14-0759

RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); PROC (Process)

(characterization of novel ligands for wild-type and natural mutant diazepam-insensitive benzodiazepine receptors)


RN 124423-85-4 CAPLUS

CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 6-chloro-3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-5-(1-methylethyl)- (CA INDEX NAME)




RN 126990-93-0 CAPLUS

CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-5-[(4-methoxyphenyl)methyl]- (CA INDEX NAME)




RN 126991-09-1 CAPLUS

CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 3-(5-(3-methyl-2-butenyl)-1,2,4-oxadiazol-3-yl)- (9CI) (CA INDEX NAME)




RN 129799-94-6 CAPLUS

CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 3-(3-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-5-(1,1-dimethylethyl)-1,2,4-oxadiazol-3-yl)- (CA INDEX NAME)




RN 163436-66-6 CAPLUS


CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 3-(5-(3-cyclopropyl-1,2,4-oxadiazol-3-yl)-6-fluoro-5-(phenylmethyl)-1,2,4-oxadiazol-3-yl)- (CA INDEX NAME)




RN 163436-67-7 CAPLUS
 CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-5-[(4-fluorophenyl)methyl]- (CA INDEX NAME)



L5 ANSWER 39 OF 70 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1995:128775 CAPLUS
 DOCUMENT NUMBER: 122:177370
 TITLE: An evaluation of column-to-column retention variability for compounds related to panadiplon (U-78,875) using three different reverse-phase HPLC separation modes
 AUTHOR(S): Scholl, J. P.
 CORPORATE SOURCE: Control Res. Dev. Lab., Upjohn Co., Kalamazoo, MI, 49001, USA
 SOURCE: Journal of Liquid Chromatography (1994), 17(16), 3369-82
 CODEN: JLCHD8; ISSN: 0148-3919
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 IT 124423-83-2 124423-84-3, Panadiplon 144860-93-5, U 78280 161602-93-3
 RL: ANT (Analyte); PRP (Properties); ANST (Analytical study) (evaluation of column-to-column retention variability for compds. related to panadiplon using three different reverse-phase HPLC separation modes)
 RN 124423-83-2 CAPLUS
 CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 5-(1-methylethyl)-3-(5-methyl-1,2,4-oxadiazol-3-yl)- (CA INDEX NAME)




RN 124423-84-3 CAPLUS
 CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-5-(1-methylethyl)- (CA INDEX NAME)




RN 144860-93-5 CAPLUS

CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-5-ethyl- (CA INDEX NAME)



RN 161602-93-3 CAPLUS

CN Imidazo[1,5-a]quinoxalin-4(5H)-one, 3-[5-(2-methylcyclopropyl)-1,2,4-oxadiazol-3-yl]-5-(1-methylethyl)- (CA INDEX NAME)



=>